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Background: This dissertation focuses on effective crisis management for people 
with borderline personality disorder. The dissertation reports a single-blind 
randomised controlled trial investigating the effectiveness of joint crisis plans (JCPs; 
a type of advance statement regarding future treatment preferences for people with 
mental health problems) compared with treatment as usual for community-dwelling 
adults meeting research diagnostic criteria for borderline personality disorder.  
 
Methods: During the developmental phase, three focus groups were held with 
mental health service users, clinicians and academics in order to adapt an existing 
joint crisis plan template, the utility of which was then tested in a small (N=13) pilot 
study. Participants in the resulting larger trial were recruited from community 
mental health teams in south London and randomised to receive either treatment as 
usual (TAU) or a joint crisis plan plus treatment as usual. Participants were assessed 
on a number of variables prior to randomisation and again at six-month follow-up 
and these included self-harm, engagement with services, therapeutic alliance and 
health-related quality of life.  
 
Results: Eighty-eight adults out of the 133 referred were eligible and consented 
before being randomised to receive a joint crisis plan in addition to treatment as 
usual (n = 46) or TAU alone (n = 42). This represented approximately 75% of the 
target sample size. Follow-up data were collected on 73 (83.0%) participants. A 
modified intention-to-treat analysis revealed no significant differences in the 
 6 
proportion of participants who reported self-harming (odds ratio (OR) = 1.9, 95% CI: 
0.53–6.5, P=0.33) or the frequency of self-harming behaviour (rate ratio (RR) = 0.74, 
95% CI: 0.34–1.63, P=0.46) between the two groups at follow-up. No significant 
differences were observed between the two groups on any of the secondary 
outcome measures. JCPs were viewed favourably by participants, who reported 
referring to their JCPs both during and between crises. Approximately half of 
participants (47%) reported a greater sense of control over their mental health 
problems and an improved relationship with their mental health team when using a 
JCP.  
 
Conclusions: This dissertation expands the knowledge about effective crisis 
management for people with borderline personality disorder, a group who have 
traditionally been alienated from mainstream mental health services and are still 
perceived to be difficult to help. The study showed that it is possible to recruit and 
retain adult service users with borderline personality disorder to a trial of joint crisis 
plans. Although the intervention was not clinically effective, the findings suggest that 
the brief intervention was perceived as helpful to participants with borderline 
personality disorder. Future research - including a definitive trial with a more 
comprehensive process analysis - may provide further information about the 
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CHAPTER 1. BACKGROUND 
Chapter 1.1.  Borderline personality disorder 
1.1.1  Introduction to borderline personality disorder 
Borderline personality disorder (BPD) is a complex mental disorder of variable 
severity, characterised by a pervasive pattern of instability in interpersonal 
relationships and self-image, in addition to marked impulsivity and impaired 
functioning (1, 2). People with BPD are frequently in crisis (3, 4) and can have 
difficulties engaging in treatment (5-8). They have maladaptive personality styles 
which emerge in a variety of contexts and lead to distinct patterns of dysfunctional 
behaviour and interpersonal relationships (7-9). People with BPD often make what 
appear to many people to be bad decisions (10-12) and this may include a cycle of 
seeking out victim roles and manipulating others to inflict harm upon them (13, 14). 
People with BPD may also undermine themselves or sabotage their previous efforts 
when a goal is about to be attained (e.g. severely regressing after a discussion of 
recent progress in therapy) (15, 16), to be highly sensitive to perceived rejection 
from others (17, 18), to have difficulty dealing with emotions (19) and to 
misinterpret non-verbal cues from others in social interactions (20-30).  
 
Research into the maladaptive psychological mechanisms underpinning BPD has 
indicated that people with the disorder have difficulties in appreciating other 
people’s mental states such as beliefs, feelings, desires and intentions (31). 
Difficulties in problem-solving are often very pronounced in people with BPD and can 
contribute to them engaging in self-harming behaviour (32). Many people with BPD 
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also experience co-morbid mental health problems and symptoms such as paranoia, 
auditory hallucinations (33), alexithymia and chronic anhedonia are prevalent in this 
group of individuals (34-37). BPD is one of the most controversial Axis II diagnoses in 
the American Psychiatric Association (APA)’s Diagnostic and Statistical Manual (DSM-
V) (38) and it presents some of the most difficult and challenging problems in all of 
psychiatry. The diagnosis has been the focus of considerable interest amongst 
researchers and clinicians in recent decades, with a more voluminous literature 
focusing on BPD than any other recognised personality disorder (39-41). 
 
1.1.2.  Diagnostic features 
The current BPD diagnosis was largely developed in the late 1970s after the 
development of a reliable diagnostic method (42, 43) and it takes the form of a 
categorical diagnosis (i.e., one either receives the diagnosis or does not) (44). This 
method allowed clinicians to reliably distinguish people with BPD from those with 
other disorders including schizophrenia and depression, in addition to establishing a 
valid threshold for making a diagnosis and identifying seven highly distinguishing 
characteristics (45). These seven characteristics, along with the addition of ‘identity 
disturbance’, formed the basis of the BPD diagnostic criteria adopted in the third 
edition of DSM (the DSM-III) produced by the APA in 1980 and the only significant 
change since this time has been the addition of ‘psychotic-like symptoms’ to DSM-IV 
in 1994 (45). According to the DSM-IV-TR (Text Revision) (1), BPD is characterised by 
a pervasive pattern of instability of interpersonal relationships, self-image and 
affects, in conjunction with marked impulsivity. Additionally, at least five out of the 
following nine criteria need to be present for a definitive diagnosis to be made:  
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(1) Frantic efforts to avoid real or imagined abandonment; 
(2) A pattern of unstable and intense interpersonal relationships characterised 
by alternating between extremes of idealization and devaluation; 
(3) Identity disturbance: markedly and persistent unstable self-image or sense of 
self; 
(4) Impulsivity in at least two areas that are potentially self-damaging (e.g. 
spending, sex, substance abuse, reckless driving, binge eating); 
(5) Recurrent suicidal behaviour, gestures or threats, or self-mutilating 
behaviour; 
(6) Affective instability due to a marked reactivity of mood (e.g. intense 
dysphoria, irritability, or anxiety usually lasting a few hours and only rarely 
more than a few days; 
(7) Chronic feelings of emptiness; 
(8) Inappropriate, intense anger or difficulty controlling anger (e.g. frequent 
displays of temper, constant anger, recurrent physical fights); 
(9) Transient, stress-related paranoid ideation or severe dissociative symptoms.  
 
These nine diagnostic criteria have an established research legacy and have thus far 
proven clinically valuable (45). Furthermore, all have been examined for their 
relative specificity, sensitivity and predictive power (45, 46). As the presence of any 
five of the nine criteria is sufficient for a diagnosis to be made, there is potential for 
extensive heterogeneity among people diagnosed with BPD (47, 48). It has been 
estimated that there are 256 different combinations of diagnostic criteria that all 
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confer the official DSM-IV-TR diagnosis (45, 49, 50). Additionally, two individuals with 
the same diagnosis may only share one of the nine diagnostic criteria (51). Grilo and 
colleagues (46) demonstrated that the combination of criterion two (intense 
unstable relationships) and criterion five (recurrent suicidal behaviours) were 
sufficient to accurately predict a diagnosis of BPD in a majority of cases. In light of 
the above, some researchers have suggested that such heterogeneity in 
presentation is a considerable barrier to effective research and clinical progress in 
the area (51, 52). Recent research has also suggested that psychiatric outpatients 
meeting just one of the nine BPD criteria displayed greater psychosocial morbidity 
than outpatients meeting none of the criteria (53). Furthermore, symptom severity 
(based on Axis II co-morbidity) has been identified as having some predictive power 
regarding treatment outcome (2). This evidence suggests that sub-threshold levels of 
severity are still of clinical significance.  
 
1.1.3.  Public health burden 
Many people with BPD suffer considerably and can place a heavy burden on those 
around them (54-56). Due in part to the high degree of symptomatic distress often 
exhibited by people with BPD, they typically make frequent use of acute psychiatric 
and primary care services (50, 54, 57-65). It has been estimated that people with 
BPD commence an average of six different outpatient therapies over the course of 
their illness and that as many as two thirds cease attending the majority of these 
programs within the first three months (66, 67). Furthermore, in one study, 80 
percent of participants with BPD were taking three or more medications 
simultaneously (68). At times, people with BPD can be extremely difficult to engage 
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in therapy in spite of efforts by therapists to keep them in active treatment and they 
can consequently use a disproportionate amount of therapeutic resources (61, 69). 
The impulsive and chaotic interpersonal functioning that is characteristic of BPD 
often makes the process of establishing a therapeutic relationship challenging (70, 
71). 
 
The overall societal and economic costs of BPD become even greater when the costs 
related to behaviours such as reckless driving, domestic violence, sexual risk 
behaviours, shoplifting, unplanned pregnancies, imprisonment and pathological 
gambling (behaviours which are more common among people with BPD than among 
those without it) are added to health service costs (72-82). People with BPD have 
less stable employment histories and are more likely to have been made redundant - 
or lost a job intentionally - than those without the diagnosis (83-85). Additionally, 
BPD negatively affects the course and treatment of coexisting medical (86-89), 
psychiatric (90-94) and substance use (95-98) disorders. The intensity and duration 
of treatment utilisation by people with BPD and their severe social dysfunction (and 
subsequent costs) underscore the disorder’s public health significance (45, 99-101) 
and reduction in quality of life (102, 103). After conducting a national survey of more 
than 10,000 people in Australia, Jackson and colleagues (104) reported that a 
diagnosis of BPD was significantly more strongly associated with having one or more 
Axis I conditions, greater mental disability and greater functional impairment than 
having no diagnosis of personality disorder. People with BPD were also more likely to 
have sought prior mental health consultations from general practitioners (GPs), 
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psychiatrists and psychologists than those with an Axis I disorder or physical health 
condition (104).  
 
1.1.4.  History of the concept 
The BPD diagnosis, and a developmental approach to understanding the disorder, is 
rooted in psychoanalytic theory and clinical observation (105). In 1938, Adolph Stern 
first used the term ‘border line group’ to describe a number of low-functioning, 
difficult-to-treat psychiatric patients whom he believed fitted into neither the 
psychotic nor the neurotic category (106). Observing that these patients presented 
with ‘a fairly definite clinical picture and fairly definite clinical symptoms’ (p.468), 
and intrigued by his inability to help these patients using the same methods that had 
proven so successful with neurotic patients, Stern compiled a list of features that 
were present in this patient group. He noted that they did not respond to standard 
psychotherapy and that their symptoms included inordinate hypersensitivity, 
insecurity, anxiety, rigid personality, deeply embedded feelings of inferiority and 
difficulties with reality testing in interpersonal relationships (106). However, it was 
not until Knight’s seminal 1953 article (107) on ‘borderline states’ that the construct 
began to gain widespread attention in the literature. In this article, Knight described 
patients who had classic neurotic symptoms and intact areas of functioning, but 
whose ability to adapt to environmental demands or form meaningful relationships 
were severely impaired (105).  
 
In modern healthcare settings, the term ‘borderline’ - based on Stern’s old theory 
that such pathology lies on the border between psychosis and neurosis - is 
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considered by some to be a misnomer; rather, the disorder is a complex syndrome 
characterised by affective instability, poor impulse control and persistent 
interpersonal difficulties (108). Common clinical features of BPD include frequent 
intense mood swings, an inability to tolerate intimacy, chronic suicidality, perceiving 
others as being either entirely good or entirely bad (with no middle ground) and 
alternating between extreme dependency and sudden hostility (13). These features 
of the disorder interact with and reinforce each other, resulting in a pattern of 
behaviour and symptoms that has been described both as an ‘unrelenting crisis’ 
(109) and ‘stable instability’ (110). Despite this, the label is accompanied by 
considerable controversy; John Gunderson, himself an outspoken advocate of BPD 
research and treatment, once wrote that ‘borderline personality disorder is to 
psychiatry what psychiatry is to medicine’ (i.e., it remains far behind other major 
disorders in terms of awareness and research) (111).  
 
1.1.5.  Concerns about the diagnosis 
In spite of the sizeable literature on BPD, its considerable public health impact and 
its high prevalence in hospital and community settings, the clinical construct of BPD 
is not without its opponents (112-114). Many criticisms have been levelled at the 
diagnosis from researchers, clinicians and members of the public alike, who state 
that it has little clinical utility, due in part to its flexible, unpredictable and 
heterogeneous presentation (38, 44, 45, 115, 116). In a 1985 article, reporting 
findings from a study in which they had examined 100 people with BPD from a 
phenomenological developmental perspective, Akiskal and colleagues (117) 
famously stated that the borderline diagnosis was ‘an adjective in search of a noun’. 
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The BPD diagnosis has even been labelled ‘the virus of psychiatry’ applied 
erroneously as a negative catch-all to difficult clients (118). Until the 1980s, some cli-
nicians and researchers viewed BPD with scepticism, often believing it was a sub-
threshold variant of another disorder such as depression or bipolar disorder (117). 
More recently, it has been claimed that BPD symptoms and features do not identify 
a latent taxon or category and that, as such, the current categorical view of the 
disorder is inaccurate and inappropriate (44). Indeed, Tyrer (116) argued that BPD 
was “neither borderline in nature, nor is it a personality disorder” and that it is a pre-
diagnosis rather than a fully formed one (115). He goes on to argue that BPD is 
incorrectly classified as a personality disorder and that it does an injustice to those 
who suffer from it, adding that it would be better classified as a condition of 
recurrent unstable mood and behaviour (116). Others have suggested that the 
diagnosis of BPD is essentially a heuristic for organising clinical information and 
guiding clinical decisions (119, 120).  
 
However, despite such opposition, and as stated above, the nine criteria currently 
used to diagnose BPD have an established research legacy and have thus far proven 
clinically valuable (45). The BPD diagnostic criteria have remained essentially 
unchanged over the past three decades and a substantial body of research has now 
established the heritability, prevalence, developmental antecedents, markers of risk, 
course and treatment of the disorder (45). Furthermore, no changes were made in 
the recent DSM-V, published in 2013. As such, until the current polythetic algorithm 
used to diagnose BPD is improved upon and accepted widely by clinicians and 
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academics, it appears that the system retains significant clinical utility and will 
continue to be used in clinical and research settings alike (121).  
 
Professional attitudes towards people with BPD are often negative and derogatory 
across mental health and emergency medicine service settings alike (57, 122-131). 
People with a diagnosis of BPD often attract more negative responses from staff 
members than those with a diagnosis of, for example, depression or schizophrenia 
(4, 143, 148). Perceptions of manipulative and threatening behaviour are common 
(132-135), with nurses in one study describing patients with BPD as powerful, 
dangerous, unrelenting forces that leave a trail of destruction in their wakes (133). 
Other research has shown that BPD appears to be associated with a greater 
likelihood of disruptive behaviours (such as yelling, screaming, verbally threatening, 
and refusing to talk with medical staff) in medical settings (136). It has also been 
suggested that receiving a diagnosis of BPD can lead to service users pre-emptively 
rejecting mental health services as a direct consequence of the stigma associated 
with the label. This, in turn, this leads to them being labelled as ‘difficult’ clients and 
a non-therapeutic vicious cycle then ensues (123, 137, 138). Consequently, many 
clinicians choose not to disclose the diagnosis to service users for fear of the above 
scenario playing out (139-141). However, much has been written about treatment 
considerations specific to people with BPD (142) and studies have shown that staff 
attitudes towards such service users can be improved as a result of education about 
BPD (122, 143-145).  
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1.1.6.  Assessment 
Assessment of BPD is best undertaken using a validated measure. Options are self-
report questionnaires and structured clinical interviews (146), of which the latter are 
widely considered to be the gold standard for diagnosing BPD (147). Structured and 
semi-structured clinical interviews typically give more reliable results than 
unstructured clinical assessment and are thus preferred by many clinicians and 
academics (52). Instruments include the Structured Clinical Interview for DSM-IV 
Axis-II Personality Disorders (SCID-II) (148, 149), the McLean Screening Instrument 
for Borderline Personality Disorder (MSI-BPD) (150), the Diagnostic Interview for 
DSM-IV Personality Disorders (151), the Diagnostic Interview for Borderline Patients 
(DIBP) (43), the Borderline Personality Questionnaire (BPQ) (152), the Minnesota 
Borderline Personality Disorder Scale (153, 154), the Borderline Syndrome Index 
(155), the Borderline Personality Disorder Severity Index (156) and the International 
Personality Disorder Examination (157). Establishing a definitive diagnosis of BPD is 
time-consuming, often occurring over the course of multiple sessions, and is not 
without difficulties. As is the case when diagnosing other personality disorders, the 
issue of mental state bias may impact on the diagnostic process; in the case of BPD, 
people who are either depressed or in a manic episode can be wrongly labelled as 
having the affective instability associated with BPD (158, 159).  
 
1.1.7.  Epidemiology 
BPD is the most prevalent Axis II disorder in both inpatient and outpatient mental 
health treatment settings (160). Approximately one to two percent of the general 
population, 10 percent of psychiatric outpatients, 20 percent of psychiatric 
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inpatients and 60-80 percent of forensic inpatients meet the diagnostic criteria for 
BPD (1, 52, 161). Additionally, between 30-60 percent of individuals with any other 
personality disorder meet the criteria for BPD (1). A recent national household study 
in the United Kingdom (UK) (54) reported a prevalence of 1.3 percent and a similar 
figure of 1.4 percent was reported in a comparable study from the USA (162), though 
other studies have reported prevalence figures as high as 5.9 percent of the general 
population in the USA (163). Torgersen and colleagues (164) suggested that BPD is 
not as prevalent as commonly assumed, reporting that just 0.7 percent of a 
representative community sample from Oslo, Norway, were diagnosed with the 
disorder.  
 
The disorder is more prevalent in individuals with substance misuse disorders (165-
169) and forensic populations (170) and it is frequently co-morbid with depression, 
anxiety and eating disorders (13, 48, 171-175). Two large-scale epidemiological 
surveys have reported greater physical and mental disability among people with BPD 
than among those without, after controlling for pre-existing medical conditions, 
socioeconomic status and Axis I disorders (102, 104). BPD is the most prevalent of all 
Axis II disorders treated in all clinical settings (99, 112). To a great extent, it is 
younger women who are diagnosed with BPD (161) and, accordingly, approximately 
75-80 percent of individuals receiving therapy for BPD are women (50, 118), 
although the ratio is more even in community samples (162, 164, 171). The 
discrepancy in prevalence estimates might potentially be explained by several 
factors: a) women may be more likely than men to seek treatment for BPD; b) 
symptoms of BPD might cause more impairment in women relative to men; or c) 
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gender bias in the categorical description of BPD may result in women being more 
likely to be given the diagnostic label of BPD (176, 177). The disorder manifests itself 
in different ways between the sexes; whilst men with BPD are more likely to present 
with substance misuse disorders (178) and co-morbid personality disorders 
(including antisocial personality disorder), women with BPD are more likely to 
present with eating disorders and posttraumatic stress disorder (PTSD) (179).  
 
1.1.8.  Aetiology 
Many people with a diagnosis of BPD have a background of early trauma (180); 
research has shown that approximately 40-50 percent of people with BPD report 
early sexual abuse by a non-family caregiver, 25 percent by their fathers (52), five 
percent from their mothers (52) and 33 percent report other severe forms of abuse 
(108). Other studies report a rate of sexual abuse as high as 91 percent and other 
childhood neglect as high as 92 percent (181). However, as physical and sexual abuse 
frequently co-occur, it is often difficult to determine whether one or both are 
necessary or sufficient for the development of BPD (52, 182, 183). It has also been 
reported that an association exists between the type of abuse experienced and 
specific borderline traits (184) and that multiple forms of trauma are associated with 
increased health service use and ongoing pharmacological interventions for people 
with BPD (185).  
 
There is considerable research evidence to suggest that genetic factors have a role in 
the development of BPD (186, 187). Genetic studies have shown that the disorder is 
significantly heritable, with 42 to 68 percent of the variance associated with genetic 
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factors (95-98). Furthermore, the major components of BPD (i.e., interpersonal 
hypersensitivity, affective dysregulation, and impulsivity) have also been shown to 
be correlated within families (188) and BPD is five times more common among first-
degree relatives of those with the disorder than in the general population . Factors 
relating to disorganised attachment systems, neurophysiological and neurobiological 
dysfunctions of emotional regulation and stress may also be contributing factors to 
the development of BPD (189).  
 
1.1.9.  Course 
BPD is typically not diagnosed until a person is 18 years old (1). Although the 
diagnosis is given to adolescents on occasion (190-192), the practice remains 
somewhat controversial and is still in its infancy (193-196), with little evidence 
regarding effective treatments (197, 198). The course of BPD is considerably 
variable, but it is often the most debilitating during late teens and early twenties 
when mood instability, impulsivity and frequent self-harming behaviour are 
especially prominent (1, 170, 199). Although the disorder was once believed to be 
immutable, empirical research has demonstrated considerable plasticity (200). There 
is a large body of research suggesting that the symptoms of BPD begin to subside or 
reduce in severity from around the mid-twenties (201-203), although there is a 
subgroup (characterised by poor functioning and enduring suicidal ideation or 
attempts) who do not fare as well (204). In 2003, Gunderson and colleagues (205) 
suggested that people with a diagnosis of BPD can make significant rapid 
improvements within a period of two years that are of sufficient duration to be 
considered remissions. In 2004, Grilo and colleagues (206) showed that less than half 
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(44 percent) of their cohort met the diagnostic criteria for BPD at two year follow-up, 
whilst an Italian study from 2011 reported that one quarter (26%) of participants no 
longer met diagnostic criteria after two years (207).  
 
The McLean Study of Adult Development (MSAD) commenced in 1993 and has 
charted prospectively the health outcomes of people with BPD since this time (208, 
209). After the first six years, Zanarini and colleagues reported that remission rates 
were high (74 percent) and that these remissions were stable (210) and were 
comparable (78% - 99%) after 16 years (211). Independent ten-year follow-up 
studies (212, 213) have each reported that the course of BPD is characterised by high 
rates of remission and low rates of relapse, yet severe and persistent impairment in 
social functioning. Research evidence suggests that many people can remain 
functionally impaired even if they no longer meet the diagnostic criteria for BPD 
(214). In Gunderson’s 2011 study (212), in which 175 participants with BPD, 312 
participants with a cluster C personality disorder (either avoidant, dependent or 
obsessive-compulsive personality disorder) and 95 participants with major 
depressive disorder (and no personality disorder) were followed-up over a course of 
ten years, 85 percent of participants with BPD reached diagnostic remission. 
Additionally, only 12 percent of participants with BPD were classified as having 
relapsed after ten years. Zanarini’s 2007 study (213) examined in greater detail the 
sub-syndromal phenomenology of BPD by assessing 24 symptoms occurring 
commonly in people with BPD (including affective instability, chronic anxiety, 
intolerance of aloneness and manipulative suicide efforts) over the course of ten 
years in a sample of 290 participants with BPD. Results showed that 12 of the 24 
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symptoms were reported at follow-up by less than 15 percent of participants who 
had reported them at baseline and that the remaining 12 symptoms also showed a 
pattern of reduction in severity, though with a less dramatic decline.  
 
Longer-term outcome studies report that about two-thirds will be ‘functioning well’ 
when evaluated 10-25 years after initial contact (215-218), with the greatest decline 
in rates occurring typically after 44 years of age (216, 219). Such findings suggest 
that BPD may consist of some symptoms that are manifestations of acute psychiatric 
illness and other symptoms that represent more enduring aspects of the disorder 
(213, 220). After following a sample of 64 people with BPD over a 27-year period, 
Paris and colleagues (221) reported that approximately ten percent eventually went 
on to commit suicide. This figure is particularly high for young women, a group in 
whom the suicide rate is typically far lower (72). Against this, however, was the rate 
of four percent reported by Zanarini and colleagues in the MSAD (210).  
 
There is a small body of research which suggests that BPD can persist - and even be 
first diagnosed - in people over the age of 50 and, indeed, in older adults (222-226). 
Research also suggests that the clinical presentation of older adults with BPD differs 
significantly from that of younger adults with BPD (227). Specifically, older adults 
with BPD are more likely to be impulsive, to self-harm and to display affective 
instability, whilst younger adults are more likely to present with co-morbid 
substance use disorders (228). However, when compared with other psychiatric 
conditions, BPD is typically associated with a relatively encouraging prognosis (39, 
229, 230), though it may take a long time to achieve a positive outcome (211). 
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Predictors of poor prognosis include a history of childhood sexual abuse, young age 
at first psychiatric contact, symptom chronicity, affective instability, aggression, 
substance abuse and other psychiatric co-morbidity (161, 214).  
 
Chapter 1.2. Treatment of borderline personality disorder 
Although much has been learned in recent decades about the treatment of BPD, 
there are still few well-validated treatments for the disorder (231). People with BPD 
often present with complex pathology and associated problems, complicating clinical 
assessments and management as well as frequently posing considerable difficulties 
for clinicians endeavouring to establish or maintain a therapeutic relationship (70, 
232). The literature contains numerous treatment options and interventions for BPD 
and these vary considerably in their theoretical approach, delivery format and 
amount of supporting evidence. According to Bateman and Fonagy (233), certain key 
principles underpin the management of BPD, irrespective of the treatment modality. 
Treatment needs to be carefully structured, with particular attention given to 
adherence, and the treatment model needs to be coherent to both service user and 
clinician (233).  
 
Successful treatment of BPD is often measured in terms of quality of life, social 
functioning and service use (234). It can be challenging and many people with BPD 
discontinue treatment prematurely (137, 235, 236), with adverse effects on clinical 
outcomes (236). Regression in psychotherapy, countertransference issues, staff 
splitting and unstable one-to-one relationships are all likely to be experienced by 
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clinicians treating people with BPD (236, 237). The ever-present risk of threats of 
suicide, or indeed completed suicide, represents another common feature of 
treatment, bringing with it a range of clinical and ethical challenges for health 
professionals (47, 238). One factor mentioned frequently in relation to treatment for 
people with BPD is the common problem of early discontinuation from therapy. 
Previous studies have indicated that people with BPD who discontinue therapy 
programmes often have significantly higher levels of anger, greater Axis I co-
morbidity and poorer therapeutic alliance - and have made significantly more suicide 
attempts - than those who complete treatment (239). Impulsiveness - a core feature 
of BPD - also plays a role in attrition from treatment. As such, it is likely that helping 
the individual to gain greater control of his or her impulsiveness early on in 
treatment is a critical issue in reducing such attrition (10, 236). It has been reported 
that as many as 60 percent of participants in trials of psychotherapy for BPD 
symptoms discontinue treatment prematurely (240). However, a 2011 systematic 
review and meta-analysis of treatment completion in psychotherapy for BPD (241) 
reported completion rates ranging from 36 to 100 percent, with an average of 75 
percent of participants completing the full course of therapy. The authors stated that 
their findings challenged the long-held association between BPD and premature 
discontinuation from psychotherapy, suggesting that such an association may no 
longer be appropriate or evidence-based.  
 
The treatment of people with personality disorder in the UK was, until recently, 
highly variable, with some parts of the country lacking any treatment services and 
with good practice concentrated in a few small centres of excellence. This situation 
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improved with the publication of national guidance from the Department of Health 
in 2003: “Personality disorder: no longer a diagnosis of exclusion” (242) which led to 
a raft of new service development and renewed enthusiasm for the management of 
personality disorders, and particularly BPD. In an attempt to ensure uniform 
treatment options across the National Health Service (NHS) for people with BPD, the 
UK National Institute for Health and Clinical Excellence (NICE) published a guideline 
on the long-term treatment and management of BPD (189) in 2009. The guideline 
incorporated a systematic review of the evidence base for psychological and 
pharmacological interventions for BPD. A brief description of these interventions is 
provided below. 
 
1.2.1.  Psychosocial and psychological interventions 
It is widely acknowledged that some form of psychosocial intervention will be 
necessary in most cases (72, 243, 244). Psychosocial interventions cover a wide 
range of approaches, all of which include some form of talking therapy, but which 
differ in intensity, complexity and method. These interventions are delivered usually 
by mental health professionals with advanced training in the method being 
implemented (189). In a 2012 systematic review of psychological therapies for 
people with BPD, Stoffers and colleagues (245) stated that numerous 
psychologically-based therapeutic interventions are used for people with BPD and 
that these vary in both their theoretical approach and methods of practical 
application. The authors stated that many problems frequently encountered by 
people with BPD may be amenable to talking treatments, but that such therapies 
remain experimental and that studies in the literature are too few and too small to 
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inspire full confidence in their results (245). Furthermore, given that BPD is 
characterised by interpersonal difficulties and disturbances in relationships, it is 
perhaps not surprising that establishing a strong therapeutic relationship is central 
to most approaches to psychosocial interventions for BPD, and that many of these 
approaches also share some common structural features (233, 246, 247).  
 
Brazier and colleagues (248) published a systematic review of psychological 
therapies for BPD, including dialectical behaviour therapy (DBT; see below) and 
concluded that, although the overall efficacy of psychological therapies appears to 
be promising, the current evidence is inconclusive. It has been claimed that research 
into effective interventions for BPD has not yet reached the stage where superiority 
over treatment as usual (TAU) can be assumed, particularly when the treatments 
being investigated have not previously demonstrated efficacy. During the course of a 
trial, rates of remission not due to the intervention may be significant, calling into 
question the conclusion that these interventions are responsible for a clinically 
significant improvement in the absence of a control group (249). More well-designed 
studies are both justifiable and urgently needed (5, 248).  
 
1.2.2.  Psychological therapy programmes 
Dialectical behaviour therapy 
Dialectical behaviour therapy (DBT) is a manualised, time-limited (12-month) 
treatment for BPD developed by Linehan to treat individuals with chronic suicidality, 
combining treatment strategies from behavioural, cognitive and supportive 
psychotherapies (243, 250). It is a variant of cognitive behavioural therapy with the 
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emphasis on behaviour, incorporating dialectics and mindfulness (251). Like many 
cognitive behavioural programs, DBT emphasises clear and precise definition of 
treatment targets, ongoing assessment of current behaviours and a collaborative 
working relationship between service user and therapist (252). The treatment is 
based on a combined motivation/capability deficit model of BPD, based on two 
assumptions; 1) people with BPD lack important skills in interpersonal interactions, 
emotion regulation, distress tolerance and self-regulation; and 2) various personal 
and environmental factors often inhibit the use of more appropriate behavioural 
skills that the person has and this reinforces ineffective borderline behaviours (253).  
 
DBT includes weekly or twice-weekly group therapy and 60-90 minutes per week of 
individual therapy, in addition to the availability of out-of-hours telephone contact 
with a therapist. The group sessions consist of psychoeducational skills training, 
emphasising the acquisition of interpersonal effectiveness, distress tolerance, 
emotion regulation and self-management capabilities (254, 255). The individual 
therapy sessions consist of directive, problem-oriented techniques (such as 
behavioural skills training and contingency management) balanced with more 
supportive techniques (such as reflection, empathy and acceptance). The treatment 
goals of individual DBT sessions are organised hierarchically by importance in the 
following order: 1) reduction of self-harm and life-threatening behaviours; 2) 
reduction of any behaviours that interfere with the process of therapy; and 3) 
reduction of any behaviours that significantly interfere with the individual’s quality 
of life (243). The first target is always high-risk self-harm behaviours because, as 
Linehan (254) stated, ‘psychotherapy is not effective with dead patients’ (p.239). 
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Whenever self-harm occurs, either part or whole of the next session is dedicated to 
discussing the event and of appropriate problem-solving strategies (254). Both 
during and between sessions, the DBT therapist actively teaches and reinforces 
adaptive behaviours (256). The overriding dialectic in DBT is its synthesis of 
validation and acceptance of the client on the one hand, set against persistent 
attention to behavioural change on the other (250).  
 
Since Linehan’s initial findings were published in 1991 (243), DBT has been widely 
implemented throughout multiple therapeutic settings and has been used 
successfully with a variety of client groups (257-271). It is currently the most 
frequently investigated intervention for BPD (255). There is some evidence to 
suggest that DBT is more effective than TAU (which is usually some form of case 
management from a community-based mental health team) for reducing the 
frequency and medical severity of suicide attempts and self-harm behaviour (272), 
the frequency and duration of inpatient psychiatric admissions, attrition from 
treatment, social maladjustment ratings and subjective ratings of anger in the 
treatment of women with BPD (208, 213, 214), especially when used in inpatient 
settings (273). As such, it should be considered as a treatment option if reducing self-
harming behaviour is a priority (189). Also, results from a recent non-randomised 
trial (274) suggest that DBT can have a positive impact on self-esteem and self-
concept, and thus on identity disturbance. An Australian quasi-experimental trial in 
2010 (275) also reported that successful completion of a DBT programme was 
associated with reduced health service utilisation, particularly by participants with 
high previous service use histories. Some authors have speculated that the focus in 
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DBT on generalising certain skills to the individual’s natural environment might 
account for some of the positive treatment outcomes (276).  
 
It must be noted that treatment failures have also been reported with DBT (277, 
278). In 2009, McMain and colleagues (278) conducted a randomised controlled trial 
of DBT versus general psychiatric management for BPD, using a sample of 180 
people with a diagnosis of BPD. At one-year and two-year follow-ups, no significant 
differences were found between the two groups (266, 278), suggesting that people 
with BPD benefited equally from DBT and a well-specified treatment delivered by 
psychiatrists with expertise in treating BPD. This finding highlights the importance of 
clearly defining the control treatment in trials of interventions for BPD (e.g. TAU vs. 
best available practice). No findings were published regarding the cost-effectiveness 
of the two trial arms.  
 
Such findings notwithstanding, the overwhelming majority of evidence supports the 
effectiveness of DBT for people with BPD, especially in reducing self-harm. Stoffers 
and colleagues (245) concluded that DBT was helpful on a range of outcomes 
(including reducing admissions to hospital and incarcerations), but the small sample 
sizes in the studies included in the review limits confidence in their results. The 
authors concluded that larger trials are urgently needed (245). The findings from a 
2010 meta-analysis of 16 studies of DBT (eight RCTs and eight non-randomised trials) 
revealed a moderate global effect and a moderate effect size for reducing suicidal 




The term ‘mentalization’ refers to a person’s capacity to conceive of conscious and 
unconscious mental states in themselves and others (279-281). It is a preconscious, 
imaginative (as the person must imagine what other people might be thinking or 
feeling) mental activity which enables a person to perceive and interpret human 
behaviour in terms of intentional mental states such as the needs, desires, feelings, 
beliefs and goals of others (282, 283). Several factors can disrupt the development of 
mentalizing, including psychological trauma during childhood (281).  
 
Mentalization-based treatment (MBT) is a psychodynamically-oriented treatment for 
people with BPD based on attachment and cognitive theory which aims to 
strengthen a person’s capacity to understand their own and others’ mental states in 
attachment contexts. This is in order to improve their interpersonal functioning, as 
well as their affect and impulse regulation, which may contribute to reducing or 
eliminating self-harming behaviour (189, 284). The focus of MBT is stabilising the 
sense of self (246) and the overall aims are threefold; 1) to promote mentalizing 
about oneself; 2) to promote mentalizing about others; and 3) to promote 
mentalizing of important interpersonal relationships (285). MBT for BPD is based on 
an understanding of BPD primarily as a disorder of the self, resulting from 
developmental disturbance of attachment in childhood and leading to a deficit in 
mentalization ability (246, 286).  
 
Trials conducted by the creators of MBT (Bateman and Fonagy) have shown that the 
intervention - when delivered by generic mental health professionals as part of a 
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partial hospitalisation program - was cost-effective and superior to TAU over a 
period of three years (287-289) and that these treatment effects remained five years 
after the cessation of all index treatment (284, 288). Findings from a recent RCT 
comparing MBT with structured clinical management (284) showed that participants 
in the MBT group displayed a steeper decline of both self-reported and clinically 
significant problems, including suicide attempts and hospitalisation. 
 
The creators of MBT have suggested that it may be useful for implementation in 
general mental health services both in the UK (284) and abroad (290). In light of 
early promising findings (291), further independent investigations of the efficacy of 
MBT are warranted.  
 
1.2.3.  Individual psychological therapies 
Cognitive behaviour therapy (CBT) 
Cognitive behaviour therapy (CBT) is a structured, time-limited, individual talking 
therapy focused on problems relating to dysfunctional emotions, behaviours and 
cognitions. It is one of the most extensively researched forms of psychotherapy and, 
although originally developed as a treatment for anxiety and depression, it has been 
adapted for an increasingly wider range of disorders and problems (189, 292, 293). 
CBT is typically less intensive in terms of clinician time than other forms of 
psychotherapy developed specifically for BPD (294). Despite this, relatively few 
randomised controlled trials (RCTs) examining the efficacy of CBT with BPD have 
been conducted (69, 294). Additionally, the cost-effectiveness of CBT for use within 
BPD populations has also been questioned (99). In one RCT by Davidson and 
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colleagues published in 2006 (69), participants receiving CBT in addition to TAU 
reported significantly reduced dysfunctional beliefs, state anxiety, psychiatric 
symptom distress and fewer suicidal acts; however no significant differences were 
observed on measures such as depression, social functioning, quality of life or 
interpersonal problems. Following these results, the authors conducted a 
prospective six-year follow-up study using this cohort of participants (295). The 
results indicated that the gains of CBT over TAU were maintained after six years and 
that 46 percent of the original total sample (44% of the CBT group vs. 48% of the 
TAU group) still met diagnostic criteria for BPD. Additionally, participants in the CBT 
group went on to have significantly fewer hospitalisations during the follow-up 
period than those in the treatment as usual group.  
 
Problem-solving therapy 
Problem-solving therapy (PST) is a brief psychological treatment based on cognitive 
behavioural principles originally designed for use with people with depression. The 
goal is for people to learn a structured method for overcoming problems that they 
believe have either precipitated their depressive state or have become increasingly 
difficult to solve as a result of their depressive state (189, 296). PST is a very 
structured and collaborative process, focussing on generating solutions to current 
problems (297). Applied to BPD, PST involves training participants in five major 
processes: problem orientation; problem definition and formulation; generation of 
alternatives; decision-making; and solution implementation and verification (298, 
299). Cognitive modelling, prompting, self-instructions, and reinforcement are all 
used during these five stages (189). Additionally, since a variety of health and mental 
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health professionals can be trained to deliver PST, it is potentially a cost-effective 
treatment option for people with BPD receiving care from community-based mental 
health teams (CMHTs) (296).  
 
PST has been used successfully with personality disordered male offenders (300) and 
was viewed in a positive light by many participants in this setting (301). However, the 
samples used in these studies with offenders were only partly made up of people 
with BPD. Further research would clarify the effectiveness of problem-solving 
therapy in an exclusively-BPD sample.  
 
Schema-focused therapy 
Schema-focused therapy (SFT) is a cognitive therapy that aims to effect structural 
change in a person’s personality by altering maladaptive core beliefs and schemas 
(189, 302). The theory behind SFT suggests that people with BPD develop such 
schemas in the context of adverse events during childhood (303). In 2009, Farrell and 
colleagues (304) published findings from an RCT in which eight months of SFT were 
compared against TAU for 32 people diagnosed with BPD. Participants in the SFT 
group (which boasted a 100 per cent retention rate, a notable finding in itself) 
reported significantly greater reductions in BPD symptoms and global severity of 
symptoms than participants in the TAU group. Additionally, 94 per cent of 
participants in the SFT group no longer met diagnostic criteria for BPD after eight 
months of treatment, compared with 16 percent in the TAU group. The authors of a 
2013 systematic review of the empirical foundations underpinning the effectiveness 
of schema therapy concluded that it is a promising and cost-effective intervention 
 45 
for BPD (305). This small research base suggests that SFT may be an efficacious, 
disorder-specific treatment for BPD, although further research is required to 
establish its effectiveness (303).  
 
Cognitive analytic therapy 
Cognitive analytic therapy (CAT) is a time-limited, integrative psychotherapy 
developed in the UK by Ryle (306-309). CAT combines elements of object relations 
theory and cognitive psychology into an integrated model of development and 
psychopathology (310). Therapy involves a number of CBT methods, with attention 
to the therapeutic relationship as the vehicle of change, aiming to develop the 
motivation, skills and opportunities for learning new patterns of relating to oneself 
and others (189). There is a limited evidence base for the effectiveness of CAT in 
BPD, although results from a 2000 trial (311) suggest that shorter-term outpatient 
weekly psychotherapy is feasible and that CAT is a promising intervention for BPD 
which requires further research.  
 
CAT has also been adapted for early intervention with adolescents and young adults 
with symptoms of BPD. Findings from an Australian RCT with participants aged 15-25 
in 2008 (310) showed that CAT yielded greater symptom improvement than TAU 
over a two-year follow-up period. Additionally, participants in the CAT group showed 
a faster rate of improvement over time, and lower levels of externalising 
psychopathology, than participants receiving treatment as usual. However, caution 
must be exercised when drawing inferences from these findings, as some 
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participants in the sample met as few as two out of nine diagnostic criteria for BPD 
and thus did not have a definitive diagnosis.  
 
Psychodynamic / psychoanalytic psychotherapy 
Psychoanalytically-oriented forms of psychotherapy for people with BPD are based 
on the assumption that unconscious conflicts are responsible for the sharply 
polarised attitudes and extreme shifts in behaviour (such as switching rapidly from 
idealisation to devaluation) often seen in people with BPD (40). By addressing these 
conflicts directly, the goal is to reduce the problematic behaviours in question. 
Clinicians engaging in psychotherapy with BPD populations have adapted the 
methods in order to achieve treatment success (303). For example, whilst 
psychoanalytic therapists have traditionally maintained neutrality and allowed the 
patient to project their inner conflicts and wishes onto them, these methods have 
been modified in working with people with BPD so that the therapist provides more 
structure and is more active in the process (189). A recent systematic review of 
factors predicting a positive outcome in psychotherapy (312) indicated that pre-
treatment symptom severity and client-rated therapeutic alliance were the two 
strongest predictors. There is limited evidence that long-term psychotherapy can be 
a useful form of treatment intervention for people with BPD (313), though more 
research is needed before substantive conclusions can be drawn from the findings.  
 
Group therapy 
One intervention format described frequently in the literature for the treatment of 
BPD symptoms is group therapy and its many variants (286-289, 314, 315). Several 
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types of group therapy for BPD have been trialled in both inpatient and outpatient 
settings and the potential advantages of these approaches are numerous; for 
example, the group format dilutes the potential for transference and 
countertransference issues commonly associated with people with BPD, thereby 
effectively reducing the anxiety associated with treating such individuals. Also, 
belonging to a group may provide its members with feelings of acceptance and 
commonality so often lacking in such populations (316, 317).  
 
Despite some questions about the generalizability of findings, many studies suggest 
that group therapy can be an effective and valued treatment option for people with 
BPD (316, 318). Other non-randomised studies have reported that group therapy can 
also be an effective adjunctive treatment for enhancing self-esteem in females with 
BPD (319). Many studies of group therapy for BPD have focused heavily on female 
samples, using samples consisting either exclusively (194, 195, 197-199) or 
predominately (320) of female participants. Future research using mixed and/or 
exclusively male samples are urgently required in order to make reliable inferences 
about the efficacy of group therapy for BPD.  
 
Summary of psychological interventions 
The overall evidence base for psychological therapies in the treatment of BPD is 
relatively poor (189). The situation is further complicated by the fact that many trials 
to date have been underpowered and caution must therefore be exercised when 
interpreting any findings. There is some evidence for the efficacy of brief 
psychological interventions, manual-assisted cognitive therapy, cognitive behaviour 
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therapy, problem-solving therapy, schema-focused therapy, cognitive analytic 
therapy, psychodynamic psychotherapy, group therapy, mentalization-based 
treatment and dialectical behaviour therapy. At the time of writing, DBT represents 
the optimal treatment for women with BPD, where the treatment focus is on 
reduction of self-harm (255, 256, 278, 321). However, there is an urgent need to 
generate the missing evidence and to improve and expand upon the services 
available to people with BPD. Larger and better-designed trials need to be conducted 
before any strong recommendations can be made (5, 189, 248, 322).  
 
1.2.4.  Pharmacological therapies 
There are currently no medications available in the UK which are indicated 
specifically for the treatment of BPD (189). However, many people with the diagnosis 
receive ongoing and long-term pharmacological treatment with antipsychotics, 
antidepressants and/or mood stabilisers (60, 189, 323-330) to manage state 
symptoms and trait vulnerability factors. Many people are prescribed multiple 
concurrent medications despite the lack of evidence supporting this practice (331). 
One longitudinal study found that 75 percent of participants with BPD were 
prescribed two or more different medications concurrently at some point in the six 
years following a hospital admission (209). This pattern of polypharmacy persists 
despite the associated heightened rate of obesity and related chronic illnesses, in 
addition to other side effects (88). Of particular note is that one of the few major 
studies of the effect of polypharmacy reported that, at follow-up, people with BPD 
fared approximately as well with one medication as they did with two (332). 
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The specific medications prescribed to people with BPD are selected typically due to 
their properties known from other psychiatric conditions such as depressive, 
psychotic, or anxiety disorders (a process termed ‘off-label use’), which mostly target 
affective or impulsive symptom clusters (60, 326). The 2009 NICE guideline (189) 
recommended that pharmacological intervention should not be used specifically for 
the treatment of BPD, nor for the individual symptoms or behaviours associated with 
BPD. Furthermore, the guideline recommended that clinicians should aim to reduce 
and eliminate the unnecessary pharmacological treatment of people with BPD by 
reviewing the existing treatment of those individuals who do not have a diagnosed 
co-morbid mental or physical illness but who are prescribed medication (189).  
 
It has been suggested in the literature that pharmacotherapy should not be used in 
the treatment of BPD as it presents unnecessary risks of harmful side effects (333). 
However, the impulsive behaviour of people with BPD, in addition to frequent 
distortions of thought and perception and lability of mood, provide some clear 
targets for pharmacotherapy (325). After conducting a systematic review of 
pharmacological interventions for BPD in 2010, Stoffers and colleagues (60) 
concluded that some beneficial effects have been observed with second-generation 
antipsychotics, mood stabilisers and dietary supplementation by omega-3 fatty 
acids. However, they noted that this evidence was based mostly on single study 
effect estimates and, as such, replicating such studies would be of considerable 
clinical and research utility (60). Despite conflicting opinions regarding a) the 
effectiveness, and b) the appropriateness of pharmacotherapy for people with BPD, 
it has been recommended as an adjunctive, symptom-targeted component of 
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treatment (334). Many other recent reviews (60, 303, 323, 326, 335-340) have 
indicated some evidence of effectiveness for certain medications including 
lamotrigine, topiramate, valproate, aripiprazole, olanzapine and omega-3 fatty acid 
supplementation.  
 
Given that impulsivity and frequent attempts to engage in self-harm are two of the 
diagnostic criteria for BPD, there is a danger that such individuals may misuse - or 
overdose on - any form of prescribed medication. However, the medical 
consequences associated with an overdose of antipsychotics are typically less serious 
than those associated with other psychotropic drugs, such as tricyclic 
antidepressants (325). Another common concern relating to medication use and BPD 
is that of polypharmacy, which may occur when a person with BPD, or their doctor, 
wishes to continue or add medications despite a lack of demonstrable benefit. In one 
study (68), more than a third (37 percent) of participants with BPD were prescribed 
three or more psychotropic medications concurrently. Furthermore, one six-year 
follow-up study showed that polypharmacy was not affected by time, with 40 
percent of participants prescribed three or more concurrent medications, 20 percent 
prescribed four or more and 10 percent of participants prescribed five or more 
medications at any follow-up period examined throughout the six-year duration of 
the study (341). The 2009 NICE guideline recommended that psychotropic 
medications with an unclear benefit should be discontinued prior to a new 
medication being initiated (189). A brief discussion of the main classes of 




Anticonvulsants and mood stabilisers 
Affective instability is a core symptom of BPD and the co-occurrence of bipolar 
disorder in people with BPD is not uncommon (39, 158, 159, 241, 250, 313, 342, 
343). Indeed, many symptoms of the onset of bipolar disorder (including impulsivity, 
wasteful spending and sexual promiscuity) are very similar to that of BPD (344-348) 
and this can frequently lead to misdiagnosis (349). Anticonvulsants and mood 
stabilisers such as lithium - common in the treatment of bipolar disorder - are 
therefore sometimes used in the treatment of mood-related symptoms in people 
with BPD (326, 350). There is limited evidence to suggest that mood stabilisers (in 
particular topiramate and lamotrigine) can be moderately effective against affective 
instability (189, 323). However, these effects are typically modest and side effects 
including obesity and associated hypertension are common. Thus, it is recommended 
that such medications should only be prescribed as adjuncts to psychotherapy (72). 
 
Antipsychotics 
Antipsychotics are often used to treat people with BPD, not only for their sedative 
effects (which may be desirable in BPD, as patients can experience high levels of 
arousal) but also because many of the licensed indications for antipsychotics are 
similar to some of the core features of BPD (e.g. cognitive and perceptual distortions, 
mood symptoms, irritability and aggression) (189, 324). RCTs have been conducted 
on classical neuroleptics and also on second generation - or atypical - antipsychotics 
(326). Some studies have reported that antipsychotics were slightly more effective 
than placebo in terms of impulsivity, interpersonal relationships and global 
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functioning (323, 351). However, other data have indicated that there may be an 
increase in self-harming behaviour in people treated with the antipsychotic 
olanzapine (60). There is also some evidence to suggest that injectable atypical 
antipsychotics (such as olanzapine or ziprasidone) may be effective, fast and safe for 
treating acutely agitated people with BPD (352). One recent trial comparing the 
impact of olanzapine and haloperidol on the management of mental and behavioural 
symptoms of people with BPD (353) reported that no significant differences were 
observed between the two medications. Another double-blind placebo-controlled 
RCT of olanzapine involving 451 people with BPD (351) reported a modest (but 
significant) benefit of olanzapine over placebo in relation to overall BPD 
psychopathology. However, as highlighted by the authors, such a benefit must be 
weighed against the risk of adverse metabolic effects associated with olanzapine, 
particularly weight gain and the subsequent health risks.  
 
A recent meta-analysis of placebo-controlled RCTs of antipsychotics for people with 
BPD (324) showed that, in the short term, antipsychotics can have significant 
beneficial effects on cognitive-perceptual symptoms, anger, and mood lability, but 
that their long-term use with this population remains controversial. Similarly, the 
NICE guideline (189) advised against the use of antipsychotic drugs for the medium- 
and long-term treatment of BPD. The short-term side effects resulting from 
neuroleptic medication, including extrapyramidal symptoms such as dystonia and 
akathesia, often contribute to noncompliance and early termination of 




Depression and symptoms of depression are common in people with BPD and many 
antidepressants, including selective serotonin reuptake inhibitors (SSRIs; 
antidepressant agents with a selective action on serotonin dysregulation), are often 
prescribed to people with BPD, though such medications have typically had little 
demonstrable benefit over placebo in controlled trials (354). For example, the results 
of an RCT published in 2002 (355) showed that no difference between the SSRI 
fluvoxamine and placebo was observed in the effect on impulsivity and aggression 
scores amongst female participants with BPD. There is some limited evidence to 
suggest that antidepressants, in particular fluoxetine, may have a modest effect 
against affective instability and impulsivity (323).  
 
In their 2011 systematic review of double-blind RCTs of medications for the 
treatment of BPD published between 1990 and 2010 (comparing both ‘active drugs 
versus placebo’ and ‘drugs versus drugs’), Bellino and colleagues (326) reported that 
there was some evidence that SSRIs may be effective in reducing affective symptoms 
including depression, anxiety and anger in people with BPD. However, most studies 
included in their review allowed for inclusion of participants with congruent mood 
and anxiety disorders and this affected the validity of findings, as SSRIs have been 
shown to be effective in the treatment of such disorders independently of BPD (326). 
As such, caution must be exercised when interpreting their findings. As with several 
other classes of medication, the NICE guideline (189) stated that more large clinical 
trials were needed to clarify the role of antidepressant medication in the treatment 
of people with BPD.  
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In summary, there are currently no medications available in the UK designed 
specifically for the treatment of BPD. However, studies have shown some evidence 
that pharmacological treatments can improve some aspects of the clinical picture by 
helping to reduce specific BPD symptoms including anger, anxiety, depression, 
hostility and impulsivity (326, 356). Other BPD features, including chronic feelings of 
emptiness, identity disturbance, avoidance of abandonment, and dissociation were 
not found to be affected significantly by any medication (189, 326). The overall 
evidence for the efficacy of pharmacotherapy is weak and it is often based on single 
studies (357). The long-term use of these medications has not been studied and 
current evidence does not support the effectiveness of any drug on the overall 
severity of BPD symptomatology (358). There is no strong evidence from any 
credible RCTs that any one medication reduces overall BPD severity in the short or 
long term. As such, a consensus about drug indications in the treatment of BPD is 
lacking and further research is urgently needed to provide reliable recommendations 
(22, 84, 241, 244).  
 
Brief psychological interventions 
In recent years, the average length of psychiatric hospitalisations has decreased and, 
consequently, effective brief inpatient treatments (defined as low intensity 
interventions lasting less than six months (189)) for people with BPD are in greater 
demand (359). Additionally, the often high rates of premature discontinuation (67) - 
combined with the typically modest effects of longer-term interventions - raise the 
possibility that briefer treatments, delivered following crises or during times of an 
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individual’s heightened motivation to change, may prove to be more cost-effective 
than longer-term interventions or therapy for treating BPD (70, 231). There is some 
evidence that brief treatments for BPD may have the potential to facilitate 
meaningful change and increase the cost-effectiveness of treatment (70, 360). 
However, the effects of brief treatment on crisis management, early discontinuation 
from therapy and symptom reduction need to be further explored.  
 
Although it has been suggested that most brief treatments are poorly-suited to 
people with BPD (as such treatments typically favour highly motivated and well-
functioning participants), the aforementioned shift towards shorter inpatient 
admissions and increased community-based cared in the UK, as a result of resource 
constraints, dictates that effective short-term treatments need to be developed 
(314).  
 
Manual-assisted cognitive therapy 
Manual-assisted cognitive therapy (MACT) is a brief (up to six sessions), cognitively-
oriented and problem-focused therapy, developed originally as a public health 
intervention for individuals engaging in repeated self-harming behaviour (361). As 
such, whilst it was not developed specifically for use with individuals with a diagnosis 
of BPD, many people in this population meet the diagnostic criteria for BPD and this 
subpopulation is therefore similar to that for which other psychological interventions 
were developed (189). The intervention is a six-session, manualised therapy that 
targets deliberate self-harm, incorporating elements of other cognitive-based 
interventions for BPD, with the option of a further two ‘booster sessions’ within six 
 56 
months. The accompanying manual covers an evaluation of the specific self-harm 
attempt, crisis skills, problem solving, basic cognitive techniques to manage negative 
thinking, and relapse-prevention strategies (189).  
 
A pilot study published in 1999 (361) showed that MACT was associated with a 
reduction in depressive symptoms and an increase in positive future thinking in a 
small sample of participants with repeated self-harm when compared to those in the 
treatment as usual condition. The authors went on to conduct a large-scale multi-
centre randomised trial comparing MACT with treatment as usual in a sample of 480 
participants with histories of repeated self-harm (179, 180). Results of this trial 
indicated that brief MACT was of limited efficacy in reducing self-harm, but the 
findings - taken in conjunction with the economic evaluation (362) - indicated that 
MACT was superior to TAU in terms of cost and effectiveness combined (363). The 
results regarding overall quality of life, however, were inconclusive. A small pilot 
study examining the efficacy of MACT as a stand-alone treatment for BPD published 
in 2010 (231) showed that, although MACT was associated with a significant 
reduction in both suicidal ideation and BPD features, less than half of the sample 
completed the full treatment.  
 
Chapter 1.3. Borderline personality disorder and crisis management 
People with BPD are at an increased risk of experiencing crises - many of which may 
include suicidal or homicidal threats, gestures or actions (364). It has been suggested 
that the DSM-IV diagnostic criteria for BPD read like an operational definition of a 
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crisis state; these include ‘frantic efforts’, ‘a pattern of unstable and intense personal 
relationships’, ‘impulsivity’, ‘recurrent suicidal behaviour’, ‘affective instability’ and 
‘inappropriate intense anger’ (365). Factors commonly associated with the onset of a 
crisis for people with BPD include: a clear precipitating event causing acute anxiety 
and emotional suffering; an acute reduction in motivation and problem-solving 
ability; and an increase in help-seeking behaviour (366). People with BPD may 
present with a range of symptoms and behaviours, including behavioural 
disturbance, self-harm, impulsive aggression and short-lived psychotic symptoms, as 
well as with intense anxiety, depression and anger (189). Crises may be triggered by 
seemingly minor incidents or precipitated by threats of separation, fear of rejection, 
or expectations for which the person assumes responsibility (367). Several features 
associated with BPD are likely to increase the frequency of acute crisis events. These 
include:  
• Alienation from lasting and meaningful relationships; 
• Difficulty learning from previous experience;  
• Inability to utilise support systems such as family and friends;  
• A history of previously experienced crises that have not been effectively 
resolved; and 
• Impulsive personality traits associated with impulsive and sometimes reckless 
behaviour (368).  
Crises may be followed by social withdrawal, admission to hospital, self-harming 
behaviour, conflict in close relationships, or any combination of these. Goals of crisis 
interventions typically include returning the distressed individual to their pre-crisis 
level of functioning and mobilising both internal and external resources (365). The 
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2009 NICE guideline on the management of BPD (189) included a section on crisis 
management and, as shown in Table 1, this focused largely on empowering the 
individual.  
 
Table 1. NICE recommendations for managing crises with people with BPD.  
 
Crisis management strategies for people with BPD; adapted from NICE (189) 
• Assess the level of risk to self or others; 
• Ask about effective management strategies used in the past; 
• Help the individual to manage anxiety by enhancing coping strategies; 
• Encourage the individual to identify manageable changes that will enable 
them to deal with the current crisis; 
• Offer a follow-up appointment to monitor progress; 
• Consider referral to a CMHT if the levels of distress and/or the risk of harm to 
self or others are a cause for concern 
 
 
The guideline also recommended that short-term use of sedative medication during 
a crisis should be considered with caution and, if implemented, should not be 
prescribed for a period of longer than one week. An individual’s capacity to consent 
to any form of treatment - including short-term medication - during times of crisis 
must also be considered in such circumstances (189). While these pragmatic 
recommendations are intended to assist clinicians in formulating a sensible and 
realistic response to crises occurring for people with BPD, empirical research in this 
area is lacking and little is known about what constitutes effective help for people 
with BPD in crisis (364, 369). In fact, one recent meta-analysis of 36 crisis 
intervention studies (370) contained no mention of BPD (or any other personality 
disorder), focusing instead on individuals with depressive disorders, PTSD and 
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suicidal ideation. A Cochrane review of crisis interventions for people with BPD 
published in 2012 by Borschmann and colleagues (371) revealed that there had been 
no completed RCTs of crisis intervention from which any firm conclusions could be 
drawn (see 1.3.1. Systematic review of crisis interventions for BPD, below). One 
ongoing randomised controlled trial was identified in which participants with BPD 
were provided with access to a 24-hour emergency crisis telephone line for 12 
months or treatment as usual (372).  
 
In recent years, several uncontrolled studies have examined the efficacy of various 
crisis interventions for people with BPD. In 2005, McQuillan and colleagues (373) 
examined the effectiveness of an intensive three-week version of DBT for 127 
outpatients with BPD who were in crisis. Although the trial was not controlled and 
participants were not randomly allocated to the intervention arm, results showed 
that treatment completion was high and participants showed statistically significant 
improvements in both depression and hopelessness measures. Importantly, the 
authors also stated that this particular approach allowed therapists to treat a large 
number of people in a relatively short period of time (373). 
 
In 2011, Berrino and colleagues (369) conducted a study to determine the efficacy of 
crisis intervention at a general hospital following self-harm (a common behavioural 
correlate of crises in BPD) in a sample of individuals meeting DSM-IV-TR criteria for 
BPD. Two hundred individuals presenting to an emergency department following 
self-harm were allocated to either TAU or crisis intervention and followed up after 
three months. The results showed that the rates of both repeated self-harm and 
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inpatient admissions were significantly lower in the intervention group than the TAU 
group. The authors concluded that crisis intervention may be a suitable management 
strategy for acutely suicidal people with BPD (369). However, this study was limited 
by its naturalistic and non-randomised design, preventing any reliable inferences 
being made about the comparative efficacy of the crisis intervention model tested.  
 
In 2011, Linehan and colleagues (374) conducted a pilot study to examine the 
feasibility of a DBT software application (or ‘app’) for a smartphone, designed to 
enhance generalisation of a specific DBT skill amongst people with BPD and a co-
morbid substance use disorder. One of the main attractions of such an app is that it 
is available to the person 24 hours a day. The results of the pilot study indicated that, 
although the smartphone app was not designed to replace the function or role of the 
individual therapist, such technology may be beneficial as an adjunct to standard 
DBT.  
 
Short-term medications, such as sedatives, are used frequently in clinical practice to 
manage crises, even though there is no evidence for the use of any specific 
medication(s) in crisis management (189). In his 2011 article about the process of 
managing medication for people with BPD, Silk (328) recommended that, during 
acute crises, it is advisable not to commence or change medications whenever 
possible. He went on to state that crises, by their very nature, come and go; as such, 
the best approach is to encourage the individual to use skills or other behavioural 





1.3.1. Systematic review of crisis interventions for BPD 
Objective 
A systematic review was conducted to assess the evidence for the effectiveness of 
crisis interventions for adults with BPD in any setting. For the purposes of the review, 
a crisis intervention was defined as ’an immediate response by one or more 
individuals to the acute distress experienced by another individual, which is designed 
to ensure safety and recovery and lasts no longer than one month’ (371).  
 
Search methods 
RB searched the following databases in September 2011: CENTRAL (The Cochrane 
Library 2011, Issue 3), MEDLINE (1948 to August Week 5 2011), MEDLINE In Process 
& Other Non-indexed Citations (8 September 2011), EMBASE (1980 to Week 36 
2011), PsycINFO (1806 to September Week 1 2011), CINAHL (1937 to current), Social 
Services Abstracts (1979 to current), Social Care Online (12 September 2011), 
Science Citation Index (1970 to current), Social Science Citation Index (1970 to 
current), Conference Proceedings Citation Index - Science (1990 to current), 
Conference Proceedings Citation Index - Social Science and Humanities (1990 to 
current) and ZETOC Conference proceedings (12 September 2011). RB searched for 
dissertations in WorldCat (12 September 2011), Australasian Digital Theses Program 
(ADTP; 12 September 2011), Networked Digital Library of Theses and Dissertations 
(NDLTD), 12 September 2011 and Theses Canada Portal (12 September 2011). RB 
also searched for trials in the International Clinical Trials Registry Platform (ICTRP).  
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RB scrutinised the reference lists of published review articles in the area to locate 
additional relevant publications not already identified by the database searches. He 
then searched the complete archives of the six journals returning the largest number 
of relevant citations (American Journal of Psychiatry, Archives of General Psychiatry, 
British Journal of Psychiatry, Journal of Clinical Psychiatry, Psychological Medicine 
and the Journal of Personality Disorders). Finally, RB contacted the ten most 
published researchers in the field of BPD (as indexed by BioMed Experts; 
www.biomedexperts.com), in addition to contacting topic experts Marsha Linehan, 
Arnoud Arntz and Paul Links about ongoing trials and unpublished data.  
 
Search terms 
Databases were searched using variants of the terms ‘borderline personality 
disorder’ AND ‘crisis’ AND ‘randomised controlled trial’ (for a full list of search terms, 
see Appendix 1).  
 
Results 
A total of 3118 articles were identified via the online database search and a further 
16 articles were located from other sources. After duplicates were removed, there 
were 1958 unique articles. The titles and abstracts of these 1958 were screened by 
two authors (RB and JH) and assessed against the inclusion criteria; 1943 were 
excluded as a result of clearly not being of relevance to the review topic. The full 
texts of the 15 articles that seemed likely to meet the inclusion criteria (or where this 
was unclear) were retrieved and read independently by RB and JH, after which 13 
were excluded. Reasons for exclusion were: lack of randomisation [N=8; (58, 369, 
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373, 375-379)], retrospective design [N=2; (380, 381)], or the intervention was a 
complex psychological therapy lasting longer than one month [N = 3; (284, 382, 
383)]. In addition to the present trial, one ongoing RCT that met the inclusion criteria 
was identified (372) with a predicted sample size of 600; this article was published in 
French and was translated in full by a native speaker.  
 
Conclusion from the systematic review 
A review of the literature did not identify any completed RCTs of crisis intervention 
compared with usual care or no intervention or a waiting list control for people with 
BPD. As such, it can be concluded that there is no evidence base to support any 
specific crisis intervention for people with BPD. In order to develop effective, 
evidence-based interventions, there is an urgent need for high-quality RCTs.  
 
1.3.2. Summary of BPD and remaining areas of uncertainty 
BPD is a chronic mental disorder marked by interpersonal difficulties and an unstable 
self-image. It is associated with high volumes of service use, frequent crises, self-
harming behaviour and considerable distress. Longer-term interventions such as DBT 
and MBT appear to be promising and effective treatments for BPD (as reflected by 
the growing literature supporting their effectiveness) and, at the time of writing, DBT 
represents the optimal treatment for women with BPD, particularly where one focus 
of treatment is self-harm reduction (255, 256, 278, 321). However, several major 
criticisms have been levelled at both DBT and MBT, including that each of these 
treatments requires 1) a minimum of three to six months to produce a significant 
reduction in self-harming behaviour; 2) individual, group and, sometimes, additional 
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treatment modalities, and 3) expensive training of therapists (384). Also, service 
users in many geographical areas have limited access to such complex interventions; 
in the UK, the major limiting factor in providing access to psychological therapies is 
the very small proportion of National Health Service (NHS) staff members trained to 
deliver these to a competent standard (189, 385). Less complex and more affordable 
brief interventions are therefore urgently needed for the large proportion of people 
with BPD who are not referred to specialist services (386) and, as such, the prospect 
of finding a briefer and less expensive treatment offers considerable public health 
advantages (387). Additionally, investigation of the effectiveness of interventions 
designed to manage acute crises in people with BPD is both a clinical and an 
economic priority, as it may contribute to a reduction in suicide-related mortality, an 
improvement in the quality of life of people with BPD and a reduction in acute health 
services use and costs (364, 371).  
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Chapter 1.4.  Self-harm 
1.4.1.  Definition and terminology 
There is much debate about what constitutes self-harm and inconsistencies are 
evident in the literature. Although no universally recognised criteria exist regarding 
the definition of self-harm, the term refers typically to a person intentionally 
engaging in one or more behaviours which cause damage, mutilation or destruction 
of bodily tissue without suicidal intent and with a non-fatal outcome (251). The 2011 
NICE guideline for the longer-term management of self-harm (388) stated that self-
harm could be divided into two broad groups: self-poisoning and self-injury. Self-
poisoning includes intentionally overdosing on licit or illicit substances. Self-injury 
includes such behaviours as cutting, bruising or biting skin, burning, scalding or 
picking/scratching skin, head-banging, hair pulling, swallowing objects or any 
combination of these (389, 390). It has been suggested that there is a spectrum of 
self-harming behaviours, with relatively minor acts intended to manage or 
communicate distress at one end and definite suicide attempts which are 
unsuccessful at the opposite end (32).  
 
Numerous phrases are used interchangeably with the term ‘self-harm’ in the 
literature (391-393); these include ‘self-mutilation’, ‘self-injury’, ‘deliberate self-
harm’ (DSH), ‘suicidal behaviour’, ‘non-suicidal self-injury (NSSI)’, ‘non-fatal 
deliberate self-harm’, ‘self-poisoning’, ‘self-injurious behaviour’, ‘self-inflicted 
violence’, ‘self-wounding’, ‘non-fatal suicidal behaviour’ and ‘parasuicide’. In this 
dissertation, the term ‘self-harm’ will be used to refer to all behaviours captured by 
the above definition.  
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Self-harm is a significant problem, across the lifespan, for people engaging in such 
behaviour, their families, health services and the wider community (251, 394). It has 
appeared throughout recorded history but, as a result of increased prevalence in 
recent decades, there has been growing interest from scientists, clinicians and the 
public (393). Indeed, self-harm is documented as a global health problem and it is 
among the leading causes of death and injury worldwide (395). Self-harm is one of 
the strongest predictors of completed suicide (392, 396) and people who self-harm 
are at significantly increased risk of premature death than the general population 
(397, 398). It is perhaps not surprising, therefore, that a reduction in self-harm is part 
of the Health For All targets of the World Health Organisation (WHO) (399).  
 
In May 2013, DSM-5 introduced the diagnostic category of ‘non-suicidal self-injury 
(NSSI)’ – a disorder of uncertain nosological status which DSM-5 recommends is the 
subject of future research (400-404). The term itself is controversial and has been 
criticised widely by European researchers (402) for a number of reasons. Firstly, NSSI 
refers to tissue damage and, therefore, repeated self-poisoning is excluded 
(somewhat arbitrarily). Secondly, suicidal intent is both difficult to measure reliably 
(405) and changeable between people and between episodes. Finally, people who 
self-harm repeatedly typically do so for multiple reasons (405) (see 1.4.6. Functions 
of self-harm, below).  
 
Research over recent decades has helped to define self-harm as a health-related 
behaviour and not merely a sign of an underlying clinical disorder (406). This 
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behaviour can occur within the context of a broad range of personal and social 
circumstances (407, 408). A range of people engage in self-harm, including those 
with and without mental illness, those with substance misuse issues, physical 
illnesses and psychosocial difficulties (409).  
 
1.4.2.  Epidemiology 
Self-harm is rare before puberty and becomes more common throughout early 
adolescence (410), with the first episode of self-harm occurring most commonly 
between the ages of 12 and 16 (392, 393). Although some self-harming behaviour 
occurs in a transient period of distress and is associated with no further risk, self-
harm is often an important indicator of mental health problems and of an increased 
risk of suicide (411). A recent Australian longitudinal cohort study reported that, 
whilst most adolescent self-harming behaviour resolved by young adulthood, 
adolescent symptoms of depression and anxiety (which may persist) were 
significantly associated with self-harming behaviour in young adulthood (199).  
 
Self-harm occurs in both clinical and nonclinical populations. In the general 
population it has been reported that approximately four percent of adults (412), 13-
45 percent of adolescents (413-415) and 14-35 percent of college students (416-418) 
have a recent history of self-harm. It is more common in women than men, amongst 
gay and bisexual people (392, 419) and in certain subcultures such as ‘goths’ (32, 
420). An elevated incidence of self-harm has also been reported in people with 
depression (421). It is particularly common among young people, a group in whom 
rates of repetitive and medically serious self-harm appear to be rising (199, 422-
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426). Some differences in the nature and presentation of self-harm across 
ethnicities, in addition to differences in the methods most commonly used, have also 
been reported (427).  
 
Approximately one third of people attending an emergency department after an 
episode of self-harm will be given a psychiatric diagnosis (usually depression) and 
about one third will have had previous contact with psychiatric services (428). 
Despite a common misconception, the majority of people who engage in self-
harming behaviour do not meet diagnostic criteria for BPD. Haw and colleagues 
(407) reported that less than half of their sample of people who had self-harmed (46 
percent) met the criteria for any personality disorder (and only 11 percent met the 
criteria for BPD), whilst affective disorders were identified in 72 percent of the 
sample. Most individuals with BPD, however, do engage in self-harming behaviour 
(429).  
 
1.4.3. Risk factors associated with self-harm 
There are many risk and protective factors associated with self-harming behaviours 
which may be related to personal, social or contextual factors (392, 428, 430-432). 




Table 2. Risk and protective factors for self-harm (adapted from Skegg, 2005 (392)).  
 
Broad variable Risk factors Protective factors 
Demographic profile Adolescent  
 Female gender  
 Low socioeconomic status  
 Low level of education  
 Living in poverty  
 Unemployed  
 Divorced / separated  
 Homosexual / bisexual   
 Criminal record  
   
Social environment Adverse childhood 
experiences 
Social support and family 
activities 
 Interpersonal difficulties in Religious affiliation 
 adolescence Cultural norms 
   
Psychiatric disorders Depression Lithium for people with 
bipolar disorder 
 Substance abuse  
 Anxiety disorder  
 Personality disorder  
 Previous psychiatric 
hospitalisation  
 
   
Psychological 
characteristics 
Impulsivity / poor problem-
solving skills 
Optimistic outlook 
 Hopelessness  
 High suicidal intent  
   
Situational factors Adverse life events  
 Media influence  
 Awareness of self-harm in 
others 
 
 Intoxication  
   
Physical illness Epilepsy  





Various forms of abuse have been studied in relation to self-harm, with mixed 
findings. In 2011, Maniglio and colleagues published a review of four previous meta-
analyses of 177 published studies (involving a total of 65,851 participants) 
investigating the relationship between childhood sexual abuse and subsequent self-
harming behaviour (433). The authors concluded that childhood sexual abuse should 
be considered one of the major risk factors for both self-harming behaviour and 
completed suicide, stating that it may interact with personality traits and psychiatric 
disorders to contribute to such behaviours in people with a history of abuse.  
 
As well as sexual abuse, bullying victimisation has emerged recently as a strong 
candidate risk factor for self-harm (434). Findings from a longitudinal study of a 
nationally representative cohort of 1116 pairs of twins in the UK, published in the 
BMJ in 2012, revealed that exposure to frequent childhood bullying was predictive of 
significantly higher rates of self-harm, even after controlling for emotional, 
behavioural and interpersonal variables (434). The authors concluded that greater 
effort needs to be invested in helping bullied children to cope more appropriately 
with the distress resulting from bullying if the rates of self-harm in young people are 
to be reduced (434).  
 
 
1.4.3.  Economic costs 
Self-harm is a major source of public health costs, as it often results in presentations 
to the emergency department and subsequent psychiatric admissions (435). In the 
UK, self-harm is one of the five most common reasons for acute admission to 
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hospital (388, 436), with 200,000 hospital admissions annually resulting from self-
harm (437), 40-50 percent of which are repeat episodes (438). Ninety percent of 
these admissions involve overdosing on licit or illicit substances (439), accounting for 
14 percent of all medical admissions (440). Approximately 15 percent of individuals 
presenting at an emergency department following self-harm will present again 
within 12 months, adding further to healthcare costs (441). The wider indirect costs 
of self-harm are unknown; however, given its prevalence, they are likely to be 
substantial, particularly in terms of days absent from work and education (391).  
 
1.4.4.  Association with suicide 
Self-harm is strongly associated with psychosocial distress, repetition of self-harm 
and subsequent completed suicide (442-445). The risk of suicide is at its highest in 
the first six months after an episode of self-harm and, by its nature, self-harm is also 
associated with an increased risk of accidental death by misadventure or permanent 
disability (388, 392). For every completed suicide in the UK, it is estimated that 30 
acts of self-harm take place (446). Following an act of self-harm, the rate of suicide 
increases to between 50 and 100 times the rate of suicide observed in the general 
population (422, 444). Approximately one percent of individuals presenting to 
emergency departments following self-harm complete suicide within a year. This 
figure rises to approximately four percent within ten years, nine percent within 22 
years and 10 percent across the lifespan (399, 447). Foster and colleagues (448) 
reported that between 28 percent and 41 percent of individuals who have engaged 
in self-harm have had prior suicidal ideation, with between 55 and 85 percent having 
made a previous suicide attempt. Approximately half of all people who commit 
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suicide have a history of self-harm, with approximately 20-25 percent having had an 
episode within the preceding year (399). Approximately one million people each year 
die by suicide worldwide and this figure is predicted to increase to an estimated 1.5 
million by 2020 (449).  
 
1.4.5.  Clinicians’ attitudes towards self-harm 
People who self-harm are often viewed in a negative light by healthcare staff in 
emergency hospital and psychiatric settings. Research suggests that healthcare staff 
may feel unskilled, unconfident and anxious when providing care to people who self-
harm (428, 440, 450-453). Service users frequently describe contact with health 
services as difficult and characterised by negative attitudes, ignorance and even 
punitive behaviour by health professionals (391). In addition, emergency 
practitioners report that they do not always have sufficient time or resources to 
provide appropriate care for people presenting with self-inflicted injuries, leading to 
feelings of frustration towards these individuals (454). Many emergency staff also 
believe that their function as healthcare professionals is to provide care for ‘the 
deserving sick’ and such a belief may cause them to deal with people who have self-
harmed in a more judgemental manner (453). A previous NICE guideline regarding 
the treatment and management of self-harm (391) acknowledged that the 
experience of care for people who self-harm is often unacceptable and contained 
recommendations about how staff members should relate to them. These included: 
1) treating people who have self-harmed with the same care, respect and privacy as 
any patient; 2) offering them a choice of male or female staff members (when 
possible); 3) involving people who have self-harmed in all discussions and decision-
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making about their treatment and subsequent care; and 4) asking people who have 
self-harmed to explain their feelings and their understanding of their self-harm in 
their own words (391).  
 
1.4.6.  Functions of self-harm 
The functions of self-harm are numerous and varied and may be related to the 
individual, to the outside world, or to both (32, 389, 392, 430, 455-463) (see Table 3). 
For many people, self-harm is an habitual coping mechanism and there is some 
evidence that these behaviours can continue even after personal problems have 
been resolved (464, 465). Other individuals use an act of self-harm as a form of 
‘trigger’ for seeking help in the absence of more constructive coping strategies (466).  
 
Table 3. Functions of self-harm reported in the literature.  
Functions of self-harm.  
• To punish oneself; 
• To express anger;  
• To elicit a caring response from, or to manipulate, others; 
• To avoid an even greater subjective harm (such as confronting the 
unbearable reality of one’s inner experience); 
• To relieve tension;  
• To restore balance; 
• To regulate emotion; 
• To distract oneself from an intolerable situation;  
• To assert one’s autonomy or establish a boundary between self and 
other; 
• To generate excitement.  
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Furthermore, people often report more than one motivation for self-harming and 
different forms of self-harm can serve different functions (392). For example, whilst 
taking an overdose often provides an escape from a difficult situation, cutting 
oneself may regulate dysphoric affect (467). Rodham and colleagues (468) reported 
that people who cut themselves think about self-harming for a shorter period than 
people who poison themselves before initiating the behaviour. They suggested that 
taking an overdose requires more time and planning than cutting and, as such, may 
indicate more serious intent and be more likely to require medical attention (468). 
Recent research by Hawton and colleagues (469) has also suggested that different 
forms of self-harm place people at different levels of risk for subsequent completed 
suicide, with methods classified as ‘more dangerous’ (e.g. self-cutting or road traffic-
related behaviours) posing a greater risk than self-poisoning. Some researchers have 
advocated creating a distinction between direct and indirect forms of self-harm (470) 
and creating subtypes of BPD on the basis of different self-harming behaviours (471). 
The precipitants of self-harm are extremely wide-ranging (472-474), though common 
problems preceding self-harm include relationship difficulties, wider social problems 
and alcohol or drug misuse (32, 475, 476).  
 
1.4.7.  Measurement issues 
Due in part to the multi-factorial nature of self-harm (477), measuring the behaviour 
accurately is difficult and much doubt has been raised about current methods of 
assessment (405, 478). At the time of writing, a versatile, easily applied ‘gold 
standard’ measure of self-harm does not exist (405, 479-481). Much of the published 
literature on the treatment of self-harm is therefore populated by studies which 
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have used un-validated measures (405). Additionally, individual items measuring 
self-harming behaviour can be found in many instruments designed for the 
assessment of broader psychopathology, developmental disorders and personality 
trait measures (482). In their 2011 systematic review of instruments to measure self-
harm in adults, Borschmann and colleagues (405) suggested that, as with the 
measurement of violent behaviour, the most reliable way of capturing episodes of 
self-harm may be to triangulate multiple data sources including self-reported 
measures, clinician/observer reported measures, case records and possibly 
contemporaneous patient-held devices such as diaries and counters. The advantage 
of such an approach is that combining multiple sources of information allows for a 
more comprehensive measure of behaviour to be constructed (482, 483). The 
disadvantage is that such an approach is time-consuming and practical constraints 
limit the number of data sources that can be used in any single study.  
 
Despite the aforementioned challenges, several instruments which purport to 
accurately capture self-harm events in a range of contexts and populations have 
been validated and published, with each possessing certain advantages and 
disadvantages (405, 484). These instruments include the Self-Harm Inventory (485), 
the Deliberate Self-Harm Inventory (417), the Self-Harm Behavior Questionnaire 
(479), the Suicide Attempt Self-Injury Interview (486), the Self-Injury Questionnaire 
(481), the Self-Injurious Thoughts and Behaviors Interview (480), the Self-Harm 
Information Form (487), the Inventory of Statements About Self-Injury (488), the 
Self-Harm Questionnaire (SHQ) (489) and Hawton’s self-report measure of self-
harming behaviours (424). Selection of the most appropriate instrument depends on 
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the client group, the method of administration required, the assessment setting and 
the time and resources available to complete the assessment. Irrespective of the 
instrument(s) used, the next step of measurement - predicting future acts of self-
harm - has thus far proven difficult, with research suggesting that severity of 
previous self-harm acts and overall BPD symptomatology are the two most accurate 
predictors of future self-harm (490).  
 
1.4.8.  Management and prevention of self-harm repetition 
Despite the scope and significance of the problems associated with self-harm, there 
are currently no evidence-based psychological or pharmacological treatments to 
reduce such behaviours (393). However, many interventions and guidelines for 
managing and preventing self-harm have been proposed (388, 399, 447). The 
common goals of such interventions typically include reducing repetition of self-
harm, reducing the desire to self-harm, preventing suicide and improving social 
functioning and quality of life, whilst exerting minimal adverse effects (491). The 
2011 NICE guideline on the management and prevention of self-harm (388) included 
key aims and objectives in the treatment of a person who has self-harmed. These are 




Table 4. NICE guideline aims and objectives in the treatment of self-harm.  
Aims and objectives: 
• Prompt assessment of physical and psychological needs; 
• Effective engagement of the individual; 
• Prompt measures to minimise pain and discomfort; 
• Implementation of harm reduction strategies; 
• Prompt and supportive psychosocial assessment (including a risk 
assessment); 
• Provision of information about the long-term treatment, management 
and risks associated with self-harm;  
• Provision of six sessions of a psychological intervention specifically 
structured for people who self-harm with the specific aim of reducing 
self-harm; this intervention may include cognitive-behavioural, 
psychodynamic or problem-solving elements;  
• Psychological, pharmacological and psychosocial interventions for any 
associated conditions (including BPD, depression, bipolar disorder or 
schizophrenia);  
• Prompt referral for further psychological, social and psychiatric 
assessment and treatment when necessary.  
 
The NICE guideline also recommended developing an integrated and planned 
approach to the problems precipitating self-harming behaviour. This includes the 
development of a care plan and a risk management plan in conjunction with the 
individual, their family, carers or significant others, with printed copies provided for 
the individual and other key healthcare professionals.  
 
There is currently little convincing evidence for the efficacy of many interventions to 
reduce self-harm (399). Furthermore, recent studies have suggested that different 
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amounts of assistance are offered to individuals presenting at emergency 
departments with injuries resulting from different forms of self-harm. For example, 
hospital services tend to offer less help to people who have cut themselves - even 
though they are far more likely to repeat - than to those who have self-poisoned 
(492). In 1997, Lewis and colleagues (493) suggested that additional interventions 
following an episode of self-harm might reduce the rate of subsequent suicide by as 
much as 25 percent. However, a systematic review of psychosocial interventions 
following self-harm conducted in 2007 by Crawford and colleagues (447) found little 
evidence to support this contention. One major obstacle to any successful 
prevention of self-harming behaviour is the tendency of almost half of all people 
presenting to emergency departments following self-harm fail to attend subsequent 
follow-up appointments (494). Consequently, it has been recommended that any 
attendance to an emergency department following self-harm should result in a 
psychosocial assessment of needs, regardless of the method of self-harm used (492).  
 
Effective interventions for managing and preventing self-harm must also take into 
account the subjective goals of the person engaging in self-harm, as these may vary 
considerably between individuals (495). For example, whilst one person’s goal might 
be to permanently stop self-harming, recover from any underlying psychiatric 
disorder and achieve a good quality of life, another person’s goal might be simply to 
reduce the frequency of self-harm or perhaps to reduce the harm associated with 
each act of self-harm (388). For others, the goal might be to improve social or 
occupational functioning. As such, interventions aimed at reducing the repetition of 
self-harm may focus on the actual behaviours themselves, or they may take a more 
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holistic approach by examining the individual’s close relationships, cognitions and 
social factors (388). After a qualitative exploration of service users’ views of 
treatment interventions for self-harm, Hume and colleagues (495) reported that 
there was a clear preference amongst service users for specialist community-based 
interventions focussing on the provision of immediate aftercare following self-harm, 
whilst simultaneously acknowledging that the management of self-harm may not 
necessarily involve its prevention.  
 
Interventions can be divided into three main categories; psychological interventions, 
psychosocial interventions and pharmacological interventions. A brief summary of 
each is below.  
 
1.4.8.1.  Psychological interventions 
As stated above, self-harm is a heterogeneous set of behaviours which can have 
different meanings and purposes for different people in different contexts (388). 
Self-harm is associated with a wide variety of psychiatric diagnoses and psychological 
problems and, as such, psychological interventions need to take account of this 
complexity. One key aim of many psychological interventions of self-harm is to 
increase understanding of the specific contributing factors in each individual (388). 
The rationale for this type of intervention is that an estimated 70 percent of self-
harm episodes are precipitated by a personal problem (496). Psychological therapies, 
therefore, are often aimed at improving social functioning as well as reducing self-
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harming behaviour (391, 497). Many different psychological interventions have been 
investigated in relation to self-harm, as outlined below.  
 
Dialectical Behaviour Therapy (DBT) 
DBT, discussed at length in section 1.2.2. Psychological therapy programmes above, 
was developed for use with individuals with chronic suicidality and the first goal of 
DBT is to reduce or eradicate the repetition of self-harming behaviour (254). DBT is 
the psychological intervention with the strongest evidence base for its effectiveness 
in reducing repetition of both self-harm and suicide attempts (47, 243, 251, 257, 
259, 388, 467, 498-500).  
 
Mentalization-Based Treatment (MBT) 
MBT is discussed at length in section 1.2.2. Psychological therapy programmes 
above and there is a limited evidence base for its effectiveness in reducing self-harm 
behaviour. Findings from a recent RCT comparing MBT with structured clinical 
management (284) showed that participants in the MBT group displayed a steeper 
decline of suicide attempts and hospitalisation (among other clinically significant 
problems) than participants in the structured care group. It was noted, however, 
that participants in both groups showed substantial improvement over the course of 
the trial.  
 
Cognitive Behaviour Therapy (CBT) 
CBT is discussed at length in relation to BPD in section 1.2.3. Individual psychological 
therapies above. There is some evidence that it can contribute to a reduction in self-
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harm in adults (294, 501) but not in adolescents (502). A 2008 systematic review and 
meta-analysis examining the effectiveness of cognitive-behavioural interventions to 
reduce suicidal behaviour (502) found strong evidence to support the hypothesis 
that CBT can reduce suicide behaviour in the short-term. The authors acknowledged, 
however, that a publication bias (i.e., whereby non-significant results did not get 
published, subsequently biasing the available data in favour of treatment effects) 
may have contributed to this finding.  
 
Randomised controlled trials of CBT treatments have yielded mixed results. In an RCT 
of brief CBT versus TAU in recurrent deliberate self-harm (the POPMACT study) 
(363), 480 self-harming participants were randomised to receive either TAU or a 
CBT-based intervention (manual-assisted cognitive therapy) in addition to TAU and 
followed up after 12 months. Results showed that there was no significant difference 
in the proportion of those repeating self-harm at follow-up between participants in 
the intervention group and those in the control group. The intervention was shown 
to be cost-effective when compared to treatment as usual after six months, although 
this difference was no longer significant after 12 months (363).  
 
In another RCT published in 2006 (the BOSCOT trial) (69), 106 people with BPD were 
randomised to receive TAU alone or CBT plus TAU for 12 months and were followed 
up at 12 and 24 months. The results showed that there was a significant reduction in 
self-harm reported by participants in the intervention group, leading the authors to 
conclude that CBT can produce worthwhile and clinically important changes in self-
harm behaviours. It is noted, however, that whilst the BOSCOT trial was focused on 
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the treatment of BPD, the POPMACT trial was focused on treating self-harm 
behaviour and the two trial samples may have differed considerably from each other 
as a result.  
 
Summary of psychological interventions 
Both DBT and MBT have been shown to be effective in reducing the incidence of self-
harm and suicide attempts (467) in people with BPD. There is also some evidence 
that CBT may be effective in reducing self-harm in people with BPD. At the time of 
writing, DBT remains the psychological intervention with the strongest evidence 
base (47, 243, 259, 467, 500).  
 
1.4.8.2.  Psychosocial interventions 
Many different psychosocial interventions to manage and reduce repetition of self-
harm have been proposed and tested, although many of these trials have not 
included a sufficient number of participants on which to base firm recommendations 
(388, 399). Large definitive trials of interventions showing promise are needed to 
provide robust evidence (399). One goal of many psychosocial interventions is to 
improve contact and engagement with health services following presentation to an 
emergency department. This is important because adherence to outpatient 
treatment programmes after an episode of self-harm is typically poor (391). 
 
In 1993, Morgan and colleagues (494) conducted an RCT randomising a sample of 
212 people who had self-harmed for the first time to either the experimental group 
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(n = 111) or the control group (n = 101). The experimental group received a “green 
card”, which contained the contact details of a trainee psychiatrist who was available 
24 hours a day via telephone if the participant experienced any further problems 
over the following 12-month period. The green card encouraged participants to seek 
help by contacting this number at an early stage, so long as no self-harm had already 
occurred on that occasion. No significant differences were observed in the reduction 
of self-harm between participants in the experimental group and those in the control 
group at one-year follow-up. Participants in the control group used more health 
services than those in the experimental group, although this difference did not reach 
statistical significance (494).  
 
In 2005, Carter and colleagues (503) conducted an RCT designed to reduce the rate 
of repetition of hospital-treated deliberate self-poisoning. A total of 772 people 
referred from a hospital emergency department in Australia were included in the 
study; 378 in the intervention group and 394 in the control group. Participants in the 
intervention group were sent eight postcards over a one-year period following their 
presentation, while the control group received standard care. Results at one-year 
follow-up showed that no significant differences were observed in the number of 
participants who had one or more repeat episodes of deliberate self-poisoning in the 
intervention group compared to those in the control group (503). However, the total 
number of repeat episodes per individual was significantly lower in the intervention 
group than the control group, as was the total number of days spent in hospital. This 
low-cost intervention (approximately $AU15 per participant for stationary and 
postage) appeared to have substantial cost effectiveness, in light of the economic 
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implications of a large reduction in service use. In 2013, a five-year follow-up of this 
study indicated that the postcard intervention was associated with a 50 percent 
reduction in self-poisoning events and a one-third reduction in psychiatric 
admissions after five years (504). The authors noted that this translated into 
substantial savings in general hospital and psychiatric hospital bed days.  
 
Other studies have also shown promising results for the use of a postcard 
intervention to reduce self-harming behaviour (505), whilst others have shown no 
effect (506). Many other psychosocial interventions have been examined in various 
trials (388, 399, 507, 508) and other low-cost interventions, including the prospect of 
a text message-based intervention to reduce self-harm (509), have also been raised 
in the literature as potential avenues to explore. However, the majority of 
completed trials have yielded insufficient evidence to determine clinically 
meaningful differences between interventions and standard care in the reduction of 
the proportion of participants who repeated self-harm (388). Considerable 
uncertainty therefore remains about which psychosocial interventions are the most 
effective for this population (399). In a pilot RCT from 2013 of a psychosocial 
intervention (which included information leaflets and a combination of phone calls 
and letters over a period of 12 months) after presenting to a hospital after an 
episode of self-harm, Kapur and colleagues (510) reported that a significantly higher 
proportion of participants who received the intervention self-harmed during the 
follow-up period when compared with participants in the control condition.  
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1.4.8.3.  Pharmacological interventions 
At the time of writing, no pharmacological interventions have clearly demonstrated a 
significant benefit in reducing rates of recurrent self-harm (491). The frequent use of 
pharmacological interventions for people who self-harm stems from the link 
between mental illness and self-harming behaviour; that is, although medications do 
not play a direct role in the management of self-harm per se, they play a 
considerable role in the management of associated conditions. Additionally, other 
co-existing physical conditions that may increase the risk of self-harm - such as 
chronic pain - may also lend themselves to pharmacological intervention(s). 
However, robust evidence for the efficacy of any pharmacological intervention to 
reduce self-harm is lacking (388). A retrospective study by Donovan and colleagues 
(511) compared the risk of self-harm by any method in 2776 individuals who had 
been prescribed either tricyclic antidepressants (TCAs) or SSRIs. Their results showed 
that significantly more self-harm events occurred following the prescription of SSRIs 
than TCAs, though the authors acknowledged that it is difficult to attribute the cause 
of such acts to any antidepressant medication in light of the complex clinical picture 
surrounding self-harm. The main limitation of the majority of such studies is that, as 
with the studies of psychosocial interventions discussed above, they have typically 
included far too few participants to detect clinically meaningful differences in rates 
of repetition of self-harm between the intervention and control groups (512). Larger 
trials, adequately powered to detect such differences, are therefore needed as a 
matter of urgency.  
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1.4.9.  Association with borderline personality disorder 
The fifth DSM criterion for BPD - “recurrent suicidal threats, gestures, or behaviours 
or self-mutilative behaviours” - is central to the borderline construct (390). Due to 
the very nature of the disorder, people with BPD are at an increased and ongoing 
risk of crises and self-harming behaviours (50, 278, 513). Within BPD populations, 
self-harm is a common - though often dangerous - coping strategy used by people in 
distress and who are unable to utilise more constructive strategies to manage this 
distress (443). Multiple suicide attempts and acts of self-harm are common in people 
with BPD and self-harm has been described as the ‘behavioural specialty’ of people 
with BPD (390, 514).  
 
Naturalistic follow-up studies extending up to 27 years of people with BPD have 
reported that the overall suicide rate for this group is approximately ten percent 
(221). Long-term follow-up studies suggest that between three and 13 percent of 
those diagnosed with BPD go on to commit suicide (256, 429, 515) and, furthermore, 
that people with BPD account for between nine and 33 percent of all suicides (516). 
Recent research has produced more conservative figures, with one prospective six-
year follow-up study in 2010 reporting two deaths by suicide from their sample of 
106 people with BPD (1.9%) at follow-up (295). Predicting suicide in people with BPD 
is extremely challenging, not least because whilst self-harm is common in people 
with BPD, suicide is a comparatively rare event. Factors associated with completed 
suicide include co-occurring disorders, co-occurring symptoms of BPD (self-harm, 
affective reactivity and dissociation), adversity during adulthood and a family history 
of completed suicide (517). Further complicating the situation is the fact that people 
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with BPD are often excluded from clinical trials due to perceived risk (518). Cross-
sectional studies have reported that childhood adversity, including bullying, sexual 
abuse and emotional neglect, is significantly associated with self-harm in individuals 
with BPD (430, 434, 519-522).  
 
In light of the association between BPD and suicide, it is perhaps not surprising that 
people with BPD represent the greatest risk of suicide of any of the personality 
disorders recognised in the DSM (215). It has also been reported that, due to the 
frequency of suicidal crises observed in both inpatients and outpatients with BPD, 
clinicians may underestimate the seriousness of people’s intent to die (523, 524).  
 
1.4.10.  Summary of self-harm and remaining areas of uncertainty 
Self-harm is a significant problem across the lifespan and is the leading predictor of 
suicide, contributing to substantial public health costs. Many psychological, 
psychosocial and pharmacological interventions have been investigated in clinical 
trials which might reduce self-harming behaviour. However, due in part to the small 
numbers of participants included in many of the trials, there remains considerable 
doubt about which interventions are effective in reducing subsequent self-harming 
behaviour and/or suicide attempts (399, 512). At present, DBT (followed by MBT) 
appears to be the most effective psychological intervention for reducing self-harm 
among people with BPD. House and colleagues (428) recommended that future trials 
should be large enough to determine whether the intervention being tested reduces 
repetition of self-harm, whilst simultaneously examining other relevant outcomes 
such as levels of service use, quality of life, mood, social functioning and 
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interpersonal difficulties. Such large trials of substantial duration are required to 
provide definitive answers about which interventions are effective for which people, 




Chapter 1.5.  Joint crisis plans 
1.5.1. Introduction to shared decision-making 
Shared decision-making in healthcare refers generally to clinician(s) and service users 
working together to agree on the most appropriate treatment(s) for the service user. 
In 1997, Charles and colleagues (525) succinctly defined shared decision-making as 
“a mechanism to decrease the informational and power asymmetry between 
doctors and patients by increasing patients’ information, sense of autonomy and/or 
control over treatment decisions that affect their well-being” (p.682). They also 
identified four key characteristics of true shared decision-making: 1) at least two 
partners (e.g. doctor and service user) are involved; 2) both partners share 
information about treatment options; 3) both partners take steps to build a 
consensus about the preferred treatment; and 4) an agreement is reached on the 
most appropriate treatment to implement. In the past two decades, the practice of 
implementing true shared decision-making, in which service users are given the 
opportunity to express their values and preferences and to participate in decisions 
about their care, has been increasingly advocated both in general medicine (525-
529) and in psychiatry (most commonly with people with psychotic disorders) (530-
534). Research has shown that there are many advantages and a robust rationale 
associated with this model of healthcare extending beyond the notions that service 
users will feel more empowered and will be more likely to adhere to treatment they 
have previously agreed to themselves. For example, advocates of shared decision-
making argue that service users - more so than clinicians - understand the realities 
and impact of their condition and its treatment on their lives, as well as how services 
could be better designed to help them (535). Furthermore, there is some evidence to 
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indicate that engaging service users can reduce healthcare costs by avoiding 
unnecessary investigation and treatment (528) and, thus, shared decision-making 
may help health systems become more sustainable. Finally, it has been suggested 
that expertise in health and illness is not restricted to medical circles and that 
working alongside service users and their families is essential to improving 
healthcare (528).  
 
In spite of the potential advantages associated with shared decision-making, many 
criticisms have also been levelled at the practice. Critics argue that many service 
users do not want to participate in decisions about their care and, rather, that they 
prefer simply to place their trust in the hands of the healthcare professionals to 
decide on the most appropriate course of action (536). Some have stated that 
revealing the uncertainties inherent in healthcare could be harmful to service users, 
whilst others have claimed that it is not feasible to provide service users with 
information about the numerous potential risks and benefits of all treatment 
options. Finally - and in contrast to the potential financial advantages mentioned 
above - critics have argued that increasing service user involvement in decision-
making will actually lead to greater demand for unnecessary, costly or harmful 
procedures which could undermine the equitable allocation of health care resources 
(536). This argument has been supported by findings from recent studies indicating 
that an increase in shared decision-making may be associated with increased 
healthcare utilisation costs (537, 538).  
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The two main types of shared decision-making formats that have been implemented 
in psychiatric settings are advance statements and joint crisis plans (JCPs).  Advance 
statements relating to mental health care aim to provide service users with more 
influence over future treatment decisions, thus reducing the occurrence of coerced 
treatment (530). One of the essential features of any advance statement is that it 
clearly documents a service user’s treatment preferences in the event that he or she 
no longer has the capacity to make important decisions in the future, often as a 
result of accident or illness.  
 
Issues of capacity are particularly relevant in the field of mental health, as service 
users - due to symptoms of their mental illness - can be deemed incapable of making 
rational decisions regarding their treatment preferences (530). As such, having the 
service user document his or her preferences clearly during a time of relative 
symptom stability can be of great benefit at a later time.  
 
1.5.2.  Introduction to joint crisis plans 
A joint crisis plan (JCP) is an advance statement containing a service user’s treatment 
preferences regarding mental health care during acute crises in the future. 
Psychiatric Advance Directives (PADs) (539) or Mental Health Advance Directives 
(MHADs) (540) are similar types of advance statements and are widely available in 
mental health care settings, though they are not widely used (530). JCPs are a variant 
of the PAD and research has indicated that they have the potential to reduce 
coercive treatment (541) and improve discussions between service users and 
clinicians which can enhance therapeutic relationships (542).  
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The JCP is created at a meeting between a service user and his or her treating mental 
health clinician, facilitated by an independent mental health practitioner (543). 
Carers, advocates, other support staff and family or friends may also be invited to 
the meeting at the service user’s discretion. Several days before the meeting, the 
service user is provided with a blank template of a JCP, consisting of a list of 
subheadings that s/he may or may not wish to include in the final JCP. The service 
user is invited to note things they wish to include in their JCP in advance of the 
meeting, so that due consideration is given to each potential subsection of the plan. 
During the meeting, all parties present openly discuss with the service user the 
perceived advantages and disadvantages of the various subheadings selected for 
inclusion and the information entered under each, until a consensus is reached 
about the information to be entered. The facilitator remains neutral in the process 
and ensures that all parties have equal opportunity to discuss their opinions and 
preferences. The JCP is therefore produced collaboratively between the service user 
and his or her treatment team, with the aim being that the plan is consulted and 
followed during any future crises (387). Importantly, the final information included in 
the JCP is of the service user’s choosing and is entered in his or her exact words. 
Within 24 hours of the meeting, the facilitator distributes a typed version of the JCP 
to all individuals specified by the service user and, with the service user’s prior 
written permission, a copy of the JCP is also attached to his or her electronic 
psychiatric records in order to maximise dissemination of the plan within the local 
mental health Trust (544, 545). This approach has been used successfully with other 
forms of electronic care plans (546).  
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JCPs are designed to be folded up and to fit into the small plastic pocket provided 
(measuring 10cm x 8cm), so that they can be easily carried by the service user at all 
times, if so desired. JCPs improve the information available to clinical staff about the 
management of a crisis and empower service users by ensuring that they are actively 
involved in the generation of their own crisis plan (387, 531). While the main aim of 
creating and implementing a JCP is to enhance the service user’s empowerment 
regarding their care, other benefits may be achieved. These include reduced levels of 
service use, reduced levels of perceived coercion, improved functioning and 
improved communication between service users, family members and service 
providers (530, 533, 539). Unlike PADs, however, JCPs do not carry any legal 
authority and the information contained within them is not legally binding (530); the 
one exception is the case of ‘advanced refusals’ (i.e., the service user refuses - in 
advance - a specific course of action) as this is covered by the Mental Capacity Act. 
 
The rationale underlying the joint nature of crisis plans – including JCPs – is multi-
factorial (547). Firstly, the service user may adhere to a treatment plan more closely 
if he or she has had substantial input into his or her crisis plan. Secondly, the treating 
mental health team will be considerably more likely to implement a chosen 
treatment or intervention if they themselves have previously agreed that it would be 
both feasible and in the best interests of the service user, and if they know they are 
also acting in accordance with the service user’s wishes. Finally, the therapeutic 
relationship between the service user and the treating clinician may be substantially 
improved as a result of having the crisis plan meeting and detailed discussion about 
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the management of future crises. In light of this, although the JCP is developed 
collaboratively, it is imperative that the final content is determined by the service 
user. This includes deciding which sections from the template are to be included in 
the final plan and deciding the exact wording to be entered under each section (as 
the JCP may be of maximum value if service users choose to carry it with them 
because they feel it is their own plan and that it serves a useful function for them 
personally). The treating clinician’s involvement during the creation of the JCP 
ensures that the service user’s preferences are more likely to be acted upon (i.e., it is 
designed such that health practitioners can manage risk and crises in a manner more 
closely related to the individual preferences of the service user (543, 544)). It is 
essential that the individual facilitating the crisis planning meeting has had no prior 
relationship with the service user, so that he or she can remain impartial during the 
discussion and creation of the JCP. The facilitator must also be able to gain the trust 
of the service user in order to encourage him or her to discuss previous crises and 
episodes of treatment (both positive and negative) with the treatment team (544). 
As such, an experienced mental health clinician who has no direct relationship with 
the service user is the preferred choice.  
 
1.5.3.  Previous research 
Sutherby and colleagues (548) assessed the feasibility of introducing JCPs to a 
community psychiatric service in the first descriptive study of the development and 
use of a form of collaborative mental health crisis plan. Forty service users assessed 
as having a high risk of future crises and a diagnosis of a psychotic illness participated 
in the uncontrolled study. An individual crisis planning meeting was attended by 
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each participant and his or her key worker and consultant psychiatrist, and 
participants were also encouraged to bring a relative or partner if they so desired. 
The aim of the meeting was to have a collaborative discussion about the contents of 
the participant’s crisis plan. Each meeting was facilitated by one of the researchers. 
Sections of the plan to be discussed included: 1) “My mental health problem or 
diagnosis”; 2) “Circumstances that may lead to me becoming unwell or that have 
done in the past”; 3) “Treatments or other things that have been helpful during 
crises or relapses in the past”; and 4) “What I would like to be done when I first start 
to become unwell.” After the meeting, a personalised crisis plan was typed up and 
provided to participants. Rates of hospital admissions over the following 12 months 
were reduced by 30 percent compared with the two years before the study 
commenced. A majority of participants reported consulting the plan either whilst 
experiencing a crisis or after being admitted to hospital (548). The study was not 
controlled and so the impact of potential confounding factors, such as the 
involvement of motivated and interested clinicians, could not be examined. In 
addition, validated rating instruments were not used. Despite these limitations, the 
authors concluded that the potential benefits of this relatively inexpensive and safe 
intervention warranted further investigation in an RCT.  
 
Several members of the same research team went on to conduct a single blind RCT 
to determine whether creating a JCP could reduce use of inpatient services and 
compulsory admission or treatment under the Mental Health Act (1983) (541). One 
hundred and sixty patients from eight CMHTs and an operational diagnosis of 
psychotic illness or non-psychotic bipolar disorder with a recent history of hospital 
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admission took part in the trial. Eighty patients were randomised to the control and 
intervention arms. Participants in the intervention group attended a meeting, as 
described above, and created a personalised JCP (containing details of mental and 
physical illnesses, treatments, indicators for relapse and advance statements of 
preferences for care in the event of a future relapse, amongst other information). 
Participants in the control group received information leaflets about local services, 
mental illness and treatments, the Mental Health Act, local provider organisations 
and relevant policies. Results at 15-month follow-up showed that compulsory 
admissions and treatment were significantly less common in the intervention group 
than the control group and that a smaller proportion of the intervention group were 
admitted (though this difference did not reach significance). This trial provided the 
first evidence that a structured clinical intervention can significantly reduce 
compulsory admission and treatment under the Mental Health Act (1983) and, to 
date, it is the only structured intervention to have done so (541).  
 
In the largest trial to date, Thornicroft and colleagues (549) conducted a three-
centre, individual-level, single-blind, randomised controlled trial of JCPs compared 
with TAU for people with a history of relapsing psychotic illness. A total of 569 
participants from 64 CMHTs were randomised either to the JCP (N=285) or TAU 
(N=284) arm of the trial and followed up 18 months post-randomisation. The 
primary outcome measure was psychiatric inpatient admissions. It was hypothesised 
that participants in the intervention arm would experience fewer inpatient 
admissions, fewer compulsory admissions and shorter inpatient stays than 
participants in the TAU arm (550). The results indicated that JCPs were not 
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significantly more effective than TAU, as no treatment effects were observed 
between the two groups for number of compulsory admissions or number of 
psychiatric admissions. However, there was a significant improvement in the 
therapeutic relationships reported by participants in the JCP arm compared to those 
in the TAU arm. The authors stated that the lack of significant findings may have 
resulted partly from the fact that the process of creating a JCP at a stand-alone 
meeting was not fully implemented in all sites. Results from an economic evaluation 
of the trial suggested a higher probability (more than 80 percent) of JCPs being the 
more cost-effective option and this value increased to 90 percent for Black ethnic 
participants (551). Thornicroft and colleagues posited that, due to the well-
documented and disproportionately high rate of detention among Black service 
users, it is possible that such service users anticipate higher levels of discrimination 
than those from other ethnic groups do. As such, being afforded the opportunity to 
create a personalised JCP may have been associated with greater feelings of being 
respected and understood than those of service users from other ethnic 
backgrounds.  
 
In 2009, Ruchlewska and colleagues (547) commenced an RCT in the Netherlands 
comparing the impact of two different types of crisis plan (facilitated by the service 
user’s advocate or their treating clinician, respectively) with a control condition. The 
study sought to examine whether crisis plans could reduce the number of 
emergency hospital attendances and/or involuntary admissions in a sample of 240 
outpatients with psychotic or bipolar disorders. They were also interested in 
investigating the possible mediator variables of the effects of the crisis plans, 
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including assessing participants’ involvement in: 1) the creation of their crisis plan; 2) 
working alliances; 3) insights into illness; 4) recovery style; 4) presence of social 
support; 5) locus of control; 6) service engagement; and 7) crisis coping style. 
Although, at the time of writing, no definitive findings have been published, the 
authors have published some preliminary findings focusing on the quality of the 
plans produced in the two different conditions (552). Quality of the crisis plans was 
assessed using a checklist consisting of ten items corresponding to the items of the 
crisis plan, which comprised four domains: 1) Relapse indicators/daily functioning; 2) 
Advance statements on what to do during a future crisis; 3) Medical information; 
and 4) Information about personal contacts. The findings indicate that crisis plans 
created with the assistance of participants’ advocates received significantly higher 
scores than those created with the assistance of participants’ treating clinicians, 
indicating a higher quality of crisis plan in the advocate arm of the trial. The authors 
concluded that an even higher quality of crisis plan might be produced by involving 
an advocate, the participant’s treating clinician and the participant in the discussion 
when creating each crisis plan. The forthcoming main results of the trial may shed 
light on the clinical effectiveness of different types of crisis plan.  
 
1.5.4.  Summary and remaining areas of uncertainty 
BPD is a common condition of considerable public health importance. The clinical 
picture of BPD frequently involves severe functional impairment and can include 
unemployment, substance misuse and marked interpersonal instability. As these 
factors often impact on the service user’s ability to commit to ongoing treatment, 
the task of keeping people with BPD in treatment depends primarily upon a strong 
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therapeutic alliance between the service user and his or her treating clinician (122). 
Therefore, maintaining a good working relationship is essential. However, 
considerable uncertainty still remains about what constitutes effective treatment for 
people with BPD, particularly with regard to effective crisis management.  
 
One common feature of BPD is repeated self-harm and this is an important 
treatment outcome for this population because of the strong association with 
completed suicide. The 2011 NICE guideline on the management of self-harm (388) 
recommended developing a care plan and a risk management plan in conjunction 
with the individual who self-harms and their family, carers or significant others, with 
printed copies to be provided for the service user and other key healthcare 
professionals. This recommendation is closely aligned with the major features of 
JCPs.  
 
Findings from previous JCP research using samples of people with psychosis have 
shown that JCPs may be associated with a reduction in compulsory admission to 
hospital, they are viewed favourably by mental health service users and that creating 
a JCP promotes a sense of self-determination and empowerment amongst service 
users (544). It is therefore possible that JCPs might also be an effective form of help 
for people with BPD when in crisis. To date, however, there have been no RCTs 
investigating the impact or effectiveness of crisis plans designed specifically for 
individuals with BPD (371). To address this gap in the literature, the aim of this trial 
was to develop and test the preliminary effectiveness of JCPs with a sample of 
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mental health service users who met the diagnostic criteria for BPD and had a recent 
history of self-harm.  
 
Chapter 1.6.  Aims & hypotheses 
1.6.1.  Aims 
It was anticipated that the results of this trial would help to elucidate the potential 
beneficial effects of JCPs for people with BPD and also provide information to aid the 
design of a definitive trial (387). As a feasibility study for a future definitive RCT, the 
main goals of the study were to gather information about recruitment processes, 
consent and attrition rates and trial procedures. With that in mind, the trial had the 
following aims:  
 
1.) To assess whether JCPs for people with BPD would have a beneficial effect on 
self-harming behaviour and to estimate the likely range of effects consistent 
with the use of JCPs;  
2.) To assess the potential benefit of JCPs on other candidate outcome variables;  
3.) To examine the feasibility of enrolling and retaining a pre-specified number 
of service users with BPD into a trial of JCPs;  
4.) To assess the consent rate for service users entering the trial;  
5.) To assess the acceptability of the concept of randomisation to participants;  
6.) To examine the most appropriate methods of collecting self-harm data for 
use in a definitive trial of JCPs for people with BPD;  
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1.6.2.  Hypotheses 
As stated above, the aims of this trial were primarily to assess feasibility. However, 
the following exploratory hypotheses were formulated:  
 
1. Participants in the JCP group would report significantly fewer self-harm 
events during the six-month follow-up period, when compared with 
participants in the control group; 
2. Participants in the JCP group would report a significant improvement in 
engagement with mental health services at follow-up, compared with 
participants in the control group; 
3. Participants in the JCP group would report a significant improvement in 
therapeutic alliance at follow-up, compared with participants in the control 
group; 
4. Participants in the JCP group would report a significant improvement in 
satisfaction with care at follow-up, compared with participants in the control 
group; 
5. Participants in the JCP group would report a significant improvement in 




CHAPTER 2. METHODS 
2.1  Feasibility study 
Development of the intervention 
Background 
Recruitment and retention of participants is a significant problem in many clinical 
trials (553-557). In a 2006 review of trials funded by the UK Medical Research Council 
(MRC) and the Health Technology Assessment (HTA) programme, McDonald and 
colleagues (558) reported that less than one third (31%) of trials had achieved their 
original recruitment target within the allocated time period. Such shortfalls may lead 
to costly extensions or failure of the trial and may delay the introduction of effective 
interventions into routine clinical practice (556, 557). One approach to addressing 
this issue is to conduct a pilot or feasibility study to determine how members of the 
target population might react to the trial design and intervention (559). Pilot studies 
can play an important role by providing useful information for planning randomised 
controlled trials. In addition to supporting trial design, a pilot study can be treated as 
a ‘dummy run’ in preparation for a larger RCT. Pilots can also encourage 
methodological rigour (560).  
 
The MRC framework for developing and evaluating complex interventions to 
improve health care states that, when designing a complex intervention, the best 
practice is to develop interventions systematically, using the best available evidence 
and appropriate theory, before testing them using a carefully phased approach (561, 
562). The framework states:  
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‘Complex interventions are built up from a number of components, which 
may act both independently and inter-dependently. The components 
usually include behaviours, parameters of behaviours (e.g. frequency, 
timing), and methods of organising and delivering those behaviours (e.g. 
type(s) of practitioner, setting and location). It is not easy precisely to 
define the “active ingredients” of a complex intervention.’ (p.2) 
 
Complex interventions often include at least some of the following characteristics: 
several elements that may act both independently and inter-dependently; complex 
explanatory pathways, either physiological or psychosocial; an intervention that is 
difficult to describe and replicate; complex systems for the delivery of the 
intervention; and a degree of uncertainty about the active ingredient or mechanism 
of action of the intervention (562, 563).  
 
Aims and objectives 
The aims and objectives of the feasibility study were:  
1.) To refine the existing JCP format to meet the needs of people with BPD; 
2.) To obtain the views of service users and clinicians about the perceived clinical 
utility of JCPs for people with BPD;  
3.) To determine the feasibility of recruiting and retaining CMHT service users to 
a study of JCPs;  
4.) To determine the time required to administer a battery of health-related 
questionnaires at baseline and again at follow-up;  
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5.) To obtain the views of service users in relation to the randomisation process.  
 
Method 
The pilot work for the forthcoming trial consisted of four stages:  
1.) Focus group consultation with mental health service users and clinicians; 
2.) Refining the JCP for people with BPD; 
3.) Questionnaire survey with mental health clinicians and clinical academics to 
obtain their views about the newly refined JCP; 
4.) Pilot study of JCP for BPD and data collection procedures.  
 
Focus group consultation 
During the initial consultation process, purposive (non-random) samples of staff 
members and service users were recruited for three separate focus groups to discuss 
and refine the existing format of JCPs (i.e., for people with psychotic illnesses) used 
in Henderson and colleagues’ 2004 trial (541). The first focus group consisted of six 
staff members from CMHTs and Accident and Emergency (A&E) departments and 
included consultant psychiatrists and community mental health nurses. The second 
focus group consisted of six clinicians working in specialist personality disorder 
services including forensic settings, eating disorders settings, intensive psychological 
treatment services and academic research. Seven service users from the Cawley 
Centre (a psychotherapeutic day hospital within the Maudsley Hospital for people 
with personality disorders) took part in the third and final focus group. Each group 
was co-facilitated by the chief investigator (PM) and the student (RB) and was 90 
minutes in duration, during which time group members explored the 
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appropriateness of the language used in the extant JCP template. Participants were 
asked to suggest changes in language or format of the JCP, asked to provide their 
views about what constitutes a ‘crisis’, and whether self-harm would be a useful 
outcome measure for a trial of JCPs. All participants were also asked for their views 
about the methods to be used in the trial of JCPs for people with BPD, including a) 
the most effective methods of recruiting participants into the trial; b) the most 
accurate way to gather information about self-harming behaviour; and c) the 
acceptability of the randomisation process. Each of the three focus groups were 
facilitated using a topic guide, were audio-taped and fully transcribed. Content 
analysis was employed to analyse the resulting data.  
 
Questionnaire survey 
After the JCP was amended on the basis of the feedback from the three focus 
groups, the revised version was emailed to members of the focus groups for further 
feedback and refining. Staff members from the first and second focus groups 
forwarded their feedback by email (nine out of 12 [75%] provided feedback). Hard 
copies of the JCP were distributed to service users from the third focus group for 
their consideration (as many did not have email accounts) and four service users 
participated in individual feedback sessions with the student (RB) to provide more 
detailed feedback.  
 
Delphi exercise 
The revised version of the JCP was then distributed to the 12 staff members from the 
focus groups and an additional group of seven clinical academics working in the field 
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of personality disorders (identified from an electronic search of bibliographic 
databases) for a final round of feedback using a Delphi methodology. The 
aforementioned staff members and academics were emailed the revised version of 
the JCP, with the following amendment: inserted under each item was a brief scale 
and all respondents were asked to rate the relevance of the item on a scale from 1 
(very irrelevant) to 5 (very relevant). Respondents were also encouraged to include 
any additional comments or suggested changes on the content or format of the JCP 
before returning it via email.  
 
Feasibility study of JCPs and data collection procedures 
In its guidance document for designing and evaluating complex interventions (561), 
the MRC recommends that sufficient piloting and feasibility work should be 
conducted to be confident that the intervention can be delivered as intended and 
that safe assumptions about effect sizes and recruitment/retention rates can be 
made for the subsequent main trial. With this is mind, a small feasibility study was 
conducted using the revised JCP template and all recruitment and data collection 
procedures to further inform the larger trial.  
 
Recruitment of participants was conducted at three community mental health teams 
(CMHTs) within the South London and Maudsley (SLAM) NHS Trust. PM and RB 
approached each CMHT (usually at a weekly staff meeting) and conducted a brief 
presentation about the aims and underlying rationale of the study and allowed staff 
members to ask questions. Clinicians were then encouraged to identify any 
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potentially eligible service users from their caseloads and to approach these service 
users to discuss the study with them.  
 
After each service user had stated that he or she was happy to be contacted by a 
member of the research team, RB contacted him or her and planned a baseline 
interview meeting at a convenient time. At this meeting, each client signed a consent 
form indicating their willingness to participate in the trial. During this meeting, all 
baseline assessments were conducted and RB then discussed the JCP template with 
the participant, answering any questions which arose. Each participant was also 
provided with a copy of the template to consider before a facilitated meeting with 
their care coordinator. RB then planned a date for the facilitated meeting with the 
participant and his or her care coordinator, as well as any significant others as 
nominated by the participant.  
 
The second meeting was facilitated by RB. Prior to the meeting, the participant’s 
care coordinator completed the Working Alliance Inventory (Therapist version [WAI-
T]) (564) and the Service Engagement Scale (SES) (565) about their working 
relationship with the participant. During the meeting, detailed notes were taken by 
RB to ensure that the participant’s exact wording was entered into his or her crisis 
plan. At the end of the meeting, the participant was provided with a copy of a brief 
self-harm diary (see Appendix 2), in which to document any episodes of self-harm 
between the facilitated meeting and the follow-up meeting. RB typed up the JCP and 
mailed a copy to the participant and a copy to any other party nominated by the 
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participant (this frequently included the care coordinator, GP, consultant and 
spouse/partner) within 24 hours.  
 
RB contacted each participant approximately six weeks after the facilitated meeting 
to make an appointment for the follow-up interview. During this third and final 
meeting, all follow-up assessments were conducted and RB collected the 
participant’s self-harm diary. Each participant was then asked whether he or she 
would have agreed to undergo randomisation if it had been required (for the 
purposes of the forthcoming RCT) in order to gauge participant opinion. Participants 
were also asked to provide feedback regarding their overall involvement in the study 
and were encouraged to suggest ways to improve the process for the trial.  
 
2.2.  The trial 
2.2.1.  Trial design 
There are many different designs available to choose from when evaluating 
healthcare interventions, including naturalistic designs, experimental designs and 
quasi-experimental designs, with different designs suited to different research 
questions (566). However, randomised controlled trials (RCTs) are widely recognised 
as the most reliable method of determining the effectiveness of a healthcare 
intervention. This is because randomisation is the most robust method of ensuring 
the even distribution of known and unknown confounding factors that may impact 
on clinical outcomes (566, 567). As such, an RCT design was selected for the present 
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study, which was a single-centre exploratory RCT of JCPs compared with a TAU 
control condition for people with BPD and a recent history of self-harm.  
 
2.2.1.1.  Choice of control group 
All RCTs require a control group against which the effectiveness of the intervention 
can be compared. This may be the best available package of care, standard care, or a 
placebo (567). Participants in this trial’s control group received TAU, which was the 
standard treatment which they would have received from their CMHT had the trial 
not been conducted. This was chosen for two reasons: firstly, it provided a fair 
comparison with routine clinical practice. Secondly, the best available current 
treatment for BPD - dialectical behaviour therapy - requires specialist referral and 
can involve lengthy waiting lists. Additionally, the inclusion of a TAU group allows for 
comparisons with previous trials involving participants with BPD. Typical case 
management provided by a CMHT in the UK, as a part of the Care Programme 
Approach (CPA) for the most vulnerable service users, includes regular contact (one 
to four times per month) with a care coordinator or allocated member of the clinical 
team, in addition to the provision for service users to receive written copies of their 
care plan, including a prescriptive ‘crisis contingency plan’ (387, 568). The quality of 
these plans, however, has been shown to be poor. A recent analysis of 424 crisis 
contingency plans by Farrelly and colleagues (569) revealed that, despite clear 
government guidance regarding the importance of individualised crisis plans, their 
implementation has been less than optimal. They found that only 15 percent of the 
crisis plans contained any individualised information about the service user, such as 
interventions that had or had not been helpful in the past, who to contact in an 
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emergency, preferences or refusals for treatment in crisis, or practical arrangements 
(for securing a flat, looking after children, pets or plants, etc.) if admission to hospital 
were to be necessary. The remaining 85 percent of crisis plans contained only 
generic information, such as information about local emergency services. On the 
basis of their findings, the authors concluded that routine crisis planning in their 
sample was not influenced by clinical risk profiles (569).  
 
In the trial, it was anticipated that the CPA arrangements above would be applied 
equally by CMHTs to both the intervention and control groups. However, it was 
acknowledged that standard care might not be consistent across sites, teams, or 
even individual clinicians within teams due to fluctuating clinical workloads and 
competing demands made on clinicians’ time. As masking of participants and all 
researchers to treatment allocation in this trial was not possible (the senior 
researcher was not blinded to allocation, but the researcher collecting all follow-up 
data was blinded), care was taken to minimise bias by blinded assessment of all 
outcome measures, as recommended in the literature (570).  
 
2.2.2.  Participants 
2.2.2.1.  Trial setting 
Participants were referred from 17 CMHTs and outpatient drug and alcohol 
treatment teams within the catchment area of either the South London and 
Maudsley (SLAM) Foundation Trust or the Oxleas Foundation Trust of the NHS. The 
CMHTs were based at 14 separate community health centres across five local 
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government boroughs in South East London. The UK Economic Deprivation Index 
(571) ranked the relative deprivation experienced by residents of each of the 354 
local authorities in the UK in 2008, with each authority receiving a rank from one 
(most deprived) to 354 (least deprived). The relatively high level of deprivation 
experienced by residents in the five boroughs in the sample is highlighted by the 
rankings obtained by each: Lambeth, 12; Southwark, 19; Lewisham, 22; Greenwich, 
24; and Croydon, 109.  
 
2.2.2.2.  Eligibility criteria 
Individuals were eligible for the trial on the basis of the following inclusion and 
exclusion criteria:  
 
Inclusion criteria 
i) Aged 18 years or older; 
ii) Current contact with a CMHT within SLAM or Oxleas NHS Foundation 
Trusts; 
iii) Primary diagnosis of borderline personality disorder (or meeting the 
DSM-IV-TR diagnostic criteria); 
iv) At least one self-reported episode of self-harm in the previous 12 months.  
 
Exclusion criteria 
(i) Aged less than 18 years; 
(ii) Unable to give informed consent; 
 113
(iii) Unable to converse in English. Fluency in English was necessary to 
complete the assessment instruments (many of which have not been 
validated in other languages) and to fully participate in the development 
of a JCP if required; 
(iv) Primary diagnosis of any psychotic illness; 
(v) Currently an inpatient or subject to a compulsory community treatment 
order; service users in these groups were not recruited to avoid any 
perceived potential coercion to participate. 
 
No other exclusions were made in order to maximise the external validity of the trial.  
 
2.2.2.3.  Identification of potential participants 
Due to the duration of the recruitment phase being considerably longer during the 
RCT than during the feasibility study (i.e., 16 months instead of four months), 
members of the research team (RB, PM, and a junior research worker, JH) presented 
the trial at team meetings on more than one occasion at each site in an attempt to 
ensure that the trial remained prominent in the minds of relevant staff members 
throughout the entire recruitment period. After considering feedback from the Trial 
Steering Committee (TSC), a more proactive method of participant identification was 
employed; this involved the student (RB) and the junior research worker (JH) making 
appointments with individual clinicians within each team and reviewing their current 
caseload, in order to identify all potentially suitable participants for the trial. This 
process was repeated approximately every three months with individual clinicians 
over the 16 month recruitment period.  
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2.2.3.  Ethical approval and trial registration 
Ethical approval was gained from the South London Research Ethics Committee 
(reference number 09/H0803/113) and the trial was registered with the 
International Standard Randomised Controlled Trial registry (ISRCTN12440268). 
 
2.2.4.  Baseline data collection 
Eighty-four baseline interviews (95.5%) were conducted at participants’ treating 
CMHT bases and four (4.5%) were conducted at participants’ homes after risk 
assessments and safety checks were performed.  
 
2.3.  Intervention 
2.3.1.  Intervention group: JCP plus TAU 
Participants in the JCP condition were posted a blank JCP template, containing 
various subheadings relating to information they may have wished to include in their 
JCP (e.g. “Situations which can lead to a crisis”, “Positive things which I have found 
helpful in the past” and “Details of current treatment and support from health 
professionals”). The JCP template is located in Appendix 2. Participants were 
encouraged to enter any information they wished to include in their JCP under the 
relevant subheadings prior to attending their crisis planning meeting, along with the 
help of carers, family members or friends if so desired.  
 
 115
Participants were then invited to attend a one-off joint crisis planning meeting at 
their local CMHT base which was facilitated by the student (RB) and attended by the 
participant and his or her treating CMHT clinician. Participants were also encouraged 
to bring a carer or friend to act as an advocate. At this meeting, all parties 
contributed to a discussion about the information which the participant wished to 
include his or her JCP, using the aforementioned template as a basis to structure the 
discussion. With the help of everyone present, the participant was encouraged to 
consider the advantages and disadvantages associated with the information he or 
she wished to include in his or her JCP and opposing opinions were discussed and 
resolved amongst the group.  
 
After the meeting, RB produced a typed version of the JCP and distributed copies to 
all parties nominated by the participant during the meeting. With the participant’s 
permission, a copy of the JCP was also uploaded onto his or her electronic psychiatric 
records. Research has indicated that uploading electronic care plans allows for 
immediate and effective dissemination of evidence-based good practice at the point 
of service delivery and eliminates many of the disadvantages associated with 
handwritten notes (546). An example of a completed (fictitious, but based on real 
statements) JCP is located in Appendix 2. All participants allocated to the JCP 
condition also continued to receive treatment as usual from their CMHT in addition 




2.4.1.  Baseline measures 
Table 5 contains the domains that were assessed at baseline and the instruments 
used to measure them. Each instrument is described in greater detail below.  
 
2.4.2.  Rating instruments used 
Demographics questionnaire (participant version) 
A bespoke 11-item questionnaire was used to collect participants’ demographic data 
including age, gender, ethnicity, employment status and geographical location. This 
questionnaire is located in Appendix 2.  
 
Demographics questionnaire (clinician version) 
A 10-item self-report questionnaire, developed by the researchers during the 
feasibility study, was used to collect socio-demographic data and information 
relating to professional qualifications and length of practice of each participant’s 
care coordinator (see Appendix 2).  
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Table 5. Domains measured at baseline and instruments used to measure them.  
Domain Instrument 
Demographic variables Demographic questionnaire 
Work and social adjustment Work and Social Adjustment Scale (WSAS): (572) 
Working alliance (client rated) Working Alliance Inventory – Client version (WAI-C): (564) 
Working alliance (clinician rated) Working Alliance Inventory – Therapist version (WAI-T): (564) 
Perceived coercion Treatment Experience Survey (TES) 
Satisfaction with CMHT care Client Satisfaction Questionnaire (CSQ): (573) 
Alcohol misuse Alcohol Use Disorders Identification Test (AUDIT): (574) 
Substance misuse Substance misuse questionnaire 
Mental health wellbeing Warwick-Edinburgh Mental Well-Being Scale (WEMWBS): (575) 
Anxiety Hospital Anxiety and Depression Scale (anxiety subscale; HADS-A): (576) 
Depression Hospital Anxiety and Depression Scale (depression subscale; HADS-D): (576) 
Quality of life EuroQoL Quality of Life measure (EQ-5D): (577) 
Self-harm Self-harm questionnaire: (424). 
BPD psychopathology Structured Clinical Interview for DSM-IV (SCID-II): (148, 149) 
Personality disturbance Standardised Assessment of Personality – Abbreviated Scale (SAPAS): (578) 
Service engagement Service Engagement Scale (SES): (565) 
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Work and Social Adjustment Scale (WSAS) 
The WSAS (572) is a five-item self-report instrument to assess social functioning. 
Respondents are asked to indicate their responses to each item on a nine-point scale 
ranging from ‘zero = no impairment at all’ to ‘eight = very severe impairment’. The 
WSAS is a valid and reliable instrument and that it offers the potential for readily 
interpretable comparisons across studies and across disorders (572). A total score is 
obtained by adding each of the five responses together, with higher scores indicating 
a higher level of impairment. Scores can range from zero to 40.  The WSAS is located 
in Appendix 2.  
 
Working Alliance Inventory – Client version (WAI-C) 
The WAI-C (564) is a 12-item self-report instrument for measuring the quality of 
alliance between client and clinician, completed by the client. Each item is scored on 
a scale from ‘one = never’ to ‘seven = always’. The WAI-C is reliably correlated with a 
variety of counsellor and client self-reported outcome measures and is widely used 
to assess alliance, with over 100 studies and several meta-analytic reviews focusing 
on the WAI-C (579). A total score is obtained by adding each of the 12 responses 
together (note that items four and 10 are reverse-scored), with higher scores 
indicating a more positive perception of working alliance. Scores can range from 12 
to 84. The WAI-C is located in Appendix 2.  
 
Working Alliance Inventory – Therapist version (WAI-T) 
 119
The WAI-T (564) is almost identical to the WAI-C (above), with the same items 
answered by the treating clinician. The scoring system is identical to that of the WAI-
C. Scores can range from 12 to 84. The WAI-T is located in Appendix 2.  
 
Treatment Experience Survey (TES) 
The TES was adapted from the Admission Experience Survey (580), a 16-item 
instrument designed to assess the perceived level of coercion experienced by 
patients during hospital admission. The Admission Experience Survey has been used 
in many studies as a measure of perceived coercion (581). In the present study, the 
wording of each of the items was amended to reflect seeking treatment from a 
CMHT, as opposed to being admitted to hospital (e.g. “It was my idea to come into 
the hospital” became “It was my idea to seek treatment”). Respondents endorse 
each item as either ‘true’, ‘false’ or ‘don’t know’. Scores can range from zero to 45. 
The TES is located in Appendix 2.  
 
Client Satisfaction Questionnaire (CSQ) 
The CSQ (573) is an eight-item measure of clients’ level of satisfaction with the 
treatment they are receiving. The CSQ takes approximately five minutes to complete 
and it possesses adequate psychometric properties (573). Respondents are 
encouraged to endorse each item on a scale from one to four and, thus, total CSQ 
scores can range between eight and 32 (with higher scores indicating a higher level 
of satisfaction with services). The CSQ is located in Appendix 2.  
 
Alcohol Use Disorders Identification Test (AUDIT) 
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The AUDIT (574) is a 10-item self-report measure to identify problematic levels of 
alcohol consumption in respondents. Items one to three assess alcohol consumption, 
items four to six relate to alcohol dependence, items seven and eight measure 
adverse reactions and items nine and 10 assess alcohol-related problems. The AUDIT 
was developed by the World Health Organization (WHO) as a simple method of 
screening for excessive drinking and to assist in brief assessment. It was validated on 
primary health care patients from six countries (Australia, Bulgaria, Kenya, Mexico, 
Norway and the USA) and is the only screening test specifically designed for 
international use. The instrument has good psychometric properties (574) and is 
widely used by both clinicians and researchers in many countries. A total score is 
obtained by adding each of the 10 responses together (the total score ranges from 0 
to 40), with higher scores indicating more problematic levels of alcohol 
consumption. The AUDIT is located in Appendix 2.  
 
Substance misuse questionnaire 
Respondents were asked about their recent substance use and asked to record any 
substances they had used recreationally in the preceding 12 months from a table in 
the questionnaire and the usual route of administration (i.e., oral, smoked) of each. 
Of those substances endorsed, respondents were then asked how many times, if 
any, they had used the substance in the preceding month. The substances listed in 
the inventory included both illicit substances (such as cannabis, cocaine and heroin) 
and licit substances (such as benzodiazepines and methadone) which were not 
prescribed and thus had been used recreationally. The substance misuse 
questionnaire is located in Appendix 2.  
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Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) 
The WEMWBS (575) is a 14-item measure of mental well-being over the preceding 
two weeks that focuses entirely on positive aspects of mental health. Each item is 
scored on a scale ranging from ‘one = none of the time’ to ‘five = all of the time’. A 
total score is obtained by adding each of the 14 responses together and thus ranges 
from 14 to 70, with higher scores indicating a higher level of wellbeing. The 
WEMWBS is located in Appendix 2.  
 
Hospital Anxiety and Depression Scale (HADS) 
The HADS (576) is a 14-item self-report scale for measuring depression and anxiety in 
outpatients. Respondents receive separate scores for depression and anxiety by 
summing scores from the appropriate items, with higher scores indicating higher 
levels of depression/anxiety. Scores for each subscale can range from zero to 21 and 
combined scores can range from zero to 42. The HADS is useful for detecting change 
in a respondent's emotional state over repeated administrations, as well as for 
assessing presence or absence of clinically significant degrees of anxiety and 
depression (576). The HADS is located in Appendix 2.  
 
EuroQoL Quality of Life measure (EQ-5D) 
The EQ-5D (577) assesses respondents’ subjective quality of life - in reference to the 
assessment date only - across five life domains: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Respondents are asked to endorse one of 
three options, ranging from ‘one = I have no problems with (domain)’ to ‘three = I 
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am unable to (domain)’. A score is obtained by summing responses to the five items, 
with lower scores indicating a higher overall subjective quality of life. Overall health 
state is measured by a sixth item, which asks respondents to indicate their subjective 
health state on a scale from zero to 100 (where zero = ‘the worst imaginable health 
state’ and 100 = ‘the best imaginable health state’). Respondents are asked to take 
into account both their physical health and mental health when indicating their 
overall health state. The EQ-5D is located in Appendix 2.  
 
Self-harm questionnaire 
Recent self-harming behaviour was measured at baseline and follow-up using a self-
harm questionnaire used in Hawton and colleagues’ 2002 survey of self-harm in 
young people (424). Participants were also encouraged to reflect on their most 
recent self-harm event and provide information relating to time spent delaying the 
act, help-seeking behaviour before and after the act and any medical consequences 
of the act. The self-harm questionnaire is located in Appendix 2.  
 
Self-harm diary 
Participants were provided with a simple self-harm diary upon completing their 
baseline assessment. This diary took the form of a brief (one-page) calendar 
commencing on the date of the baseline meeting and containing every day of the six-
month follow-up period. Participants were encouraged to circle the day on which 
any episodes of self-harm occurred during the follow-up period and then to return 
the diary to the research worker (JH) at the follow-up assessment. The self-harm 
diary is located in Appendix 2.  
 123
 
Electronic psychiatric records 
Each participant’s electronic psychiatric records were also screened upon completion 
of their follow-up interview in order to establish the number of events of self-harm 
that had been recorded by clinicians during the follow-up period.  
 
Structured Clinical Interview for DSM-IV (SCID-II) – Borderline Personality Disorder 
subsection  
The SCID-II (148, 149) is a semi-structured interview for diagnosing the Axis II 
personality disorders of the DSM-IV-TR. It was designed with the primary goal of 
providing a rapid clinical assessment without sacrificing reliability or validity (149). 
The present study used only the BPD subsection, consisting of nine items. 
Respondents receive a score of either ‘one = absent or false’, ‘two = sub-threshold’ 
or ‘three = threshold or definitely present’. A score for each respondent is calculated 
by summing the number of items rated as positive, with higher scores indicating a 
greater degree of personality disturbance. A score of at least five out of nine is 
required in order for the respondent to meet DSM-IV-TR criteria for BPD. 
Additionally, the total number of personality disorder items present may be an 
indication of overall personality pathology (149). The BPD subsection of the SCID-II is 
located in Appendix 2.  
 
Standardised Assessment of Personality – Abbreviated Scale (SAPAS) 
The SAPAS (578) is an eight-item screening interview to identify the presence and 
severity of personality disturbance. Each item is scored as either ‘yes’ or ‘no’ and a 
 124
total score (ranging from zero to eight) is calculated by summing the number of 
items rated as positive, with higher scores indicating a greater degree of personality 
disturbance. The SAPAS has satisfactory psychometric properties and, in the original 
validation study, a score of three or more positive responses on the SAPAS correctly 
identified the presence of a DSM-IV personality disorder in 90 percent of cases (578). 
The SAPAS has since been used successfully in a variety of populations (582-587) and 
a copy is located in Appendix 2.  
 
Service Engagement Scale (SES) 
The SES (565) is a 14-item self-report scale, completed by a service user’s treating 
clinician - in this trial a care coordinator or key worker - to measure the service user’s 
level of engagement with community mental health services. Each item is rated from 
“zero = Not at all or rarely” to “three = Most of the time”. Positively worded items 
are reverse scored so that higher scores reflect a greater level of difficulty engaging 
with services (565). Scores can range from zero to 42. The Service Engagement Scale 
is located in Appendix 2.  
 
2.5.  Outcome data collected at six-month follow-up     
Table 6 shows the instruments completed by participants and clinicians at the 




Table 6. Instruments used at different data collection points.  
 




Participant Demographics    
WSAS    
WAI-C    
TES    
CSQ    
AUDIT    
Substance misuse    
WEMWBS    
HADS    
EQ-5D    
Self-harm    
SCID-II    
SAPAS    
JCP template    
Clinician Demographics    
SES    
WAI-T    
 
 
2.6.  Sample size and power calculation 
Sample size calculations are not required for most pilot studies because the primary 
aim is to gather information about trial procedures, recruitment processes, and 
consent and attrition rates. Nevertheless, one aim of the trial was to determine 
whether it was feasible to recruit and retain a pre-determined number of people 
with borderline personality disorder into a trial of JCPs and, for this reason, a power 
calculation was undertaken in order to provide a target sample size for which to aim. 
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For the purposes of this power calculation, the variable ‘proportion of each trial arm 
self-harming during the follow-up period’ was selected as the primary outcome. In 
the POPMACT trial, a previous RCT of cognitive therapy versus TAU for people who 
self-harmed (363), 36 percent of participants in the TAU group reported an episode 
of self-harm in the first six months following randomisation. It was envisaged that 
the incidence of self-harm in participants in the trial’s TAU arm would be similar to 
the POPMACT trial. In an RCT of ‘green cards’ versus TAU for individuals with a first 
presentation of self-harm, the proportion of participants who self-harmed in the 
green card group was one-third (33.3%) that observed in the TAU group (494). Given 
that the green card was not an individualised intervention (whereas the JCP is), it 
was envisaged that the JCP intervention would result in a larger effect, with a lower 
proportion (one third) of people at risk of self-harm after randomisation (33% risk 
ratio=0.33). Participants were followed up for six months with a predicted 36 
percent and 12 percent of patients repeating self-harm in the TAU group and JCP 
group respectively. On the basis of these predictions, and accounting for 10 percent 
loss to follow-up, an overall sample of 120 participants (randomised 1:1 to TAU: JCP) 
would provide 80 percent power to detect an observed difference between the two 
groups based on a two-sided log-rank test at the five percent significance level.  
        
2.7.  Randomisation 
Randomisation was performed at the individual participant level. All participants 
were informed about both arms of the trial and about the randomisation procedure. 
All participants were randomised to either the intervention (JCP+TAU) arm or the 
TAU arm of the trial at an approximate ratio of 1:1. Randomisation was managed 
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electronically by the Clinical Trials Unit (CTU) at the Institute of Psychiatry , King’s 
College London. Confirmation of eligibility, written informed consent and baseline 
data were obtained prior to randomisation. Bias in the randomisation process was 
avoided by having randomisation performed electronically by the CTU (and without 
input from the research team), thereby also maintaining concealment from the 
research worker responsible for collecting all follow-up data.  
 
2.7.1.  Stratification 
Stratification is used to ensure an approximately even balance of participant 
characteristics in the intervention arm and control arm of trials (588). This is 
because, by chance (and especially in smaller trials), the trial arms may not be well 
matched for important baseline characteristics. Stratification ensures that the 
numbers of participants allocated to each arm are closely balanced within each 
stratum, so that (for example) not all participants with high depression scores are 
entered into the intervention arm by chance. As alcohol misuse and depressive 
symptoms have been shown to be correlated with self-harm (35-38), it was thought 
that both depression and alcohol use were likely to be prognostically important 
variables in relation to self-harm. For this reason, participants were randomised 
using the method of minimisation with a random component stratified by alcohol 
misuse scores (as measured by the AUDIT: low<8; medium=8-15; high>15) and 
depression scores (as measured by the HADS depression subscale: low<8; 
medium=8-10; high>10). This methodology ensured equal allocation of participants 
to the two arms within each stratification category.  
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2.7.2. Allocation concealment        
After each new participant was randomised into one of the treatment arms, the 
senior researcher on the study (RB) received an automated email containing the 
participant’s initials, date of birth, study number, date of randomisation and 
treatment allocation. At the same time, the research worker (JH – responsible for 
collecting all six-month follow-up data) received an identical email minus the 
treatment allocation. RB was located in a different office to JH and used different 
storage facilities (i.e., locked filing cabinets, password-protected electronic files, 
locked offices) to ensure JH’s allocation blindness was maintained throughout the 
study.  
 
2.7.3.  Implementation 
Participants were informed of their treatment allocation via a letter mailed to their 
home address. Each participant’s treating CMHT clinician (typically their care 
coordinator) was also advised of their allocation via email and reminded not to 
discuss this with the research worker collecting the follow-up data. Participants in 
the JCP group were contacted by telephone after the initial letter to make an 
appointment for the crisis planning meeting.  
 
2.8.  Data entry 
Immediately following each participant’s baseline meeting, and again after their six-
month follow-up meeting, all data were entered into a MACRO database managed 
by the CTU. After the completion of follow-up data collection and entry, all data 
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were extracted by the senior data manager at the CTU and converted into SPSS 15.0 
(Statistical Package for the Social Sciences) (589) format for data analyses.  
 
2.9.  Statistical analyses 
All analyses were based on the modified intention-to-treat sample using a statistical 
analysis plan finalised by the trial statistician (JMH) and approved by the principal 
investigator (PM) in advance of conducting any analyses.  
 
2.9.1.  Analysis of outcome measures 
All 88 participants randomised into the trial were retained in their allocated 
treatment arm for a modified intention-to-treat analyses. No interim analyses were 
conducted and all tests for significance were two-tailed. Continuous variables were 
summarised as mean (SD) and categorical variables as n (%). Self-harm (yes or no) 
was assessed with a logistic regression model with treatment and two stratification 
factors (alcohol misuse [AUDIT] and depression [HADS]) as covariates. Model 
assumptions were checked by the use of diagnostic plots. Models were undertaken 
with the assumption that data were missing at random. Categorical data were 
compared using Fisher’s Exact test. Secondary outcomes were analysed in a 
generalised linear model (GLM) framework; covariates in the model were treatment 
group, baseline value of outcome, alcohol misuse and depression. For the frequency 
of self-harm at six-month follow-up, a negative binomial distribution was specified 
with a log link. Logistic regression was utilised for binary outcomes and clinical scales 
were analysed using the assumption of a normal distribution. Results of the 
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treatment effects were summarised as odds ratios (ORs; logistic and ordinal logistic 
regression), incidence rate ratios (RRs; negative binomial distribution GLM) and 
effect sizes (Gaussian models) at six-month follow-up with two-sided 95% confidence 
intervals. 
 
2.9.2.  Analysis of JCP contents 
Data from all 41 joint crisis plans were analysed iteratively using a thematic analysis 
framework (590). Analysis began with two raters (RB and KT) independently 
conducting open coding of all JCPs, with the codes being rooted in the data. The two 
raters then compared their codes and a preliminary coding frame was constructed. 
This frame, and the initial categories, were scrutinised by two senior clinical 
researchers (CH and PM) and the coding frame was further developed. Some units of 
text were assigned several codes to reflect the multifarious nature of participants’ 
statements. The two initial raters then actively searched for data that did not fit into 
the coding frame (i.e., deviant cases). Revisions to the coding frame were again 
cross-checked by senior clinical (CH, PM) and service user (DR) researchers and 
further refined through discussions of the appropriateness of each of the codes, with 
any initial disagreements resolved iteratively through consensus. Microsoft Word 
was used for indexing material and for retrieval of text chunks pertaining to the 
same or similar codes. This procedure ensured reliability of the analysis as it relied 
on the multiple coding and combined assessment of five raters (591). In terms of 
validity, this procedure was transparent and has been argued to be a proxy for 
validity in qualitative analysis (592).  
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CHAPTER 3. RESULTS 
3.1.  Results from developmental phase 
Feedback from focus groups 
Participants in the service users’ focus group, without exception, endorsed the use of 
the term ‘crisis’, stating that they could personally identify with the term and it did 
not carry any negative connotations. They also discussed the acceptability of the 
randomisation process in the forthcoming trial and acknowledged that it was likely 
that there would be some people who would consent to the process and people who 
would not. During the consultation process, the section of the JCP under the heading 
“My mental health problems and diagnosis” was changed to “My mental health 
problems”, then to “My difficulties”, and finally to “My difficulties as I see them 
now.” It was also suggested during the service user focus group that the information 
should be divided into two sections: one section for the service user and one section 
for health professionals. This amendment was implemented in all subsequent 
revisions. Members of all three focus groups agreed that it would be essential for the 
JCP to include a list of emergency telephone numbers for use in times of crisis, unlike 
the original JCP for people with psychotic illnesses.  
 
After the focus groups, the title of the trial was changed from ‘The effectiveness of 
joint crisis plans for people with borderline personality disorder: a pilot randomised 
controlled trial’ to ‘The effectiveness of joint crisis plans for people who have self-
harmed: a pilot randomised controlled trial’. The decision to make this alteration 
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was well considered and emerged from the consultation work with mental health 
service users and professionals alike. It was suggested during the service user focus 
group that many participants in the study may not be aware that they have been 
given a diagnosis of personality disorder and that an interview with a research 
worker was not the appropriate forum in which to discover this. Given that all 
participants will, by definition, be aware of their own self-harm histories, the title of 
the study was amended to minimise any potential sources of conflict or 
disagreement. These changes were discussed with - and agreed upon by - the Project 
Advisory Group [PAG].  
 
Delphi exercise feedback 
Sixteen out of 19 (84.2%) professionals provided feedback about the relevance of 
items to be included in the JCP. The mean scores for items ranged from 4.4 to 4.9 
out of five, suggesting that each item was highly relevant. On the basis of the above 
consultation work, the finalised version of the JCP was used in the feasibility study.  
 
Feedback from feasibility study participants 
Feedback about the JCPs - and the procedures of the overall forthcoming study - was 
mainly positive, with several participants stating that they believed all service users 
accessing CMHTs should be allowed to create their own JCPs. One participant stated 
that paramedic staff members had been unable to open his JCP as it was soaked 
through with blood following an episode of self-harm and suggested that it would be 
helpful to ensure that the JCP is protected somehow in the trial. In response to this, 
it was agreed that each JCP in the subsequent RCT would be placed inside a small 
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clear envelope to protect it from all liquid and other daily wear and tear. As the 
primary objective of the feasibility study was to determine the feasibility of 
recruiting and retaining CMHT clients to a study of JCPs, no data analysis was 
performed on the pre-intervention and post-intervention data obtained.  
 
3.2.  Findings from the trial 
3.3.  Recruitment to the trial 
All participants were recruited over a 71-week period between December 2009 and 
April 2011 (see Figure 1). Follow-up data collection continued until October 2011.  
 
 
Figure 1. Pattern of participant recruitment to the trial.  
 
A total of 133 potential participants were referred to the trial. Of these initial 
referrals, 30 people (22.6%) declined to take part in the study on the basis of a small 
number of recurring reasons (i.e., not interested in research, lack of insight into 



























mental disorder, unwillingness to acknowledge the possibility of a future crisis, or 
only willing to participate in the trial if they could be guaranteed to be placed into 
the intervention arm). Twelve people (9.0%) did not meet the inclusion criteria (five 
[3.6%] had not self-harmed in the preceding 12 months and seven [5.3%] did not 
meet the SCID-II diagnostic criteria for BPD). A further three individuals (2.3%) were 
excluded from participating as they required an interpreter. The remaining 88 
people (66.2% of those initially referred) provided written informed consent to 












Declined to participate: 
N=30 
 




(not meeting BPD  
criteria: N=7; 
no self-harm in past  
12 months: N=5) 
Randomised: 
N=88 
Treatment as usual  
(TAU): N=42 
Joint Crisis Plan 
(JCP+TAU): N=46 
Followed up: N=34 
Lost to follow up: N=8 
Did not attend  
JCP meeting: N=3 
Died: N=1 
 
Analysed for primary 
outcomes: N=37 
Followed up: N=36 
Lost to follow up: N=5 
Died: N=1 
 




Table 7 shows the distribution of participants by recruitment borough.   
Table 7. Number of participants recruited by borough. 
  
Site JCP group TAU group Total 
Lambeth 4 (8.7%) 7 (16.7%) 10 (11.4%) 
Southwark 18 (39.1%) 17 (40.5%) 36 (40.9) 
Lewisham 7 (15.2%) 3 (7.1%) 10 (11.4%) 
Croydon 10 (21.7%) 14 (33.3%) 24 (27.2%) 
Greenwich 7 15.2%) 1 (2.4%) 8 (9.1%) 
Total 46 (52.3%) 42 (47.7%) 88 (100.0%) 
 
 
Of these 88 participants, 71 (80.1%) were female and the average age of participants 
was 35.8 years (SD=11.6). The demographic characteristics of participants are shown 




Table 8. Demographic characteristics of participants at baseline.  
 






     
Gender Male 10 (21.7%) 7 (16.7%) 17 (19.3%) 
 Female 36 (78.3%) 35 (83.3%) 71 (80.7%) 
     
Age Mean (SD) 35.6 (11.1) 36.1 (12.4) 35.8 (11.6) 
     
Ethnicity White 34 (73.9%) 31 (73.8%) 65 (73.9%) 
 Black 6 (13.0%) 3 (7.1%) 9 (10.2%) 
 Asian 0 (0.0%) 1 (2.4%) 1 (1.1%) 
 Mixed 3 (6.5%) 4 (9.5%) 7 (8.0%) 
 Other 3 (6.5%) 3 (7.1%) 6 (6.8%) 
     
Marital 
status 
Married 2 (4.3%) 1 (2.4%) 3 (3.4%) 
Cohabiting 6 (13.0%) 4 (9.5%) 10 (11.4%) 
 Widowed 0 (0.0%) 1 (2.4%) 1 (1.1%) 
 Separated 2 (4.3%) 1 (2.4%) 3 (3.4%) 
 Divorced 6 (13.0%) 2 (4.8%) 8 (9.1%) 
 Single 30 (65.2%) 33 (78.6%) 63 (71.6%) 











 Unemployed 11 (23.9%) 9 (21.4%) 20 (22.7%) 
 Permanently 







 Homemaker 1 (2.2%) 1 (2.4%) 2 (2.3%) 
 Student 0 (0.0%) 2 (4.8%) 2 (2.3%) 
 Other 8 (17.4%) 4 (9.5) 12 (13.6%) 
School  
leaving age 
< 17 35 (76.1%) 34 (81.0%) 69 (78.4%) 
≥ 17 11 (23.9&) 8 (19.0%) 19 (21.6%) 
Further education 
since school 
Yes 31 (67.4%) 30 (71.4%)  61 (69.3%) 
No 15 (32.6%) 12 (28.6%) 27 (30.7%) 
 
 
Forty-six participants (52.3%) were randomised to the intervention arm and 42 
(47.7%) were randomised to the TAU arm. Of the 46 participants in the intervention 
arm, a total of 41 (89.1%) attended a JCP planning meeting within two weeks of 
randomisation. The remaining five participants (10.9%) did not create a JCP, due to 
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their treating clinicians or the participants themselves being unable to attend the 
crisis planning meeting as agreed. Eight participants (19.5% of those who created a 




Participants endorsed an average of 6.9 of the nine diagnostic criteria on the SCID-II 
(SD = 1.3, range = 5-9) at baseline. All participants endorsed the self-harm criterion, 
as this was an inclusion criterion for the trial. Table 9 displays each criterion and how 
commonly it was endorsed.  
 
Table 9. Number of SCID-II criteria endorsed by participants at baseline.  






Have you often become frantic when you thought 
that someone you really cared about was going to 
leave you? 
35 (83.3) 32 (69.6) 67 (76.1) 
Do your relationships with people you really care 
about have lots of extreme ups and downs? 
32 (76.2) 32 (69.6) 64 (72.7) 
Does your sense of who you are and where 
you’re headed often change dramatically?  
25 (59.5) 31 (67.4) 56 (63.6) 
Have you often done things impulsively?  32 (76.2) 34 (73.9) 66 (75.0) 
Have you tried to hurt or kill yourself or ever 
threatened to do so? 
42 (100.0) 46 (100.0) 88 (100.0) 
Do you have a lot of sudden mood changes? 37 (88.1) 43 (93.5) 80 (90.9) 
Do you often feel empty inside? 34 (81.0) 39 (84.8) 73 (83.0) 
Do you often have temper outbursts or get so 
angry that you lose control?  
23 (54.8) 26 (56.5) 49 (55.7) 
When you are under a lot of stress, do you get 
suspicious of other people or feel especially 
spaced out? 
31 (73.8) 33 (71.7) 64 (72.7) 
 
The average number of SCID-II criteria endorsed by participants in the JCP group was 
6.9 (SD=1.44, range=5-9) and the average number endorsed by the TAU group was 
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also 6.9 (SD=1.22, range=5-9), meaning that no significant difference was observed 
(t=0.12, p=.90).  
 
Personality disturbance 
At baseline, the mean (SD) SAPAS score was 5.21 (SD=1.66, range=1-8) for 
participants in the JCP group and 5.30 (SD=1.57, range=1-8) for those in the TAU 
group. This difference was not statistically significant (t=0.24, p=0.81).  
 
Alcohol misuse 
At baseline, participants obtained a mean score of 13.2 from a possible 40 on the 
AUDIT (SD=12.0, range=0-40). There was no significant difference in the AUDIT 
scores reported by participants in the JCP (M=13.5, SD=12.3) and TAU (M=12.8, 
SD=11.8) groups at baseline; t(85)=-2.4, p=0.81.  
 
Illicit substance use 
Table 10 shows the substance misuse patterns reported by participants at baseline. 
The most commonly used substance in the 12 months prior to baseline was 
cannabis, with 50% of participants from the TAU group and 39% of participants from 
the JCP+TAU group reporting that they had used it (more than half of whom had also 
used it in the preceding month). Other drugs that participants reported using (and 
the number who reported using them) were herbal highs (1), ketamine (2), 
mephedrone (1), 2CI (1), dimethyltryptamine (DMT) (1) and non-prescribed 





Table 10. Substance misuse patterns reported at baseline.  
 
Substance JCP arm: 








Used in past 
12 months; 
N(%) 
Cannabis 18 (39.1) 21 (50.0) 39 (44.3) 
Amphetamine 1 (2.2) 6 (14.3) 7 (8.0) 
Cocaine 9 (19.6) 11 (26.2) 20 (22.7) 
Ecstasy / MDMA 5 (10.9) 5 (11.9) 10 (11.4) 
Solvents / glue 0 (0.0) 1 (2.4) 1 (1.1) 
Benzodiazepines 6 (13.0) 7 (16.7) 13 (14.8) 
LSD 3 (6.5) 2 (4.8) 5 (5.7) 
Methadone 2 (4.3) 5 (11.9) 7 (8.0) 
Codeine / DF118 6 (13.0) 10 (23.8) 16 (18.2) 
Crack cocaine 7 (15.2) 8 (19.0) 15 (17.0) 
Heroin 4 (8.7) 7 (16.7) 11 (12.5) 
Other 1 (2.2) 5 (11.9) 6 (6.8) 
 
 
Follow-up data collection 
Seventy-three participants (83.0%) were followed-up after approximately six months 
(participants in the JCP arm were followed up a mean of 190 days [SD = 12.9] post-
randomisation and those in the TAU a mean of 192 days [SD = 11.6] post-
randomisation). At six-month follow-up, 13 participants (14.8%) could not be 
contacted; eight from the JCP+TAU arm and five from the TAU arm. A further two 
(2.3%) participants (one from the JCP arm and one from the TAU arm) died between 
baseline and follow-up. The death of the participant in the intervention arm 
occurred after the participant suffered a heart attack (there was no evidence that 
self-harm was involved). The death of the participant in the TAU arm occurred after 
a fatal overdose of medication. No participants who were able to be contacted 
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declined to take part in the follow-up interview. The total attrition at six-month 
follow-up was therefore 17.0%.  
 
3.4.  Primary outcome measure 
Self-harm 
Table 11 shows the mean number of self-harm episodes reported by participants in 
each arm of the trial, along with the dichotomised self-harm data at baseline and six-
month follow-up. At follow-up, the proportion of participants reporting self-harm 
had fallen in both trial arms. However, there was no significant difference in the 
proportion reporting self-harm between the JCP+TAU and TAU arms (OR 1.9, 95% CI: 
0.53 - 6.5; p=0.33; see Figure 3). There were also no significant differences in the 
frequency of self-harm acts reported between the two groups (RR 0.74, 95% CI: 0.4 - 
1.63; p=0.46).  
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Table 11. Comparisons of the differences in self-harm at six months between participants in the TAU and JCP arms.  
 
 TAU JCP+TAU 
Self-harmed in the past 12 months (baseline) / 6 months (follow-up) 
 N  Self-harmed N (%) N  Self-harmed N (%) 
Baseline 42 42 (100%) 46 46 (100%) 
Month 6   36 20 (55.6%) 36 25 (69.4%) 
Odds ratio of self-harm in comparison to TAU ( 95% CI; p-value)  
Month 6    72 1.86 (0.53 to 6.51; p=0.33) 
Number of self-harm episodes in the past 12 months (baseline) / 6 month (follow up) 
 N  Mean (SD)  Median (IQR) N  Mean (SD)  Median (IQR) 
Baseline 42 56.2 (102.2) 5.5 (47) 46 51.2 (126.4) 6 (37) 
Month 6   36 20.3 (67.0) 1 (3.5) 36 20.6 (89.7) 2 (7.0) 
Rate ratio of frequency of self-harm in comparison to TAU ( 95% CI; p-value) 
Month 6   72 0.74 (0.34 to 1.63; p=0.46) 
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Figure 3. Proportion of participants in each trial arm who reported self-harming 




* Figure shown with 95% confidence intervals. Unadjusted figure.  
 
Self-harm diaries 
Fifteen participants out of 73 (20.5%) returned their self-harm diaries at six-month 
follow-up; the remaining 58 participants (79.5%) stated that they had either lost 
their diaries or had forgotten to complete them during the follow-up period. As the 
response rate was <50%, missing data were not imputed and no analyses were 
conducted.  
 
Self-harm events recorded on electronic psychiatric records 
There was a relative lack of information in participants’ electronic psychiatric records 
regarding the incidence and prevalence of self-harming behaviour and, as such, it 
was not possible to subject these data to any quantitative or qualitative analysis. 























ethical permission to search participants’ emergency department records had not 
been obtained, the trial was reliant on self-reported self-harm.  
 
3.5.  Secondary outcome measures 
Table 12 contains a summary of the secondary outcome measures data at baseline 
and follow-up for both trial arms. There was no evidence of a statistically significant 
difference between the two arms at follow-up on any of the secondary outcome 
measures.  
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N Mean (SD) N Mean (SD) 
Highest score is most desired outcome 


















































Lowest score is most desired outcome 


































































* Follow-up value is higher than baseline value as the WEMWBS was introduced mid-trial 
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Depression and anxiety 
Table 13 shows the mean depression and anxiety scores, as measured by the HADS, 
reported by participants in each arm of the trial at baseline. None of the differences 
between the groups were statistically significant.  
 
Table 13. Mean HADS depression and anxiety scores (with standard deviations) 
reported by participants in the JCP and TAU arms.  
 
  JCP TAU Total p-value 
Baseline Depression 11.8 (4.98) 11.8 (4.30) 11.8 (4.64) 0.98 
 Anxiety 14.5 (4.08) 14.5 (4.49) 14.5 (4.25) 0.98 
Follow-up Depression 10.2 (4.96) 10.5 (3.54) 10.3 (4.29) 0.80 
 Anxiety 14.6 (3.83) 12.9 (4.55) 13.8 (4.25) 0.10 
 
 
Satisfaction with care 
At baseline, participants in the TAU group obtained a mean score of 18.6 on the CSQ 
(SD=1.5, range=14-21) and the mean score in the JCP group was 19.9 (SD=1.5, 
range=17-23). At follow-up, participants in the TAU group obtained a mean score of 
19.6 (SD=1.3, range=17-22) and those in the JCP group scored a mean of 20.0 
(SD=2.0, range=17-27). None of these differences were statistically significant.  
 
Working alliance (participant rated) 
At baseline, participants in the TAU group obtained a mean score of 63.4 on the 
WAI-C (SD=17.9, range=12-84) and those in the JCP group scored an average of 58.5 
(SD=18.5, range=19-81). At follow-up, participants in the TAU group obtained an 
average score of 60.5 (SD=15.9, range=26-82) and those in the JCP group scored an 





An assessment of mental wellbeing was introduced after data collection had 
commenced and following consultation with the Project Advisory Group (PAG).  A 
total of 40 out of 88 (45.4%) participants completed the WEMWBS at baseline. All 
participants who were followed-up completed the WEMWBS at 6-month follow-up. 
At baseline, participants in the TAU group reported an average score of 31.7 
(SD=10.1, range=14-52), whilst participants in the JCP group reported an average of 
29.7 (SD=11.1, range=14-51). The mean scores of participants from both groups 
increased at follow-up; participants in the TAU group reported an average score of 
35.3 (SD=10.3, range=17-61), whilst participants in the JCP group reported an 
average of 34.3 (SD=11.4, range=14-57). The difference between the increased 
scores of the two arms was not significant (p=0.97).  
 
Quality of life 
At baseline, participants in the TAU group reported an average quality of life score of 
45.2 out of 100 on the EQ-5D (SD=17.5, range=0-80) and those in the JCP group 
reported an average of 45.1 (SD=17.2, range=10-90). At follow-up, participants in the 
TAU group reported an average score of 53.1 (SD=21.7, range=5-90) and those in the 
JCP group reported an average of 47.0 (SD=19.0, range=5-85). None of these 
differences were statistically significant.  
 
Working alliance (clinician rated) 
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At baseline, responding clinicians of participants in the TAU group obtained an 
average score of 61.3 on the WAI-T (SD=11.1, range=33-83) and those clinicians with 
participants in the JCP group scored an average of 63.7 (SD=8.7, range=44-78). At 
follow-up, the TAU clinician group obtained an average score of 63.0 (SD=10.7, 
range=40-84) and the JCP clinician group scored an average of 64.7 (SD=10.9, 
range=40-85). None of these differences were statistically significant.  
 
Service engagement (clinician rated) 
At baseline, responding clinicians of participants in the TAU group obtained an 
average score of 5.3 on the SES (SD=1.6, range=2-8) and those clinicians with 
participants in the JCP group scored an average of 5.2 (SD=1.7, range=1-8). At follow-
up, the TAU clinician group obtained an average score of 10.9 (SD=5.6, range=0-23) 
and the JCP clinician group scored an average of 8.6 (SD=6.1, range=0-25). The 
difference between the increased scores of the two arms was not significant 
(p=0.16). 
 
Use of JCPs 
Participants were asked to provide details of how frequently (and in which context) 
they had used their JCPs during the follow-up period. Table 14 contains a summary 




Table 14. Reported JCP use by participants in the JCP+TAU arm.  
 
Self-harm parameters Month 6 TAU JCP+TAU 
Did you make a JCP?*  No 35 (97%) 3 (8%) 
Yes 1 (3%) 33 (89%)  
Do you still have your 
JCP? 
No - 3 (9%) 
Yes 1 30 (91%) 




Privacy concerns - 
Disagreed with contents - 
Out of date** 1 
Other (become unhelpful) 1 
Did you use your JCP in a 
crisis? 
No 9 (26%) 
Yes 25 (74%) 
If you used your JCP in a 
crisis, how did you use it?   
 
Total n=25 
Looked at / referred to  20 (80%) 
Number of times; mean (sd) 4.8 (4.4) 
Asked someone else to look at it  9 (36%) 
Number of times; mean (sd) 2.8 (1.7) 
Care coordinator/other professional referred 8 (32%) 
Number of times; mean (sd) 5.1 (3.7) 
Carer/other person suggested referred 7 (28%) 
Number of times; mean (sd) 3.3 (2.6) 
Other 3 (12%) 
Number of times; mean (sd) 1 (-) 
If you used your JCP in a 
crisis, how did you feel 
after looking at it?  
 
Total n=25   
Felt better/ reassured 10 (40%) 
Changed what I was doing and did what was 
agreed JCP 
12 (48%) 
Care coordinator/other professional changed what 
they were doing and did what was agreed JCP 
3 (12%) 
Carer/other person changed what they were doing 
and did what was agreed JCP 
5 (20%) 
No impact 3 (12%)  
Other  2 (8%) 
Did you use your JCP in 
another situation (not a 
crisis)? 
No 19 (56%0 
Yes  15 (44%)  
If you used your JCP in 
another situation, how 
did you use it?  
 
Total n=15 
Looked at / referred to  9 (60%) 
Number of times; mean (sd) 4 (2.8) 
Asked someone else to look at it  7 (47%) 
Number of times; mean (sd) 5.4 (8.7) 
Care coordinator/other professional refer 5 (33%) 
Number of times; mean (sd) 2.4 (1.1) 
Carer/other person suggested refer 2 (13%) 
Number of times; mean (sd) 1.5 (0.7) 
Other 1 (7%) 
Number of times; mean (sd) - 
Overall, did you follow 
your JCP?  
No 3 (9%) 
Yes 16 (47%) 




Table 14. Reported JCP use by participants in the JCP+TAU arm (continued).  
 
Overall, was your JCP 
followed by health 
professionals who saw it? 
No 17 (50%) 
Yes 13 (38%) 
Partly / somewhat 3 (9%)  
If you didn’t refer to or 
use your JCP, why not?  
 
Total n=10 
Didn’t need it / no crisis  4 (12%) 
Lost it 3 (9%) 
Didn’t agree with contents 1 (3%) 
Out of date  - 
Other 4 (12%) 
As a result of creating 
your JCP, has there been 
any change in any of the 
following areas?  
 
Total n=34  
Relationship with mental health 
team  
Much better 4 (12%) 
A bit better 12 (35%) 
No change 14 (41%) 
A bit worse 3 (9%)  
Much worse - 
Care you receive from mental 
health team 
Much better 4 (12%) 
A bit better 9 (26%) 
No change 18 (53%) 
A bit worse 1 (3%) 
Much worse 1 (3%) 
Satisfaction with care Much better 5 (15%) 
A bit better 8 (24%) 
No change 18 (53%) 
A bit worse 3 (9%)  
Much worse - 
Control over problems Much better 5 (15%) 
A bit better 11 (32%) 
No change 15 (44%) 
A bit worse 2 (6%) 
Much worse 1 (3%)  
How you feel about continuing 
contact with your mental health 
team 
Much better 8 (24%) 
A bit better 6 (18%) 
No change 16 (47%) 
A bit worse 2 (6%) 
Much worse - 
Would you recommend a 
JCP to other service 
users? 
No 1 (3%) 
Yes 29 (85%) 
Don’t know 4 (12%)  
Have you recommended 
a JCP to other service 
users? 
No 29 (85%) 
Yes 5 (15%)  
* Only those participants who answered yes are applicable to answer the remaining  
   questions  




3.6.  JCP content analysis 
Experience of crises 
When reflecting on their experiences of previous crises, participants described a 
state of acute distress associated with a disruption in their daily functioning. When 
they were in this state, many reported failing to meet basic self-care requirements 
such as eating, drinking and bathing. Many reported withdrawing from ‘the outside 
world’ and avoiding all contact with friends and family members for the duration of 
the crisis. Additionally, it was common for such isolation to result in further 
complications (e.g. essential bills not being paid during times of crisis).  
 
Connecting with / disconnecting from others during a crisis 
Many participants emphasised the importance of having the opportunity to connect 
with people in their personal and/or professional networks during times of crisis and 
the benefits associated with this. Conversely, other participants preferred to 
disconnect completely from other people during a crisis. Table 15 displays illustrative 
examples of situations and actions perceived by participants as being helpful or 
unhelpful during crises.  
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Table 15. Illustrative examples of situations and actions listed as being helpful and unhelpful by participants seeking to connect with, or 
disconnect from, other people during times of crisis.  
 
 Courses of action perceived as  
helpful during a crisis 
Situations and circumstances perceived as 
unhelpful during a crisis 
Participants seeking to connect 
with other people during a crisis 
Seeking help from my community mental health team 
or the home treatment team 
Isolating myself from the outside world 
 Calling my care coordinator Being trapped in my house and feeling alone 
 Spending time with friends Not having anyone to talk to 
 Reaching out and asking for help, either from friends, 
my doctor or my sister 
Withdrawing myself 
 
 Spending time with my daughters Being ‘cooped up’ in the house alone 
 Calling the Samaritans1 and talk with somebody about 
my feelings 
Isolating myself (as this can make me feel worse) 
Participants seeking to disconnect 
from other people during a crisis 
Spending time on my own Being forced to go out in public 
 Taking a time-out by myself Being forced to socialise 
 Going to bed for a sleep Being forced to talk when I don’t want to talk  
 Going out for a walk and giving myself some space Not being left alone when I want to be alone 
 Removing myself from the situation and going for a 
walk 
Being surrounded by people 
  Being around too many people 
1 Anonymous telephone counselling service in the UK.  
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Perpetuating factors 
Many participants described situations and behaviours which had contributed to 
exacerbating previous crises and elected to include these in their JCPs as reminders 
of what to avoid in the event of a future crisis. These fell into one of two categories: 
“Interpersonal interactions” (such as seeing friends, family members or 
acquaintances that the participant did not wish to see or, conversely, being in 
isolation when the participant did not wish to be alone), or “Self-destructive 
behaviours” (such as self-harming, using or misusing drugs/alcohol, engaging in risky 
sexual behaviour or spending excessive amounts of money).  
 
Interactions with mental health professionals during crises 
Many participants recalled unhelpful interactions with mental health professionals 
during previous crises and expressed a desire to avoid similar interactions in the 
future. Phrases used to describe clinicians during previous crises included: 
‘judgmental’, ‘dishonest’, ‘dismissive’, ‘condescending’, ‘disrespectful’, ‘sarcastic’, 
‘misleading’, ‘impatient’, ‘patronising’, ‘not taking [the participant] seriously’ and 
‘treating [the participant] like a child’. Specific actions performed previously by 
clinicians that were deemed unhelpful during a crisis included ‘not following through 
on promises’ (including not returning telephone calls), ‘not being discrete in front of 
others’, ‘comparing [the participant] to other clients’ and ‘giving [the participant] 
religious advice’. Table 16 displays illustrative examples of statements from 




Table 16. Illustrative examples of specific actions that participants stated they wanted mental health professionals to do during future 
crises.  
 
 Specific action 
Emotional support ‘Talk to me; don’t just sit there doing active listening.’ 
 ‘Be upbeat and positive.’ 
 ‘Reassure me that things will be alright.’ 
 ‘Don’t force me to speak.’ 
Practical support ‘Discuss options with me about where to go from here.’ 
 ‘Involve me in the decision-making process.’ 
 ‘Help me to plan out my next day.’ 
 ‘Ask me to hand over any excess medication.’ 
Respect ‘Please don’t speak to me so loudly that everyone in the room can hear my business; please respect my privacy.’ 
 ‘Non-judgmental responses.’ 
 ‘Please treat me with respect and don’t be rude to me.’ 
 ‘Treat me as a person, not as a person with mental health problems.’ 
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Specific refusals regarding treatment 
Thirty-seven participants (90.2%) included at least one specific refusal regarding 
treatment during future crises. Preferences regarding medication and involuntary 
treatment were the two most common refusals. Medication refusals were most 
often based on: a) a preference to avoid being treated with specific medication(s) 
(56.1%); b) undesirable side effects of specific medication(s) (17.1%); or c) known 
allergies to certain medication(s) (12.2%). Eleven participants (26.2%) expressed a 
preference not to receive treatment involuntarily when in a crisis.  
 
Dissemination of JCPs 
At the request of participants, copies of their JCPs (either paper copies or electronic 
copies) were distributed to a range of health and statutory bodies involved in their 
care. The two most frequently requested recipients were community care 
coordinators and GPs (see Table 17). 
 
Table 17. Individuals and services nominated by participants to receive a copy of 
their JCPs.  
 
Recipient of JCP N % 
Service user 41 100.0 
CMHT care coordinator 39 95.1 
GP 37 90.2 
Electronic psychiatric records 23 56.1 
Other health professional(s) 10 24.4 
Parent(s)/child(ren) 8 19.5 
Friend(s) 7 17.1 
Partner/spouse 5 12.2 
Social worker 3 7.3 
Drug & alcohol worker 2 4.9 
Emergency department at local hospital 2 4.9 
Probation officer 1 2.4 
Other family member(s) 1 2.4 
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CHAPTER 4. DISCUSSION 
4.1.  Summary of main findings 
The trial investigated the impact of joint crisis plans on the self-harming behaviour of 
88 community-dwelling adults recruited from community mental health teams in 
south London, all of whom met DSM-IV-TR diagnostic criteria for borderline 
personality disorder. The findings did not support any of the five hypotheses as there 
were no significant differences between the intervention and control groups on any 
primary or secondary outcome measures. Possible explanations for the negative 
findings are discussed in section 4.2 General methodological considerations, below.  
 
4.2.  General methodological considerations 
Trial design & randomisation 
Randomised controlled trials (RCTs) are widely recognised as the most reliable 
method of determining the effectiveness of healthcare interventions (593) and this is 
due to the randomisation process itself. Randomisation is the most robust method of 
ensuring the even distribution of all known and unknown confounding factors that 
may impact on clinical outcomes (566, 567). Without randomisation, treatment 
comparisons may be consciously or unconsciously prejudiced by selecting a 
particular participant to receive a particular intervention (588). For randomisation to 
be truly effective, two interrelated steps must occur; firstly, a sequence must be 
generated which is sufficient to prevent selection bias. Secondly, neither 
investigators nor participants should be able to foresee the result of any 
randomisation episode, thereby preventing detection bias (594). Each of these 
conditions was met in the trial as randomisation was conducted externally by the 
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Clinical Trials Unit at King’s College London using a process of electronic stratified 
randomisation. As such, members of the research team could not have predicted the 
assignment of any given participant. Furthermore, randomisation was not an 
influential factor during the recruitment phase, as only one potential participant 
declined to participate because he could not be guaranteed of being randomised to 
the JCP+TAU arm of the trial.  
 
The lack of statistically significant differences between the groups on primary or 
secondary outcomes in the face of high user acceptability was counterintuitive. 
However, significant clinical differences between the two groups may not have been 
detected for a number of reasons and the trial had several important limitations 
which may have impacted on the outcomes. Each of these is discussed below. 
 
4.3.  External and internal validity of the trial 
When designing or interpreting a trial, the two main concerns of the researcher are 
the internal validity and external validity of the trial (595). Internal validity relates to 
the extent to which systematic error or bias is minimised, whilst external validity 




The internal validity of a trial can be threatened by several types of bias, including a) 
selection bias, b) detection bias, and c) attrition bias and missing data. Each of these 
is discussed below in relation to the trial.  
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a) Selection bias 
The risk of selection bias was minimised as a result of the centrally-operated 
stratified randomisation process used in the trial. The lack of selection bias was 
evidenced by the similarity of the intervention and control groups in both size and 
demographic characteristics.  
 
 
b) Detection bias 
When an investigator who should be blinded to participant allocation becomes 
unblinded, this is an example of detection bias, as the investigator’s knowledge of 
the participant’s allocation may (intentionally or otherwise) influence the 
assessment of outcome variables (594). The trial was a single-blind trial (i.e. follow-
up data were collected by a research worker blinded to each participant’s 
allocation). Due to the nature of the trial, it would not have been possible to use a 
double-blind methodology (i.e. it would have been impossible to keep participants 
and clinicians blinded to allocation status or to have a ‘placebo JCP’ condition). The 
research worker collecting all follow-up data was unblinded in eight (9.1%) cases; on 
seven occasions the unblinding was a result of the participant’s actions and on one 
occasion it was a result of the actions of a CMHT clinician. All instances of unblinding 
occurred prior to follow-up data collection being conducted and, as a result, the 
research worker may have been unable to conduct the follow-up interview in an 
unbiased manner. Although this happened in only a small minority of cases, it may 
have impacted on the data obtained. 
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d) Attrition bias and missing data 
The experience of recruiting from CMHTs was similar to that reported in the 
literature, as some clinicians were inherently more receptive to research and 
produced more referrals than others (555, 556). Other clinicians refused to complete 
the required measures either at baseline or follow-up (or both) and one clinician 
stated unambiguously that he disagreed with the trial’s methodology and would not 
be completing any trial paperwork as a result. This stance by such clinicians, in 
addition to the participants who were lost to follow-up, resulted in a small amount 
of missing data throughout the trial. Missing data (particularly if differential between 
trial arms) can compromise internal validity and also lead to a loss of power in trials 
(596). However, as the amount of missing data in the trial was minimal, no 
substantial loss of power resulted. Additionally, rates of attrition from the trial and 
the subsequent amount of missing data were approximately even in the two groups. 
The impact of missing data was minimised by using modified intention-to-treat 
analyses throughout (see below).  
 
Intention-to-treat analysis 
Intention-to-treat refers to the process of all randomised participants, regardless of 
their outcome after randomisation, being retained within their original groups during 
data analyses (596). This is because participants who are not followed up (for any 
reason) are likely to be different from participants who go on to complete a trial 
(594) and intention-to-treat analyses helps to avoid selection bias. Although 
intention-to-treat analysis is likely to provide a reduced estimate of treatment effect 
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when adherence to treatment is low (299), this was not the case in this trial as 
adherence to treatment was high.  
 
External validity 
External validity relates to the extent to which the findings from a trial provide a 
robust basis for generalising the results to other populations, settings and variables – 
that is, its generalizability and applicability (588, 594). The findings of a trial with 
good external validity can more easily be applied to real clinical settings (597). 
External validity depends on the characteristics of the sample, the setting, the 
intervention, the outcome measures used and the social, economic and cultural 
environment in which the trial is conducted (588). Participants in the trial were 
recruited from inner-city CMHTs in south London and they all met DSM-IV diagnostic 
criteria for BPD. Most were white British, female, aged in their thirties, single, 
unemployed, and in receipt of long-term government disability benefits. A majority 
had left school prior to the age of 16, many were moderate to heavy consumers of 
alcohol and approximately half had used illicit substances in the  
previous 12 months. Demographically, the sample was broadly similar to those seen 
both in secondary care in the UK and in other trials in the field of BPD research (284, 
302), indicating high external validity.  
 
Choice of control group 
Despite the existence of clinical guidelines, the concept of ‘treatment as usual’ for 
BPD can potentially vary greatly between CMHTs, between clinicians and between 
individual service users. Indeed, when the trial was conducted, there was no 
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standard definition of TAU specifically for people with BPD in the UK. Some 
participants reported not having seen their care coordinator during the six-month 
follow-up period despite still being registered as an active service user with the 
CMHT, whilst other participants reported being in contact with their care 
coordinator several times each week during the follow-up period. The net result of 
this was that participants in both trial arms received considerable variation in 
treatment. This is, however, consistent with previous research which states that 
different service users receive different levels of care from their treating clinicians 
(598-600).  
 
Contamination of TAU group 
It is possible that some participants in the TAU group may have received a generic, 
but equally efficacious, crisis contingency plan as part of their concurrent treatment 
as usual under the CPA, thereby potentially diluting the true impact of the JCP 
intervention. However, as stated earlier, recent findings published by Farrelly and 
colleagues (569) highlighted a low (15 percent) level of individualised crisis plan 
content amongst 424 CMHT service users, with the majority of crisis plans containing 
only generic information. Additionally, a 2007 audit of South London and Maudsley 
Trust service users who had attended the Maudsley emergency clinic (followed up 
nine months later) revealed that 42 percent of those under the standard CPA did not 
have a crisis contingency plan on their electronic records (unpublished data). Of 
those that did, only 37 percent of crisis plans contained any information which was 
specific to the service user, with the remaining plans consisting solely of generic 
information. It seems unlikely, therefore, that such generic crisis contingency plans 
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(which were written by the clinician, without input from the service user), would 
have contributed to the absence of a significant difference between intervention and 
control groups in this trial. 
 
Lack of statistical power (Type II error) 
Type II error occurs  when a non-significant result is obtained and the null hypothesis 
is accepted incorrectly (597). There was a shortfall in predicted recruitment to the 
trial by approximately 30 participants (i.e., 25% of the initial target sample size) and 
this resulted in the trial being underpowered to detect a difference in self-harming 
behaviour. As such, there is a chance that the null hypothesis was accepted 
incorrectly (i.e., a Type II error was committed). Perhaps the most significant 
methodological limitation was that the trial was underpowered.  
 
Additionally, it has been reported that less than one third of publicly funded trials 
manage to recruit according to their original plan (601) and the current under-
recruitment may have reflected a generic problem relating to conducting research in 
the NHS, especially during a period of extensive service restructuring. Fewer referrals 
were made by clinicians and the rate of attrition was higher than anticipated when 
designing the trial. These findings emphasise the need to allow for a longer 
recruitment phase and larger inflation factors in the calculation of sample sizes for 
trials involving people with BPD. It is worth noting that, of the 30 individuals who 
declined the invitation to take part in the study, the majority stated that they did not 
wish to take part in research of any kind and only one stated that he disagreed with 
the trial’s methodology. 
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Problems with measuring self-harm 
Data collection via self-report methods 
Data relating to the main outcome measure - self-harm - were obtained 
retrospectively via self-report. Although similar self-report methods have been used 
in previous RCTs aiming to reduce self-harming behaviour (286), there is an inherent 
risk associated with using this methodology for obtaining self-harm data, as it is 
dependant entirely upon respondents’ candour, awareness and comprehension of 
questionnaire items (405). It may also be susceptible to reporting bias (unintentional 
or otherwise) and the occurrence of both false negatives and false positives is 
possible. Additionally, participant recall at six months may not have been accurate 
(602) and this may have impacted on the findings observed. 
 
Severity and behavioural intention of self-harm 
With the exception of the most recent act of self-harm, the medical severity of 
participants’ self-harm was not measured and nor was their behavioural intention. 
Given that such intentions may vary considerably between individuals and even 
within the same individual at different times, these may have been important data 
to collect. 
 
Challenges relating to data collection 
Three methods of capturing self-harm events were used concurrently to maximise 
the accuracy of self-harm data collected: participant interviews, contemporaneous 
diaries and screening of participants’ electronic psychiatric records. All participants 
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were provided with a brief (one-page) self-harm diary (see Appendix 2) at baseline 
and asked to record all episodes of self-harm during the follow-up period before 
bringing the diary to their follow-up appointment. Fifteen participants (20.5%) 
brought their diary to their follow-up appointment; the remaining 58 (79.5%) stated 
that they had either lost their diaries or had forgotten to complete them during the 
follow-up period. Although a minority of participants reported no self-harm events 
during the follow-up period (and, thus, returning their self-harm diary would not 
have provided any additional information), the majority of all trial participants (62.5 
%) did self-harm during the follow-up period and their diaries may have provided 
valuable data.  
 
Each participant’s electronic psychiatric records were also screened upon completion 
of their follow-up interview in order to establish the number of events of self-harm 
recorded by clinicians during the follow-up period. Both the quantity and quality of 
information regarding participants’ self-harming contained within their electronic 
records was poor, with episodes of self-harm reported by participants rarely 
featuring in their electronic records. There are two possible explanations for this 
finding; firstly, that participants were not informing their treating clinicians of the 
true extent of their self-harming behaviour or, secondly, that clinicians were aware of 
the true extent but did not, for various reasons, accurately document such behaviour. 
Given that self-harm is associated with considerable stigma and most self-harm is not 
associated with help-seeking behaviour (418, 603, 604), it is likely that the former 
explanation accounted for this finding. 
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In their 2011 systematic review of instruments designed to measure self-harm in 
adults, Borschmann and colleagues (405) posited that the most reliable way of 
capturing episodes of self-harm may be to triangulate multiple data sources such as 
self-report accounts, clinician/observer accounts, medical records and 
contemporaneous patient-held devices such as brief diaries. The findings from this 
trial suggest that participant diaries were not an effective method of capturing self-
harm events contemporaneously, as they were misplaced frequently by participants. 
One alternative might be for participants to document episodes of self-harm using 
their phones (for example, by sending a text message to a pre-set number), as they 
may be less likely to lose their phone than a self-harm diary. Electronic records 
under-documented the incidence of self-harm and face-to-face follow-up interviews 
with participants appeared to provide the most complete account (i.e., the least 
missing data) of self-harming behaviour during the follow-up period. However, it 
must be noted that self-report is associated with recall bias and, as such, is also not 
without limitations.  
 
Generalizability of findings 
It is possible that eligible non-participants (i.e., those service users who declined to 
take part in the trial) may have differed significantly on key demographic or outcome 
measures from the participants who chose to enter the trial and this may have 
impacted on the results obtained. Previous studies have also reported that non-
participants in health-related studies are more likely to be of lower socioeconomic 
status (i.e., worse living conditions, lower educational level and poorer employment 
status) (605), to have a lower level of functioning (as measured by global assessment 
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of functioning scores) (606), to have increased rates of substance misuse (607) and 
to have poorer general physical (608) and mental (609, 610) health than participants. 
It is therefore possible that potential participants who declined to be involved in the 
trial may have had poorer overall outcomes - including elevated rates of self-harming 
behaviour - than trial participants. 
 
Seventy-three per cent of all referred service users were both eligible and willing to 
take part in the trial. The 30 service users who declined an offer to participate all 
cited one or more of the following reasons for their decision: 
1) The client failed to acknowledge the possibility of future crises; 
2) The client was unwilling to undergo the randomisation process; 
3) The client did not agree with trial design; 
4) The client stated s/he was too busy to participate; 
5) The client had participated in a sufficient number of research studies prior to 
being approached about the trial. 
 
Recruitment to the trial was facilitated with the assistance of local CMHT clinicians 
and, due to the conditions of the trial’s ethical approval, no potential participant 
could be contacted by a researcher without having previously consented to such 
contact via their treating clinician. As such, researchers were limited to an extent in 
relation to a) the identification of potential participants, b) the initial approach of 
potential participants, and c) the provision of contact details for potential 
participants. Some sites - and some individual clinicians - were more productive in 
relation to the identification of potential participants than others and the practice of 
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‘gatekeeping’ (i.e., allowing or denying access to the study (556)) by some clinicians 
impacted adversely on the recruitment process throughout the trial. As the research 
team was, by definition, unaware of potentially suitable participants until notified by 
CMHT clinicians, this phase of the recruitment process was open to a range of 
selection biases (intentional or otherwise) on behalf of clinicians. It is possible that 
any potential participants who were not approached for the present study may have 
differed significantly from the group of participants who did take part. 
 
Loss to follow-up 
Fifteen participants (17.0%) could not be followed up; nine (19.6%) from the JCP arm 
and six (14.3%) from the TAU arm. Attrition can often be substantial when treating 
people with BPD (299) and, in light of the underlying psychopathology, this is 
perhaps understandable; difficulties with collaboration, flight from exploratory work 
and defence against change are observed frequently in this population (611). 
However, the attrition rate was considerably lower than rates observed in previous 
interventions involving this population. Reporting on a trial of psychotherapy for 
BPD, Gunderson and colleagues (240) reported that more than half (60%) of 
participants had dropped out of the study after six months. Skodol and colleagues 
(67) reported that 40 percent of participants with BPD had dropped out of their trial 
of outpatient treatment after three months, whilst Waldinger and Gunderson (612) 
reported a mean dropout rate of 47 percent after six months of people with BPD 
after a survey of private psychotherapy practices. Finally, de Panfillis and colleagues 
(6) reported a dropout rate of 33.3% within the first three months from outpatient 
care for people with BPD. By comparison, the dropout rate of 17.0% after six months 
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in the trial was low and may have reflected the relatively low intensity of the JCP 
intervention, in addition to participants being required to attend only one follow-up 
appointment after six months.  
 
Barriers to recruitment 
One prospective participant re-scheduled her baseline appointment five consecutive 
times, at which point she was excluded from entering the trial. Exactly one quarter 
of participants did not attend at least one appointment during the trial and a further 
seven potential participants were excluded after failing to attend three consecutive 
baseline appointments.  
 
Barriers to intervention implementation 
One clinician in the present trial was the care coordinator for two participants, both 
of whom were randomised into the JCP+TAU arm. However, as a result of the 
clinician being unable to attend the JCP planning meeting (on several occasions), 
neither of these participants was provided an opportunity to create their JCP. Both 
participants, however, did attend the follow-up appointment. Another participant 
delayed the completed version of her JCP being approved by more than two months, 
during which time more than 20 emails were sent between the research team and 
the participant. This resulted in her not having a JCP for more than one third of the 
follow-up period. Finally, one participant stated in her JCP the desire to attend the 
local emergency department when she was feeling at risk to herself but further 
stated that she did not wish to speak to any health professionals (and, rather, that 
she would feel safe simply by sitting there by herself). Unbeknownst to those 
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present at her JCP planning meeting, this wish directly contradicted the protocols of 
the local NHS emergency department and she was required (against her wishes) to 
speak with staff members the next time she attended in a crisis. This was not well 
received by the participant and she did not go on to participate in the follow-up 
interview several months later. 
 
Barriers to data collection 
The experience of recruiting from CMHTs was similar to that reported in the 
literature, as some clinicians were inherently more receptive to research and 
produced more referrals than others (555, 556). Other clinicians refused to complete 
the required measures either at baseline, follow-up or both. In contrast to this, the 
research team received a considerable amount of positive feedback from clinicians 
throughout the trial, in relation to both their clients’ JCPs and the trial overall.  
 
Problems relating to JCP content 
Two participants stated during their JCP planning meetings that they wished to 
include the statement “If I overdose, I do not wish to be resuscitated” in their JCPs 
under the heading “Practical help in a crisis”. It was agreed that this course of action 
would not be in keeping with the true ethos of an appropriate crisis plan and, after 
further discussion, both participants agreed to include the statement “However, I 
fully understand that treating health professionals may choose not to follow this 
wish in an emergency” after the initial statement.  
 
Crisis definition and frequency 
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Although this was a trial of joint crisis plans, the number of crises experienced by 
participants during the follow-up period was not measured. This was because the 
JCPs were not designed to reduce the number of crises experienced by participants; 
rather, they were designed to help participants to better navigate future crises 
(however frequently or infrequently they may occur). Additionally, as highlighted in 
the literature review, there is no universally agreed definition of a ‘crisis’ and so it 
was not possible to operationalise this outcome for the trial. However, at follow-up, 
when reflecting upon their experiences, participants described similar emotional and 
contextual states that they regarded as crises; during previous crises, many 
participants reported that they had failed to meet their basic self-care requirements, 
including eating, drinking and bathing and had been unable to think or behave in a 
rational manner. As such, despite the absence of a clear definition of crises, it is 
reasonable to assume that participants were experiencing similar behavioural 
events.  
 
Adherence to protocol and use of JCPs 
Adherence to the protocol was high, as a total of 41 out of 46 participants in the 
JCP+TAU group (89.1%) attended their JCP planning meeting and consequently 
received the active intervention. There were relatively few protocol deviations and 
these are discussed below under “Deviations from protocol”. Data gathered at 
follow-up indicated that JCPs were used both during and between crises and were 
viewed favourably by the majority of participants. More than 90 percent of 
participants were still in possession of their JCP at follow-up (two participants stated 
that they had lost their plans) and approximately three quarters stated that they had 
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used their JCP during a crisis. This is comparable to the findings by Henderson and 
colleagues (544), in which 36 out of 45 (80.0%) of participants were still in 
possession of their JCP at 15-month follow-up.  
 
Forty-four percent of participants had referred to their plans in other (non-crisis) 
situations. Despite the lack of clinically significant results observed, the process of 
creating (and owning) a JCP appeared to have a positive impact on the experience of 
receiving mental health care. Many participants stated that, since creating their JCPs, 
there had been an improvement in their relationship with their treating mental 
health team (47%), they a greater feeling of control over their problems (47%), they 
had an increased satisfaction with the care they received (39%) and there was an 
improvement in the quality of mental health care they received (38%). A total of 85 
percent of participants stated that they would recommend JCPs to other service 
users in similar circumstances. 
 
Deviations from protocol 
Addition of new outcome measure 
The measure of mental wellbeing used in the trial (the WEMWBS) did not feature in 
the original protocol of the trial (387) and was introduced after data collection 
commenced, following consultation with the Project Advisory Group (PAG), whose 
view was that it was important to capture these additional data as part of the 
feasibility work. As such, less than half of participants (40; 45.4%) completed the 
WEMWBS at baseline and there were some missing data relating to mental 
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wellbeing. However, these were fully accounted for during analysis (see ‘Missing 
Data’, above).  
 
4.4.  Strengths of the study 
In addition to the above limitations, the trial also had several strengths that warrant 
discussing. Firstly, it was conducted in routine NHS settings, with recruitment taking 
place across five separate and demographically disparate boroughs during a period 
of considerable service restructuring and efficiency savings. Despite this, 
approximately 75 percent of the target sample size was recruited and approximately 
80 percent were retained at follow-up. The refusal rate (25 percent) was comparable 
with those reported in previous RCTs involving service users with BPD (286, 302) 
and, as stated above, the attrition rate was low when compared with previous BPD 
research (67, 240, 612). Also, the response rate of 75 percent was twice as high as 
that reported in a previous large scale RCT of joint crisis plans (541). The majority of 
service users (77.4%) who were invited to participate in the trial consented and were 
willing to undergo the randomisation procedure. Although a further nine percent 
later proved to be ineligible, such a high response rate was somewhat unexpected as 
the concept of randomisation has been discussed in the literature as a common 
difficulty associated with successfully recruiting people with BPD into trials (52, 233). 
Furthermore, this rate was considerably higher than the 53.2% response rate 
achieved in a recent large-scale RCT of JCPs for people with psychosis (550). Finally, 
in relation to data collection, although the trial could not have utilised a double-blind 
methodology, all follow-up data were collected by a research worker blinded to 
treatment allocation and this blindness was maintained in 62 of 73 (84.9%) cases. 
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4.5.  Discussion of hypotheses in light of trial findings 
This was primarily a feasibility (and not a hypothesis-testing) trial. However, five 
exploratory hypotheses were formulated and each of these is discussed below in 
relation to the findings obtained.  
4.5.1.  Primary outcome 
Hypothesis 1: Participants in the JCP group would report significantly fewer self-harm 
events during the six-month follow-up period, when compared with participants in 
the control group; 
Findings showed that there was no significant difference in the mean number of self-
harm events reported over the follow-up period between participants in the JCP 
group and the TAU group. Although the mean frequencies were very similar, 
participants in the JCP group reported a marginally higher number of self-harm 
events during follow-up (20.6 vs. 20.3) and also a higher median number of events 
(two vs. one). Additionally, a higher proportion of participants in the JCP group 
reported self-harming during the follow-up period (69.4% vs. 55.6%), though this 
difference was also not significant.  
 
4.5.2.  Secondary outcomes 
Although no specific hypotheses were formulated in relation to the secondary 
outcome measures investigated, several exploratory hypotheses were posited 
regarding secondary outcomes. A brief discussion of each is below.  
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Hypothesis 2: Participants in the JCP group would report a significant improvement 
in engagement with mental health services at follow-up, compared with participants 
in the control group; 
Although the mean score of participants in the JCP group decreased over the follow-
up period (indicating an improvement in engagement) and the mean score of 
participants in the TAU group increased (indicating a reduction in engagement), this 
difference was not statistically significant. As such, this hypothesis was not 
supported. It is possible that crisis plans which are integrated with a more detailed 
psychological treatment programme (i.e. those requiring greater engagement) may 
be required to help people with BPD who repeatedly self-harm (409, 613).  
 
Hypothesis 3: Participants in the JCP group would report a significant improvement 
in therapeutic alliance at follow-up, compared with participants in the control group; 
The results demonstrated that there was no significant difference in the change in 
mean therapeutic alliance scores at follow-up between participants in the two 
groups and, as such, this hypothesis was not supported. Despite this, the change in 
therapeutic alliance scores at follow-up was greater - and in the hypothesised 
direction - in the intervention group than in the control group. As with service 
engagement, the heterogeneity of care received by participants in both arms may 
have contributed to this finding.  
 
Hypothesis 4: Participants in the JCP group would report a significant improvement 
in satisfaction with care at follow-up, compared with participants in the control 
group; 
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No significant differences were observed between the mean satisfaction scores by 
participants in the intervention and control groups. In Sutherby and colleagues’ pilot 
study of crisis plans (548), a majority of participants reported that they felt more 
positive, more involved in their care and more in control of their mental health 
problems at follow-up as a result of developing their plans. It is noted, however, that 
satisfaction was not measured in the control group and, as such, no direct 
comparison can be made. Other forms of psychiatric advance directives have also 
resulted in increased feelings of empowerment and self-determination amongst 
mental health service users, as the service users believe that such directives have the 
potential to facilitate stronger client-service relationships (614). 
 
Hypothesis 5: Participants in the JCP group would report a significant improvement 
in quality of life at follow-up, compared with participants in the control group; 
Mean quality of life scores increased marginally across both groups at follow-up, 
although neither of these increases were significant and nor was the difference 
between the two groups. Previous studies have reported mixed findings regarding 
the impact of interventions on the health-related quality of life in people with BPD. 
Davidson and colleagues (294) reported no significant differences in quality of life at 
12 or 24 months follow-up in a trial of CBT for BPD and McMain and colleagues (278) 
also showed no significant improvements in quality of life (using the same 
instrument that was used in this trial, the EQ-5D) in a trial of DBT. Against this, 
Giesen-Bloo and colleagues (302) showed significant improvements in health-related 
quality of life in outpatients with BPD receiving schema-focused therapy compared 
with those receiving transference-focused psychotherapy. Likewise, Carter and 
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colleagues (615) reported a significant improvement in quality of life scores of 
people with BPD receiving DBT in an Australian trial compared to those receiving 
treatment as usual.  
 
4.6.  Qualitative findings 
Participants made considered choices to include useful information in their JCPs both 
for themselves and for health care professionals with whom they might interact 
during future crises. There is no standardised definition of a crisis (387), although 
participants clearly described a similar and coherent pattern of distress accompanied 
by a sudden disruption in functioning following an acute life event. During previous 
crises, participants reported that they had failed to meet their basic self-care 
requirements, including eating, drinking and bathing. Subsequently, many 
participants chose to include in their JCPs a reminder to themselves to address these 
basic needs during future crises, suggesting that thoughtfully constructed written 
advance statements such as JCPs can provide practical, immediate utility for people 
with BPD during acute crises. 
 
Participants were divided on the issue of connecting with others (i.e., having a 
meaningful and reciprocal exchange with another person) whilst in a crisis. For 
many, having the opportunity to connect with others was seen as both vital and 
beneficial, whilst many others described it as unhelpful, instead preferring to be left 
alone when in a crisis. This discrepancy highlights the need for clinicians to actively 
discuss this issue with participants when reviewing crisis plans. The NICE guideline on 
the management of BPD (189) recommended that regular reviews of crisis plans 
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should be conducted with service users and their family members or carers if 
possible and that service user autonomy should be promoted at all times. For those 
seeking to be left alone during a crisis, ‘being forced’ into proximity with others 
(whilst sometimes being necessary as a last resort in order to manage risk) is also 
potentially traumatic and may increase underlying feelings of powerlessness which 
often play out in interactions with clinicians (616). 
 
Treatment preferences regarding medication and involuntary treatment were the 
two most common treatment refusals. The NICE guideline (189) stated that, 
although medication is commonly started when a person with BPD presents in crisis, 
there is no evidence for the use of any specific drug or combination of drugs in crisis 
management. Additionally, at the time of writing, there are no medications licensed 
in the UK for the treatment of BPD. The choices expressed by participants in the trial 
regarding medication therefore appear to be choices that clinicians should not have 
difficulty following. In this regard, the findings are similar to research into the 
content of psychiatric advance directives produced in the US by people with severe 
mental illnesses (534, 614). 
 
Goals of crisis interventions for people with BPD typically include returning people to 
their pre-crisis level of functioning by mobilising both internal and external resources 
(365). These were, for the most part, reflected by participants and mirror the goals 
of the recovery orientation which is central to mental health policy in the 21st 
century throughout the Western world (617, 618).  
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4.7.  Possible reasons for negative findings 
Intervention in isolation 
It remains possible that crisis plans for people with BPD may be more successful 
when the crisis plan is more fully integrated with other components of 
comprehensive long-term treatment for BPD (233, 613), as opposed to the one-off 
intervention offered to participants in this trial.  
 
Brief follow-up period 
Finally, the follow-up period was limited to six months and it is possible that a longer 
follow-up period may have led to the detection of significant clinical change. 
Ultimately, it is possible that the findings may have been influenced by any of the 
aforementioned limitations - or a combination of them - or by other factors not yet 
understood.  
 
4.8.  The trial in context 
Using the most recent MRC framework for developing and evaluating complex 
interventions (561) as a guide, the trial was designed iteratively after considering 
advice and input from service users with BPD, clinicians and academics working with 
people with BPD and the results of a brief pilot study. Although other intervention 
trials involving participants with BPD have included a crisis management component 
as an ingredient of treatment (243, 284), findings from Borschmann and colleagues’ 
2012 Cochrane review indicated that this was the first RCT of a crisis intervention 
specifically tailored to people with BPD (371). The findings from the trial revealed 
that it is feasible to recruit and retain people with BPD to a clinical trial of joint crisis 
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plans. Approximately three-quarters of the target sample size were recruited and 
more than 80 percent of participants were retained at follow-up. Moreover, the 
intervention appeared to have high face validity with participants as JCPs were used 
both during and between crises and were viewed favourably by participants. 
Approximately half of participants reported a greater sense of control over their 
problems and an improved relationship with their mental health team as a result of 
creating a JCP and the large majority of participants stated that they would 
recommend creating a JCP to other service users. At follow-up, the proportion of 
participants reporting self-harm had fallen in both groups; however, there was no 
significant difference in the proportions reporting self-harm between the groups, 
and no significant differences between the groups on any of the secondary outcome 
measures. Despite the lack of statistically significant differences between the two 
groups on any of the secondary outcome measures, the change in mean scores for 
several variables (including working alliance, mental wellbeing, work and social 
adjustment, perceived coercion, depression and engagement with services) was 
greater - and in the hypothesised direction - in the intervention group than in the 
control group. As the trial was underpowered (see ‘General methodological 
considerations’, above), it remains a possibility that an adequately powered trial 
may have detected significant differences between the two groups on one or more 
of these outcome measures. 
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4.9.  Implications 
4.9.1.  Implications for research 
The trial highlights important implications for researchers working with people with 
BPD and/or people who self-harm. Firstly, the findings showed that it was possible to 
recruit and retain a sample of individuals with BPD to a trial of JCPs and that the 
intervention was viewed favourably by participants. The high face validity associated 
with JCPs observed in the trial mirrors that seen in previous large trials of JCPs for 
people with psychotic disorders (544, 550). Future studies would benefit from the 
inclusion of a robust process evaluation in order to help understand why the 
experience of receiving this intervention was so positive in this trial in the absence of 
clinically significant findings (545). This might include in-depth interviews with JCP 
recipients and also clinicians who attended the JCP planning meetings to explore 
their experiences of the intervention and the overall trial.  
 
The current MRC guidance for developing and evaluating complex interventions 
(561) promotes an iterative model which involves the development, 
feasibility/piloting, evaluation and implementation of an intervention. Whilst these 
four elements can helpfully be thought of as stages, it is often the case that they do 
not follow a linear (or even cyclical) sequence (562). The guidance states that 
interventions are best developed systematically using a carefully phased approach 
and amended iteratively on the basis of previous findings. Applying this framework 
to the trial, one possibility is that future studies may benefit from re-visiting the 
‘development’ stage mentioned above and - if the modelling suggests that other 
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outcomes should be measured - including additional outcome variables during the 
next ‘feasibility/piloting’ stage, as it remains possible that JCPs may influence other 
(as yet unmeasured) variables. Furthermore, future JCP research would be 
strengthened by the inclusion of a fidelity measure to assess how much variation 
there was in the creation of participants’ JCPs, as this was identified as a possible 
limitation in previous large-scale JCP research (550). 
 
One interesting finding from the trial was that, at six-month follow-up, the 
proportion of participants reporting self-harm had fallen in both the intervention 
arm and the control arm. It is possible that this is due in part to the Hawthorne effect 
(the commonly-observed phenomenon in health research whereby participants in an 
experimental study modify their behaviour simply in response to knowing they are 
being observed, rather than in response to any experimental manipulation). Another 
possibility is that there may have been a regression toward the mean (i.e., 
participants may have been highly motivated to enter the study as their recent levels 
of self-harm were relatively high and participants in both arms may have wished to 
address this). This finding has implications for future trials because it may represent 
an additional variable to consider when hypothesising about rates of self-harm over 
the course of an experimental trial or other type of study. 
 
As stated earlier, people who self-harm do so typically as a result of multiple 
motivations and contextual factors (455, 458). As such, it is likely that one relatively 
brief intervention may not be sufficient to adequately address the motivations of a 
heterogeneous sample of people who self-harm.  
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4.9.2.  Implications for clinical practice 
The trial also highlights important implications for clinicians involved in the day-to-
day care of people with BPD and/or those who self-harm. Firstly, the findings 
demonstrated that self-harm was substantially under-recorded in participants’ 
electronic psychiatric records and this may reflect clinicians being unaware of the 
true extent of a given service user’s patterns of self-harm. The consequences of this 
lack of awareness are potentially lethal, as clinicians may fail to refer appropriately 
or recommend the best available treatment to help service users address their self-
harming. Secondly, it is possible that, during the process of collaboratively creating a 
JCP with a service user, clinicians may increase their awareness of that service user’s 
extant self-management strategies. That is, by systematically discussing the JCP 
template subheadings together, clinicians may learn more about the coping 
strategies, resources and support mechanisms available to each individual service 
user. Thirdly, the findings from the trial highlight the difficulties of successfully 
implementing personalised care in the context of the non-personalised NHS 
framework. This concept was demonstrated in the case described above of the 
participant who wished to attend the local emergency department during times of 
crisis but, specifically, did not wish to be seen by any members of staff. Due to NHS 
duty of care requirements, this wish was not fulfilled and the participant later 
reported that she felt worse after attending the emergency department than she 
had felt beforehand.  
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Fourthly, qualitative analyses revealed that much of the content of participants’ JCPs 
related to previous unsatisfactory interactions that participants had experienced 
with healthcare professionals and a desire to avoid such negative interactions in the 
future. There are clear staff training issues related to this; although people with BPD 
often elicit less empathic responses from clinicians than people with other diagnoses 
(125), research has shown that clinician attitudes toward this population can be 
improved as a result of targeted clinical education about BPD (143, 144). Future 
training could focus on providing clinicians with more detailed information about the 
aetiological factors and prognosis associated with BPD, in addition to therapeutic 
responses and attitudes toward BPD (122). The present findings underscore the 
importance of the Department of Health’s Personality Disorder Capabilities 
Framework (619), which seeks to ensure that members staff working with people 
with personality disorders are equipped with the requisite education and experience 
to work effectively with this population. As the views of healthcare professionals 
regarding working with people with BPD can be negatively biased and unfavourable 
(57, 126), it could be argued that people with BPD have the greatest need for skilful 
professional care (143) and the findings from the trial demonstrated many 
participants’ desire for meaningful interactions during times of acute crisis. This 
unambiguous finding provides a clear message to clinicians working with people with 
BPD about what is perceived as helpful and unhelpful during times of crisis.  
 
At the request of participants, JCPs were distributed to a range of health and 
statutory bodies involved in their care. More than 90% of participants requested that 
their GP should be provided with a copy of their JCP. People with BPD are high 
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consumers of primary health care services (5) and often receive input from their GPs 
during acute crises. As such, advance statements that can be shared with GPs, such 
as JCPS, may be particularly valuable. Finally, the high face validity of JCPs with 
participants in this trial is an important finding during a period in healthcare in which 
shared decision-making (528) is becoming used more frequently.  
 
Clinicians working with people with BPD may wish to make use of JCPs in routine 
practice as a method of discussing the differing risk factors, protective factors and 
treatment preferences of each individual service user. One of the strengths of JCPs is 
that they are written in the service user’s own words and are, therefore, largely free 
of the medical jargon seen in electronic psychiatric records and earlier forms of crisis 
plan.  
 
Participants included unambiguous and insightful statements in their JCPs, the 
majority of which related to a clear desire to recover from the crisis and continue 
living productive lives. This finding challenges misconceptions held by many clinicians 
that people with BPD either consistently make self-destructive life choices (10) or 
lack the requisite capacity to make sensible life choices (620-622). This highlights the 
fallacy whereby clinicians may sometimes make unfavourable generalisations about 
the level of functioning of people with BPD during their daily lives on the basis of 
their presentation during crises. The findings also demonstrate that the same issues 
of dignity, respect and autonomy identified in global surveys of discrimination 
amongst people with severe mental illness (623, 624) are important to people with 
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BPD and add further support to the NICE recommendations for improving the 
experience of care for people using NHS mental health services (625). 
 
The qualitative analysis of 41 JCPs highlighted several important issues. Firstly, 
people with BPD do not (as many presume) make exclusively destructive life choices. 
Secondly, as highlighted by the statements relating to interactions with staff, the 
issues of dignity, respect and autonomy are as critically important to people with 
BPD as they are to people with severe mental illness. Thirdly, the variation observed 
in the treatment preferences of participants underscores the importance of involving 
service users with BPD in genuinely collaborative working relationships. In the UK, 
the NICE guideline for the treatment and management of BPD (189) recommends 
involving people with BPD in the decision-making process - including in relation to 
their crisis plans - regarding their future treatment. The findings highlight some clear 
domains in which people with BPD can be more involved in planning their future 
care during crises and also highlight important lessons for practitioners and policy-
makers regarding future care planning for this population.  
 
4.10.  Summary and conclusions 
Previous research using JCPs and other psychiatric advance statements has found 
that they promote self-determination and empowerment among service users (544) 
and that they have the potential to facilitate stronger relationships between service 
users and providers (614). Fostering collaborative relationships is essential in the 
treatment of people with BPD (189) and JCPs may provide one approach to ensuring 
that the values and treatment preferences of people with BPD remain central when 
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they experience crises. This trial, using data obtained from 88 self-harming 
outpatients receiving treatment from CMHTs in south London and meeting 
diagnostic criteria for BPD, showed that it is possible to recruit and retain adult 
service users with BPD to a research study of joint crisis plans. JCPs were used both 
during and between crises and were viewed favourably by participants. 
Approximately half of participants reported a greater sense of control over their 
mental health problems and an improved relationship with their mental health team 
as a result of creating their JCP. However, creating a JCP was not associated with a 
statistically significant reduction in self-harm at follow-up. The findings suggest that 
a brief and relatively simple intervention is perceived as helpful to people with BPD – 
a group who have traditionally been alienated from mainstream mental health 
services and are still perceived to be difficult to help (8). Reducing hospitalisation 
through improvements in outpatient services would reduce healthcare costs and 
benefit people with BPD (64). 
 
Although JCPs had high face validity for people with BPD, evidence of clinical efficacy 
was not established and so the trial did not provide a robust justification to 
recommend the use of JCPs in clinical practice. Given the exploratory nature of this 
trial, the small sample size involved and the lack of significant improvements in the 
primary outcome measure, a decision to fund JCPs in addition to treatment as usual 
may be premature. However, as the trial was underpowered, it remains possible that 
the JCP is an effective intervention for people with BPD. Future research should 
include a robust process evaluation to help understand why the experience of 
receiving this intervention in this trial was rated so positively by participants. Such an 
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evaluation may also provide further useful information about the clinical and 
economic benefits of using joint crisis plans in a population of people with borderline 
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5.) Work and Social Adjustment Scale (WSAS) 
6.) Working Alliance Inventory (Client version) (WAI-C) 
7.) Working Alliance Inventory (Therapist version) (WAI-T) 
8.) Treatment Experience Survey (TES) 
9.) Client Satisfaction Questionnaire (CSQ) 
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12.) Warwick Edinburgh Mental Wellbeing Scale (WEMWBS) 
13.) Hospital Anxiety and Depression Scale (HADS) 
14.) EuroQOL Quality of Life measure (EQ-5D) 
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16.) Self-harm diary 
17.) The Structured Clinical Interview for DSM-IV (SCID-II) – Borderline Personality 
Disorder subsection  
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     My Joint Crisis Plan 
 
We would like to help you put together a plan for you to use when you are in a crisis. 
By ‘crisis’, we mean urgent situations where you feel that you are not coping and 
may need some extra help.  
 
The plan will be finalised at a meeting between you and key staff from your CMHT, 
which we will facilitate. The idea is that you might choose to use the plan when you 
encounter a health professional who doesn’t know you well, for example a member 
of A&E staff.  
 
This form is to help you decide what you would like to be included on your crisis 
plan. Some sections can be simply filled in by you if you want them included. 
Elsewhere you may want to select an item but wait to discuss the details with your 
treatment team at the facilitated meeting.  You can include as much or as little 
information as you wish. Whatever you have chosen or agreed at your crisis planning 
meeting will then be made up into your own personal crisis plan.  
 
It is important that your joint crisis plan is kept up to date. If you feel that it needs to 
be updated at any time please contact your treatment team. Please tick which of the 
following you would like on your crisis plan. Please provide details if at all possible. 
 
 
 My name:   ................................................................ 
 Address:   ................................................................ 
     ................................................................ 
 Tel no.:    ................................................................  
 
 GP's name:   ................................................................ 
 Address:   ................................................................ 
     ................................................................ 
 Tel no.:    ................................................................  
 
 Consultant's name:  ................................................................ 
 Address:   ................................................................ 
     ................................................................ 
 Tel no:    ................................................................  
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 Care coordinator’s name: ................................................................ 
 Address:   ................................................................ 
     ................................................................ 
 Tel no:    ................................................................  
 
 Other (e.g. social worker): 
 (please name)   ……….....................................................   
 Address:   ................................................................ 
     ................................................................ 
 Tel no:    ................................................................  
 
 
 Do you have a friend or family member who might be willing to help and 
support you in a crisis? If so, it might be helpful if you could invite them along 
to the planning meeting.  You can add their name and contact details below.   
 
 Who to contact if I need extra support:   
 
  Name  ....................................................................... 
  Address ....................................................................... 
    ....................................................................... 
  Tel no: Home ...................................Work................................... 
  Mobile  ………………………. 
 


















My difficulties, and things which may help me in a crisis: 
 
Please tick the boxes you would like on your crisis plan. You may want to fill in the 
details yourself or you can discuss them with your treatment team at your crisis 
planning meeting. 
 










 Positive things which I have found helpful when faced with problems or when 

















 Things I sometimes forget to do when I am experiencing a crisis and which I 






INFORMATION WHICH HEALTH PROFESSIONALS MIGHT FIND USEFUL TO KNOW 
ABOUT ME:  
 
My current treatment / support: 
 





 When I am distressed, I find it unhelpful if staff talk or relate to me in the 





 Specific refusals regarding treatment during a crisis (Here you can describe 










 Anything else that people need to know about me, or would be helpful to 





 I do / do not have dependants (e.g. children, elderly relatives).  
 If I am in a crisis, I may need extra support to care for them. The person 









 Useful telephone numbers: (e.g. Samaritans, Crisis, Salvation Army, NHS 










 treatment team – name, details 
 out of hours team –name, details 
 local A & E department – name, details 
 GP – name, details 
 my nominee (the person listed at the top of page 2; please name) 
 other (please name) ....................................................................... 
 
 
Date of crisis planning meeting:........................................ 
 
 
Present at meeting: 
 
Name Role or profession  















 Institute of Psychiatry, De Crespigny Park, London, SE5 8AF.  Tel. 020-7848-5093 
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This Joint Crisis Plan has been developed 






Please make every effort to fulfil this 
agreement in the event of a crisis.  
 
Advance statements regarding preferences 
for care included in a Joint Crisis Plan are 
not legally binding. Where a Joint Crisis Plan 
includes a valid advance refusal of 
treatment, that specific statement is legally 
binding, but may be over-ruled in certain 
circumstances such as treatment under the 
Mental Health Act. This plan is part of a 
research study designed to improve 
communication between the service user 
and professionals in the event of a crisis. For 
details about the study, please contact Dr. 
Rohan Borschmann at King’s College on  

























* EXAMPLE ONLY * 
 
 
My name: John Paxson 
Address: 5 Nightingale Lane, 
Lewisham, SE13 5CB 
Tel. no:  07936.XXX.XXX 
 
My GP:  Dr. Lance Patel  
Address:  53 Livingstone street,  
Lewisham SE15 7FG 
Tel. no:  XXX-XXXX-XXXX  
 
My psychiatrist: …. 
Address:  …. 
Tel. no:  …. 
 
My CPN:  …. 
Address:  …. 









In a time of crisis, I would like the 
person below to be contacted as 
soon as possible and to be informed 
of what is happening:  
 
Name:  Phil Paxson (father) 
Address:  5 Nightingale Lane,  
Lewisham, SE13 5CB 
Home tel:  XXX-XXXX-XXXX 
Work tel:  XXX-XXXX-XXXX 
Mobile:  XXXXX.XXX.XXX 
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Information for me: 
 
 
Positive things I can do when I am in a 
crisis:  
Play music in my room 
Walk my dog 
Avoid contact with my ex-partner 
 
Things which have not been helpful when I 
have been faced with crises in the past:  
Getting into arguments 
Using alcohol or drugs 
 
Things I sometimes forget to do when I am 
in a crisis & may need to be reminded 
about: 
Tell my college I won’t be coming in 
Remember that I have survived previous crises 
 
Specific refusals regarding treatment 
during a crisis:  
I do not want to be given any injections if 




Useful telephone numbers: 
 
Samaritans:   08457-90-90-90 
NHS Direct:   0845-46-47 




Information for healthcare 
professionals:  
 
My difficulties as I see them now: 
Paranoia and mental health problems 
 
Details of any current treatment / support 
from health professionals: 
I see my CPN every Wednesday at Lewisham 
CMHT;  I also see my GP every 4 weeks 
 
Physical illnesses & medication: 
I am asthmatic. My current medication is my 
Ventolin inhaler and Olanzepine: 10mg at night 
 
Situations which can lead to a crisis:  
Problems with money or with my ex-partner.  
 
Things I would like professionals to do 
which may help me when I am in a crisis:  
I’d like a quiet room if possible as noise makes 
me more likely to get distressed.  
 
Things which professionals have said or 
done which have not been helpful in the 
past:  
Increasing my medication;  not listening to me 
when I am talking;  not treating me with respect 
 
When I am distressed, I find it unhelpful if 
staff talk or relate to me in the following 
way: 
I like people to keep their distance while they’re 
talking with me, as feeling closed in makes me 
get more distressed. Not being listened to.  
 
Practical Help in a Crisis: 
 
 
I have two daughters; when I am distressed, 
my ex-partner Helen (their mother) can take 
care of them. She can be reached on XXX-
XXXX-XXXX.  
 
I have a pet dog and my neighbour Tony (at 
number 91) is happy to look after him.  
 
Agencies or people that I would like to 
have copies of this Joint Crisis Plan:  
 
√ myself 
√ my GP 
√ my treatment team 
√ my father, Phil Paxson (father) 
√ other (please name) 
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Registration/Demographics Form (participant) 
 
01. Participant Initials  
 
 
    
   
 





    
Day              Month          Year                  
 
  /   /     
 
03. Gender 1 Female 
0 Male 
 




1 Married / civil partnership 
2 Cohabiting 
3 Spouse / partner deceased 
4 Separated 
5 Divorced 
6 Single / non-cohabiting partner 
7 Other (please specify) Go to 04b 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 




05. Who do you 
usually live with? 
1 Alone 
2 Spouse/partner 
3 Spouse/partner and child or children 
4 Child or children (but no spouse/partner) 
5 Other relatives 
6 Other (unrelated) Go to 5b 
7 Supervised/assisted living 
8 Homeless 
9 None of the above 
(please specify) 
Go to 5b 
777 Not available or not applicable 















06a. Which of the 
following ethnic 
groups do you 
consider you 
belong to? Circle 
ONE only: 
1 Asian     
2 Black  
3 White 
4 Mixed  
5 Other – please specify: Go to 6b 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 




07a. Which one of these 
best describes your 
current situation? 
Circle ONE only 
1 In paid work (including self-employed) 
2 Unemployed  
3 Permanently sick or disabled  
4 Retired 
 
5 Looking after home or family   
 
6 Full-time student 
7 Other – please specify:    Go to 7b 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 




08. Please give the title 
of your present or 
most recent paid 
job: 
(drop down list or text field?) 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
09.  At what age did 
you leave school? 
   
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
10. Have you been in 
further or higher 
education since you 
left school? Circle 
1 Yes  
0 No 
777 Not available or not applicable 
888 Not done  
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5 Other, please specify Go to 11b 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 






Care Coordinator’s Details 
Please complete the following questions about yourself.  
 





777 Not available or not applicable 
888 Not done 
999 Unknown 
 
02. Which of the 
following ethnic 
groups do you 
consider you 
belong to? Circle 
ONE only: 
1 Asian     
2 Black  
3 White 
4 Mixed  
5 Other – please specify:  
777 Not available or not applicable 
888 Not done  
999 Unknown 
 




03. Classification of 
your professional 
qualifications 
1 Occupational therapist 
2 Community psychiatric nurse 
3 Psychologist 
4 Other   
777 Not available or not applicable 
888 Not done  
999 Unknown 
 





4. Length of your 
relationship with 
this client  
(in months) 
 
   
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
5. Your date of birth   
   /   /     
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Day              Month          Year              
 
 




7. Your initials 
 
   
 
8. Length of time you 
have been working 
in this field (in 
months) 
 
   
 
9. Your first language  
 
10. Type of Care  
Co-ordinator/main 
contact 
1 Temporary Care Coordinator 
2 Substantive/permanent Care Coordinator 
3 Psychiatrist 
4 Other  Go to question 10b 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 






Work and Social Adjustment Scale 
 
Rate each of the following questions on a 0 to 8 scale: 0 indicates no impairment at 
all and 8 indicates very severe impairment. 
 
1. Because of my 
[disorder], my 




not at all impaired 
and 8 means very 
severely impaired
 
to the point I can't 
work. 








8 indicates very severe impairment 
777 Not available or not applicable 
















or children, paying 
bills)
 

















8 indicates very severe impairment 
777 Not available or not applicable 












other people, such 






















8 means very 
severely impaired. 
8 indicates very severe impairment 
777 Not available or not applicable 









































8 indicates very severe impairment 
777 Not available or not applicable 





5. Because of my 
[disorder], my 












not at all impaired 












8 indicates very severe impairment 
777 Not available or not applicable 




Working Alliance Inventory - Client 
On the following pages there are sentences that describe some of the different 
ways a person might think or feel about his or her therapist (counsellor). As you 
read the sentences mentally insert the name of your therapist (counsellor) in place 
of  __________ in the text. 
 
Below each statement inside there is a seven point scale: 
 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
If the statement describes the way you always feel (or think) circle the number 7; if 
it never applies to you, circle the number 1. Use the numbers in between to 
describe the variations between these extremes. 
 
This questionnaire is confidential neither your therapist nor the agency will see 
your answers.   
 
Work fast, your first impressions are the ones we would like to see. (PLEASE DON’T 
FORGET TO RESPOND TO EVERY ITEM.) 
 
Thank you for your corporation.   
 
1. _________________ and I agree about the things I need to do in treatment 
to help improve my situation. 
 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
2. What I am doing in treatment gives me new ways of looking at my problem. 
 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 




3. I believe _________________likes me. 
 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 








4. ______________does not understand what I am trying to accomplish in 
treatment 
 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
5. I am confidant in _________________ability to help me. 
 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
6. _________________and I are working toward mutually shared goals. 
 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 




7. I feel that _________________ appreciates/ accepts me. 
 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
8. We agree what is important for me to work on. 
 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 





9. _________________and I trust one another. 
 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
10. _________________and I have different ideas on what my problems are 
 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
11. We have established a good understanding of the kind of changes that 
would be good for me. 
 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
12. I believe the way we are working with my problem is correct. 
 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 









Working Alliance Inventory – Therapist version 
 
On the following pages there are sentences that describe some of the different 
ways a person might think or feel about his or her client. As you read the sentences 
mentally insert the name of your client in place of _____________in the text. 
 
Below each statement inside there is a seven point scale: 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
If the statement describes the way you always feel (or think) circle the number 7; if 
it never applies to you circle the number 1.Use the numbers in between to describe 
the variations between these extremes. 
 
Work fast, your first impressions are the ones we would like to see. (PLEASE DON’T 
FORGET TO RESPOND TO EVERY ITEM.) 
 
Thank you for your corporation.   
1. _______________ and I agree about the steps to be taken to improve 
his/her situation. 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
2. My client and I both feel confident about the usefulness of our current 
activity in therapy. 
  1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
3. I believe _______________ likes me.   
1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 




4. I have doubts about what we are trying to accomplish in therapy. 
1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
5. I am confident in my ability to help _______________. 
1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
6. We are working towards mutually agreed upon goals. 
1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
7. I appreciate _______________ as a person. 
1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
8. We agree on what is important for _______________ to work on. 
1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
9. _______________ and I have built a mutual trust. 
1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
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10. _______________ and I have different ideas on what his/her real problems 
are. 
1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
11. We have established a good understanding between us of the kind of 
changes that would be good for _______________. 
1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 
888 Not done  
999 Unknown 
12. _______________ believes the way we are working with her/his problem is 
correct. 
1                2                   3                        4                 5              6                  7  
Never     Rarely       Occasionally    Sometimes      Often   Very Often    Always 
 
777 Not available or not applicable 






Treatment Experience Survey 
You are going to read some statements about your treatment.  Please tick one box, 
either ‘True’ or ‘False’ or ‘Don’t know’ for each question. To answer each question 
individually, no matter how similar it may sound to another.   
1. I have felt free to 







3 Don’t know 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
2. People have tried 





3 Don’t know 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
3. I have had enough 
of a chance to say 





3 Don’t know 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 





3 Don’t know 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 






3 Don’t know 
777 Not available or not applicable 








get me to come 
into treatment 
 
3 Don’t know 
777 Not available or not applicable 






7. It has been my idea 




3 Don’t know 
777 Not available or not applicable 
888 Not done 
999 Unknown 
8. Someone 
physically tried to 





3 Don’t know 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
9. No one seemed to 
want to know 
whether I wanted 




3 Don’t know 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 






3 Don’t know 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
11. They said they 





3 Don’t know 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
12. No one tried to 





3 Don’t know 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 






3 Don’t know 
777 Not available or not applicable 






14. I have had a lot of 
control over 





3 Don’t know 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
15. I have had more 
influence than 
anyone else on 





3 Don’t know 
777 Not available or not applicable 





Client Satisfaction Questionnaire 
 
Please answer the following questions about your level of satisfaction with your 
CMHT. We are interested in your honest opinion, whether they are positive or 
negative. Please answer all of the questions.  
 
1. How would you rate the quality of service you received? 
 
        4                 3             2             1 
Excellent        Good        Fair        Poor 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
2. Did you get the kind of service you wanted? 
 
          4                               3                           2                          1 
No, definitely not    No, not really     Yes, generally     Yes, definitely 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
3. To what extent has this CMHT met your needs? 
 
          4                                           3                               2                                      1 
Almost all of my              Most of my needs     Only a few of my           None of 
my needs 
needs have been met     have been met          needs have been met    have 
been met 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
4. If a friend were in need of similar help, would you recommend this CMHT to 
him or her? 
          4                               3                           2                          1 
No, definitely not    No, not really     Yes, generally     Yes, definitely 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
5. How satisfied are you with the amount of help you have received?  
 
          4                                           3                               2                                      1 
Quite dissatisfied       Indifferent or mildly         Mostly satisfied         Very 
satisfied  
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                                                Dissatisfied                          
777 Not available or not applicable 





6. Have the services you received helped you to deal more effectively with 
your problems? 
 
               4                                      3                                   2                                             
1 
Yes they have helped        Yes they helped       No they really didn’t      No 
they seemed to make  
      A great deal                     somewhat                         help                                
things worse 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
7. In an overall, general sense, how satisfied are you with the service you have 
received? 
          4                                3                                    2                                            1 
Very satisfied         Mostly satisfied          Indifferent or mildly          Quite 
dissatisfied        
                                                                            Dissatisfied                          
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
8. If you were to seek help again, would you come back to this CMHT? 
 
          4                                   3                             2                             1 
No, definitely         No, I don’t think so      Yes, I think so     Yes, definitely 
777 Not available or not applicable 





AUDIT (Alcohol Use Disorders Identification Test) 
 
PATIENT: Because alcohol use can affect your health and can interfere with certain 
medications and treatments, it is important that we ask some questions about your 
use of alcohol. Your answers will remain confidential so please be honest. 
 
Place an X in one box that best describes your answer to each question. 
 
01. How often do you 
have a drink 
containing alcohol? 
0 Never 
1 Monthly or less 
2 2-4 times a month 
3 2-3 times a week 
4 4 or more times a week 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
02. How many drinks 
containing alcohol 
do you have on a 
typical day when 
you are drinking? 
0 1 or 2 
1 3 or 4 
2 5 or 6 
3 7 to 9 
4 10 or more 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
03. How often do you 
have six or more 
drinks on one 
occasion? 
0 Never 
1 Less than monthly 
2 Monthly 
3 Weekly 
4 Daily or almost daily 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
04. How often during 
the last year have 
you found that you 
were not able to 
stop drinking once 
you had started? 
0 Never 
1 Less than monthly 
2 Monthly 
3 Weekly 
4 Daily or almost daily 
777 Not available or not applicable 




05. How often during 
the last year have 
you failed to do 
what was normally 




1 Less than monthly 
2 Monthly 
3 Weekly 
4 Daily or almost daily 
777 Not available or not applicable 






06. How often during 
the last year have 
you needed a first 
drink in the 
morning to get 
yourself going 
after a heavy 
drinking session? 
0 Never 
1 Less than monthly 
2 Monthly 
3 Weekly 
4 Daily or almost daily 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
07. How often during 
the last year have 
you had a feeling 
of guilt or remorse 
after drinking? 
0 Never 
1 Less than monthly 
2 Monthly 
3 Weekly 
4 Daily or almost daily 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
08. How often during 
the last year have 




because of your 
drinking? 
0 Never 
1 Less than monthly 
2 Monthly 
3 Weekly 
4 Daily or almost daily 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
09. Have you or 
someone else been 
injured because of 
your drinking? 
0 No 
2 Yes, but not in the last year 
4 Yes, during the last year 
777 Not available or not applicable 
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888 Not done  
999 Unknown 
 
10. Has a relative, 
friend, doctor, or 
other health care 
worker been 
concerned about 
your drinking or 
suggested you cut 
down? 
0 No 
2 Yes, but not in the last year 
4 Yes, during the last year 
777 Not available or not applicable 
888 Not done  
999 Unknown 
 
11. Total  
777 Not available or not applicable 




We are asking everybody some questions about specific drugs they may have used 
within the past year. As with the rest of this interview, your answers are treated with 
strict confidence. In the past twelve months, have you used: 





Yes = 1 
 No = 0 
 
3. If yes, no. of times 
used in last month? (e.g. 
daily, 20x, 10x, etc.)  
 
Coded as: 
1. Once daily 
2. Twice daily 
3. Three times daily 
4. four times daily 
5. As required 




5. Usual route 




















































































































































































































The well-being scale  
 
 













I’ve been feeling optimistic about the future  1 2 3 4 5 
I’ve been feeling useful  1 2 3 4 5 
I’ve been feeling relaxed  1 2 3 4 5 
I’ve been feeling interested in other people  1 2 3 4 5 
I’ve had energy to spare  1 2 3 4 5 
I’ve been dealing with problems well  1 2 3 4 5 
I’ve been thinking clearly  1 2 3 4 5 
I’ve been feeling good about myself  1 2 3 4 5 
I’ve been feeling close to other people  1 2 3 4 5 
I’ve been feeling confident  1 2 3 4 5 
I’ve been able to make up my own mind about 
things  
1 2 3 4 5 
I’ve been feeling loved  1 2 3 4 5 
I’ve been interested in new things  1 2 3 4 5 
I’ve been feeling cheerful  1 2 3 4 5 
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Hospital Anxiety and Depression Scale 
INSTRUCTIONS: Doctors are aware that emotions play an important part in most 
illnesses. If your doctor knows about these feelings he or she will be able to help you 
more. This questionnaire is designed to help your doctor know how you feel. Read 
each item and indicate the reply which comes closest to how you have been feeling 
in the PAST WEEK. Don't take too long over your replies: your immediate reaction to 
each item will probably be more accurate than a long thought out response. 
 





3 Most of the time  
2 A lot of the time 
1 Time to time, occasionally  
0 Not at all 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 





3 Nearly all of the time 
2 Very often  
1 Sometimes  
0 Not at all 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
3. I still enjoy the 
things I used to 
enjoy 
 
0 Definitely as much 
1 Not quite so much 
2 Only a little 
3 Not at all 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
4. I get sort of a 
frightened feeling 
like ‘butterflies in 
the stomach’ 
0 Hardly at all 
1 Occasionally 
2 Quite often  
3 Very often 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
5. I get a sort of 
frightened feeling 
3 Very definitely and quite badly 
2 Yes, but not too badly 
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as if something 




1 A little, but it doesn’t worry me 
0 Not at all 
777 Not available or not applicable 









6. I have lost interest 
in my appearance 
 
3 Definitely 
2 I don’t take as much care as I should 
1 I may not take quite as much care  
0 I take just as much care as ever 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
7. I can laugh and see 
the funny side of 
things 
0 As much as I always could 
1 Not quite so much now 
2 Definitely not so much now 
3 Not at all  
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
8. I feel restless as if I 
have to be on the 
move 
3 Very much indeed 
2 Quite a lot  
1 Not very much 
0 Not at all 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
9. Worrying thoughts 
go through my 
mind 
3 A great deal of the time  
2 A lot of the time 
1 Not too often 
0 Very little 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
10. I look forward with 
enjoyment to 
0 As much as I ever did 
1 Rather less than I used to 
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things 2 Definitely less than I used to 
3 Hardly at all 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
11. I feel cheerful 3 Never  
2 Not often 
1 Sometimes 
0 Most of the time 
777 Not available or not applicable 












12. I get sudden 
feelings of panic 
3 Very often indeed 
2 Quite often 
1 Not very often 
0 Not at all 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
13. I can sit at ease 
and feel relaxed 
0 Definitely 
1 Usually 
2 Not often 
3 Not at all 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
14. I can enjoy a good 





2 Not often 
3 Very seldom 
777 Not available or not applicable 









   
 
16. Anxiety score total 
 
 









For each group below, please indicate which statements best describe your own 
health state TODAY. 
 
 
1.  Mobility  
  
 
1 I have no problems in walking about 
2 I have some problems in walking about 
3 I am confined to bed 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
2.  Self Care 
  
 
1 I have no problems with self-care 
2 I have some problems washing or dressing 
myself 
3 I am unable to wash or dress myself 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
3.  Usual Activities 
  
(e.g. work, study, 
housework, family or 
leisure activities) 
1 I have no problems with performing my usual 
activities 
2 I have some problems with performing my 
usual activities 
3 I am unable to perform my usual activities 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
4.  Pain/Discomfort 1 I have no pain or discomfort 
2 I have moderate pain or discomfort 
3 I have extreme pain or discomfort 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
5.  Anxiety/Depression 1 I am not anxious or depressed 
2 I am moderately anxious or depressed 
3 I am extremely anxious or depressed 
777 Not available or not applicable 














To help people say how good or bad a health state 
is, we have drawn a scale (rather like a 
thermometer) on which the best state you can 
imagine is marked 100 and the worst state you 
can imagine is marked 0. 
 
We would like you to indicate on this scale how 
good or bad your own health is today, in your 
opinion. Please do this by drawing a line from 
the box below to whichever point on the scale 






















6.  Your own health 
state today:    
 
777 Not available or not 
applicable 



























There may be times in a person’s life when they become very low and depressed and 
may feel like taking drastic action because of these feelings. 
 
1. Have you ever 
deliberately taken 
an overdose (eg of 
pills or other 
medication) or 
tried to harm ? 
 
Please tick the box 
which applies to 
you 
 
0 No  
1 Yes, once 
2 Yes, more than once 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
2. In the past year, 
have you 
deliberately taken 
an overdose (eg. of 
pills or other 
medication) or 
tried to harm 
yourself in some 
other way (such as 
cut yourself)? 
 
Please tick the box 
which applies to 
you 
0 No  
1 Yes, once 
2 Yes, more than once Go to Question 2a 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
2a. If so, how many 
times? 
 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
The following questions are about the LAST TIME you took an overdose or tried to 
harm yourself.  
 
3. When was the LAST 
TIME you took an 
overdose or tried 
to harm yourself? 
0 less than a month ago 
1 between a month and a year ago 
2 more than a year ago 
777 Not available or not applicable 




3a. Describe what you 
did to yourself on 
that occasion: 
 
Please give as much 
detail as you can 
(for example, the 
name of the drug 





4. How long before 
you took the 
overdose or tried 
to harm yourself on 
that occasion had 
you started to think 
about doing it? 
0 less than an hour 
1 more than an hour but less than a day 
2 more than a day but less than a week  
3 more than a week but less than a month 
4 a month or more 
777 Not available or not applicable 




5. Did you talk or try to get any help beforehand from 

































































6. Did you try to get 
any help 
afterwards for the 
problems that led 
you to take an 
overdose or try to 
harm yourself on 
that occasion? 
0 No Go to Question 6a 
1 Yes 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
6a. If ‘no’, please say 
why you didn't try 
to get any help. 
 
 
7. Did you go to 
hospital because of 
this overdose or 




777 Not available or not applicable 




8. On that occasion, did you receive help from any of 
































































9. Have you EVER 
gone to hospital 
because you took 





777 Not available or not applicable 
888 Not done 
999 Unknown 
 
10. Have you EVER 
seriously wanted to 
kill yourself when 
you have taken an 
overdose or tried 





777 Not available or not applicable 
888 Not done 
999 Unknown 
 
11. Have you EVER told 
someone you were 




2 a few times 
3 often 
 316
777 Not available or not applicable 




Harm to others 
 
12. Have you ever 
intentionally tried 




1 Yes Go to question 13 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
13. If yes, how often? 0 Once 
1 Twice 
2 More than twice 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
14. What methods 








5 Other  - Specify Go to question 14a 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 








777 Not available or not applicable 
888 Not done 
999 Unknown 
 
** Major: homicide, sex attacks, attempted or actual serious assault 
Non-major incidents requiring attendance of police or on-ward seclusion or special 
civil-law admissions to a place of safety 
 
16. In the past year, 
have you ever 
intentionally tried 
to harm or injure 
another person? 
0 No 
1 Yes Go to question 17 
777 Not available or not applicable 




17. If yes, how often? 0 Once 
1 Twice 
2 More than twice 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
18. What methods 








5 Other  - Specify Go to question 18a 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 








777 Not available or not applicable 
888 Not done 
999 Unknown 
 
** Major: homicide, sex attacks, attempted or actual serious assault 
Non-major incidents requiring attendance of police or on-ward seclusion or special 
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The Structured Clinical Interview for DSM-IV (SCID-II) 
 
personality disorders: BPD subsection 
 
Borderline Personality Disorder: A pervasive pattern of instability of interpersonal 
relationships, self-image, and affects and marked impulsivity beginning by early 
adulthood and present in a variety of contexts, as indicated by five (or more) of the 
following: 
 
1. Have you often 
become frantic 
when you thought 
that someone you 
really cared about 
was going to leave 
you? 
 
1 absent or false  
2 sub threshold 
3 threshold or true 
0 inadequate information 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
2. Do your 
relationships with 
people you really 
care about have 
lots of extreme ups 
and downs? 
 
1 absent or false  
2 sub threshold 
3 threshold or true 
? inadequate information 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
3. Does your sense of 






1 absent or false  
2 sub threshold 
3 threshold or true 
0 inadequate information 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 




1 absent or false  
2 sub threshold 
3 threshold or true 
0 inadequate information 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
5. Have you tried to 
hurt or kill yourself 
or ever threatened 
1 absent or false  
2 sub threshold 
3 threshold or true 
322 
 
to do so? 
 
0 inadequate information 
777 Not available or not applicable 







6. Do you have a lot 
of sudden mood 
changes? 
 
1 absent or false  
2 sub threshold 
3 threshold or true 
0 inadequate information 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
7. Do you often feel 
empty inside? 
 
1 absent or false  
2 sub threshold 
3 threshold or true 
0 inadequate information 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
8. Do you often have 
temper outbursts 
or get so angry 
that you lose 
control?  
 
1 absent or false  
2 sub threshold 
3 threshold or true 
0 inadequate information 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
9. When you are 
under a lot of 
stress, do you get 
suspicious of other 




1 absent or false  
2 sub threshold 
3 threshold or true 
0 inadequate information 
777 Not available or not applicable 





Standardised Assessment of Personality – Abbreviated Scale (SAPAS) 
 
I’d like to ask you some questions about yourself. Your answers will help me better 
understand what you are usually like. If the way you have been in recent weeks or 
months is different from the way you usually are, please look back to when you 
were your usual self.  
 
 




0 0. No 
1 1. Yes 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
2. Would you 
normally describe 
yourself as a loner? 
 
0 0. No 
1 1. Yes 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
3. In general, do you 
trust other people? 
 
1 1. No 
0 0. Yes 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
4. Do you normally 
lose your temper 
easily?  
 
0 0. No 
1 1. Yes 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
5. Are you normally 
an impulsive sort 
of person? 
 
0 0. No 
1 1. Yes 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
6. Are you normally a 
worrier? 
 
0 0. No 
1 1. Yes 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
7. In general, do you 
depend on others a 
0 0. No 





777 Not available or not applicable 
888 Not done 
999 Unknown 
 
8. In general, are you 
a perfectionist? 
 
0 0. No 
1 1. Yes 
777 Not available or not applicable 





Service Engagement Scale (SES) 
Please complete the following questions about this client.  
1. The client seems to 
make it difficult to 
arrange 
appointments 
0 Not at all or rarely 
1 Sometimes 
2 Often 
3 Most of the time 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
2. When a visit is 
arranged, the 
client is available  
0 Not at all or rarely 
1 Sometimes 
2 Often 
3 Most of the time 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
3. The client seems to 
avoid making 
appointments 
0 Not at all or rarely 
1 Sometimes 
2 Often 
3 Most of the time 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
4. If you offer advice, 
does the client 
usually resist it? 
0 Not at all or rarely 
1 Sometimes 
2 Often 
3 Most of the time 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
5. The client takes an 
active part in the 
setting of goals or 
treatment plans 
0 Not at all or rarely 
1 Sometimes 
2 Often 
3 Most of the time 
777 Not available or not applicable 










0 Not at all or rarely 
1 Sometimes 
2 Often 
3 Most of the time 
777 Not available or not applicable 
888 Not done 
999 Unknown 




0 Not at all or rarely 
1 Sometimes 
2 Often 
3 Most of the time 
777 Not available or not applicable 
888 Not done 
999 Unknown 
8. The client finds it 
difficult to ask for 
help 
0 Not at all or rarely 
1 Sometimes 
2 Often 
3 Most of the time 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
9. The client seeks 
help to prevent a 
crisis 
0 Not at all or rarely 
1 Sometimes 
2 Often 
3 Most of the time 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
10. The client does not 
actively seek help 
0 Not at all or rarely 
1 Sometimes 
2 Often 
3 Most of the time 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
11. The client agrees 
to take prescribed 
medication 
0 Not at all or rarely 
1 Sometimes 
2 Often 
3 Most of the time 
777 Not available or not applicable 





12. The client is clear 
about what 
medications 
he/she is taking 
and why 
0 Not at all or rarely 
1 Sometimes 
2 Often 
3 Most of the time 
777 Not available or not applicable 




13. The client refuses 
to co-operate with 
treatment 
0 Not at all or rarely 
1 Sometimes 
2 Often 
3 Most of the time 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
14. The client has 
difficulty in 
adhering to the 
prescribed 
medication 
0 Not at all or rarely 
1 Sometimes 
2 Often 
3 Most of the time 
777 Not available or not applicable 
888 Not done 
999 Unknown 
 
 
  
 
 
  
 
